# Bortolozzi_2024_New Advances in the Pharmacology and Toxicology of Lithium A Neurobiologically Oriented Overview.

1521-0081/76/3/323–357$35.00
PHARMACOLOGICAL REVIEWS
U.S. Government work not protected by U.S. copyright

dx.doi.org/10.1124/pharmrev.120.000007
Pharmacol Rev 76:323–357, May 2024

ASSOCIATE EDITOR: ROBERT DANTZER

New Advances in the Pharmacology and Toxicology of
Lithium: A Neurobiologically Oriented Overview

Analia Bortolozzi,1 Giovanna Fico,1 Michael Berk, Marco Solmi, Michele Fornaro, Joao Quevedo, Carlos A. Zarate, Jr.,
Lars V. Kessing, Eduard Vieta,2 and Andre F. Carvalho2
Institut d’Investigacions Biom(cid:1)ediques de Barcelona (IIBB), Spanish National Research Council (CSIC), Barcelona, Spain (A.B.); Institut
d’Investigacions Biom(cid:1)ediques August Pi i Sunyer (IDIBAPS), Barcelona, Spain (A.B., G.F., E.V.); Centro de Investigaci(cid:3)on Biom(cid:3)edica en Red de
Salud Mental (CIBERSAM), ISCIII, Madrid, Spain (A.B., G.F., E.V.); Hospital Clinic, Institute of Neuroscience, University of Barcelona,
Barcelona, Spain (G.F., E.V.); IMPACT- The Institute for Mental and Physical Health and Clinical Translation, School of Medicine, Deakin
University, Geelong, Victoria, Australia (M.B., A.F.C.); Department of Psychiatry, University of Ottawa, Ontario, Canada (M.S.); The
Champlain First Episode Psychosis Program, Department of Mental Health, The Ottawa Hospital, Ontario, Canada (M.S.); Department of
Child and Adolescent Psychiatry, Charit(cid:3)e Universit€atsmedizin, Berlin, Germany (M.S.); Section of Psychiatry, Department of Neuroscience,
Reproductive Science and Odontostomatology, Federico II University of Naples, Naples, Italy (M.F.); Center of Excellence on Mood Disorders,
Faillace Department of Psychiatry and Behavioral Sciences, McGovern Medical School, The University of Texas Health Science Center at
Houston (UT Health), Houston, Texas (J.Q.); Experimental Therapeutics and Pathophysiology Branch, National Institute of Mental Health,
National Institutes of Health, Bethesda, Maryland (C.A.Z.); Copenhagen Affective Disorders Research Centre (CADIC), Psychiatric Center
Copenhagen, Rigshospitalet, Denmark (L.V.K.); and Department of Clinical Medicine, University of Copenhagen, Denmark (L.V.K.)

Abstract . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 324
Signiﬁcance Statement . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 324
I. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 325
II. Clinical Use in Mood Disorders . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 325
A. Acute Mania . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 326
B. Acute Depression . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 326
C. Maintenance and Prophylaxis of Mood Episodes in Bipolar Disorder
. . . . . . . . . . . . . . . . . . . . 326
D. Antisuicidal Effect
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 327
E. Neuroprotective and Neurotrophic Effects of Lithium . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 327
III. Mechanism of action . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 328

A.

Inositol Monophosphatase, Posphoglucomutase, and Glycogen Synthase Kinase-3
Inhibition . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 328
B. Protein Kinase C and Myristoylated Alanine-Rich C Kinase Substrate Inhibition . . . . . . . . 331
C. Enhancement of Trophic Factors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 332
D. Factors Affecting Apoptotic Signaling . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 333
Intracellular Signaling Cascades
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 333
E.
1. PI3K/Akt Pathway . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 333
2. MEK/ERK Pathway . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 334
3. Wnt/b-Catenin Pathway . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 334
4. Calcium/Calmodulin-Dependent Protein Kinase II/CREB Pathway and Calcium Channels . 334
F. Oxidative Stress Pathways and Mitochondrial Dysfunction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 335
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 336
G. Protein Quality Control Mechanisms

Address correspondence to: Dr. Andre F. Carvalho, Deakin University, P.O. Box 281, Geelong, Victoria, Australia 3220. E-mail:

andrefc7@hotmail.com

This work was supported by Grant PID2019-105136RB-100 funded by MCIN/AEI/10.13039/501100011033 and by “ERDF A way of making
Europe” (to A.B.). M.B. is supported by a NHMRC Senior Principal Research Fellowship and Leadership 3 Investigator Grant (1156072 and
2017131). G.F.’s work is supported by a fellowship from “La Caixa” Foundation (ID 100010434 - fellowship code LCF/BQ/DR21/11880019).

E.V. has received grants and served as consultant, advisor, or CME speaker for the following entities: AB-Biotics, AbbVie, Angelini, Biogen,
Biohaven, Boehringer-Ingelheim, Celon Pharma, Compass, Dainippon Sumitomo Pharma, Ethypharm, Ferrer, Gedeon Richter, GH Research,
Glaxo-Smith Kline, Idorsia, Janssen, Lundbeck, Medincell, Novartis, Orion Corporation, Organon, Otsuka, Rovi, Sage, Sanoﬁ-Aventis, Sunovion,
Takeda, and Viatris outside the submitted work. G.F. has received CME-related honoraria or consulting fees from Angelini, Janssen-Cilag, and
Lundbeck, Abbot. A.B. has received grants and served as a consultant for miCure Therapeutics. The other authors do not have an actual or
perceived conﬂict of interest with the contents of this article.

1A.B. and G.F. contributed equally to this work as ﬁrst authors.
2E.V. and A.F.C. contributed equally to this work as senior authors.
dx.doi.org/10.1124/pharmrev.120.000007.

323

324

Bortolozzi et al.

H.

1. Ubiquitin-Proteasome System and Autophagy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 336
2. Endoplasmic Reticulum Stress and Unfolded Protein Response Pathway . . . . . . . . . . . . . . . . . 336
Immunomodulatory Role of Lithium . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 337
IV. Ketamine, Lithium, and the Targeting of Homeostatic Synaptic Plasticity . . . . . . . . . . . . . . . . . . . 337
V. Biology of Lithium’s Response . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 339
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 340
VI. Lithium-Modiﬁed microRNA Pathways
VII. Repurposing Lithium for Brain Disorders Beyond Bipolar Disorder . . . . . . . . . . . . . . . . . . . . . . . . . . 342
A. Parkinson Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 342
B. Huntington Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 343
C. Alzheimer Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 343
D. Amyotrophic Lateral Sclerosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 344
E. Traumatic Brain Injury . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 344
F. Stroke . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 345
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 346
A. Renal Funcion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 346
B. Thyroid and Parathyroyd Function . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 346
C. Lithium and Pregnancy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 346
D. Metabolic Effects
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 346
E. Skin and Hair Disorders . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 347
F. Cognitive Effects . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 347
G. Toxicity in Overdose . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 347
IX. Conclusions and Future Directions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 347
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 348

VIII. Limitations for Lithium Treatment

Abstract——Over the last six decades, lithium has
been considered the gold standard treatment for the
long-term management of bipolar disorder due to its efﬁ-
cacy in preventing both manic and depressive episodes
as well as suicidal behaviors. Nevertheless, despite nu-
merous observed effects on various cellular pathways
and biologic systems, the precise mechanism through
which lithium stabilizes mood remains elusive. Further-
more, there is recent support for the therapeutic poten-
tial of lithium in other brain diseases. This review offers
a comprehensive examination of contemporary under-
standing and predominant theories concerning the
diverse mechanisms underlying lithium’s effects. These
ﬁndings are based on investigations utilizing cellular
and animal models of neurodegenerative and psychiatric
disorders. Recent studies have provided additional sup-
port for the signiﬁcance of glycogen synthase kinase-3
(GSK3) inhibition as a crucial mechanism. Furthermore,
research has shed more light on the interconnections
between GSK3-mediated neuroprotective, antioxidant,
and neuroplasticity processes. Moreover, recent advance-
ments in animal and human models have provided valu-

able insights into how lithium-induced modiﬁcations at
the homeostatic synaptic plasticity level may play a piv-
otal role in its clinical effectiveness. We focused on ﬁnd-
ings from translational studies suggesting that lithium
may interface with microRNA expression. Finally, we are
exploring the repurposing potential of lithium beyond bi-
polar disorder. These recent ﬁndings on the therapeutic
mechanisms of lithium have provided important clues to-
ward developing predictive models of response to lithium
treatment and identifying new biologic targets.

Signiﬁcance Statement——Lithium is the drug of
choice for the treatment of bipolar disorder, but its mech-
anism of action in stabilizing mood remains elusive. This
review presents the latest evidence on lithium’s various
mechanisms of action. Recent evidence has strengthened
glycogen synthase kinase-3 (GSK3) inhibition, changes at
the level of homeostatic synaptic plasticity, and regula-
tion of microRNA expression as key mechanisms, provid-
ing an intriguing perspective that may help bridge the
mechanistic gap between molecular functions and its
clinical efﬁcacy as a mood stabilizer.

ABBREVIATIONS: AD, Alzheimer disease; Akt, serine/threonine kinase; ALS, amyotrophic lateral sclerosis; AMPAR, a-amino-3-hydroxy-
5-methyl-4-isoxazolepropionic acid receptor; Ab, b-amyloid; Bcl-2, B-cell lymphoma 2; BD, bipolar disorder; BDNF, brain-derived neurotrophic
factor; CaMKII, calcium/calmodulin-dependent protein kinase II; cAMP, cyclic adenosine monophosphate; CREB, cAMP response element
binding protein; ER, endoplasmic reticulum; ERK, extracellular signal-regulated kinase; FDA, Food and Drug Administration; GDNF, glial
cell line–derived neurotrophic factor; GSK3, glycogen synthase kinase-3; GWAS, genome-wide association studies; HD, Huntington disease;
I-2, protein phosphatase-1/inhibitor-2 complex; IGF,
inositol monophosphatase;
IP3, inositol 1, 45-triphosphate; ISPC, induced pluripotent stem cell; MDD, major depressive disorder; miRNA, microRNA; mTOR,
mammalian target of rapamycin; NCS-1, neuronal calcium sensor protein 1; NF-jB, nuclear factor j-light-chain-enhancer of activated
B cells; NMDAR, N-methyl-D-aspartate receptor; PD, Parkinson disease; PGM, posphoglucomutase; PI3K, phosphatidylinositol
3-kinase; PKC, protein kinase C; PP1, protein phosphatase 1; PRS, polygenic risk score; SNP, single nucleotide polymorphism; STAT,
signal transducer and activator of transcription; TBI, traumatic brain injury; TLR4, Toll-like receptor 4; TrkB, tropomyosin receptor kinase B;
UPR, unfolded protein response.

insulin-like growth factor; IL,

interleukin; IMPase,

Potential Therapeutic Effects of Lithium

325

I. Introduction

Lithium is an element of the alkali-metal group with
an atomic weight of 6.94 (de Laeter et al., 2003). Lithium
salts, which include lithium cation, lithium citrate,
lithium carbonate, and lithium sulfate, possess mood-
stabilizing properties and have been used for the treat-
ment of manic-depressive illness ever since John Cade’s
discovery in the mid-20th century (Shorter, 2009).
Lithium was ofﬁcially approved to treat acute manic
episodes by the US Food and Drug Administration
(FDA) in 1970 and affective recurrences in 1974 af-
ter more than 30 years of recollected clinical evidence
on its efﬁcacy (Cade, 1949; Gershon, 1970; Davis and
Fann, 1971). However, its pharmaceutical promotion was
initially discouraged due to its low price and unpatent-
ability, along with the potential for serious adverse effects
(McKnight et al., 2012; Rybakowski et al., 2022) that lim-
ited lithium’s commercial appeal and uptake. Despite its
demonstrated clinical efﬁcacy, lithium’s use has witnessed
a considerable decline in recent years (Rhee et al., 2020;
Carvalho et al., 2021; Bauer, 2022), concurrently with the
discovery and marketing of second-generation anti-
psychotics for the treatment of bipolar disorder (BD)
(Yatham, 2005), that proved equal efﬁcacy in the
management of acute manic episodes (Segal et al.,
1998; Berk et al., 1999).

The FDA-labeled indications of lithium are limited to
the maintenance treatment of BD as well as the treat-
ment of acute manic episodes in BD; however, its use is
not limited to these conditions. Lithium is mainly used
for the prophylaxis of recurrence and in the acute treat-
ment of manic, hypomanic, and depressive episodes in
patients with BD (Carvalho et al., 2014; Malhi et al.,
2015; Fountoulakis et al., 2017; Verdolini et al., 2021;
Nestsiarovich et al., 2022), although its efﬁcacy may be
greater preventing mania than depression when consider-
ing its polarity index (Popovic et al., 2012; Carvalho et al.,
2014; Vieta et al., 2018). Lithium is additionally employed
as an adjunctive treatment, augmenting the effect of anti-
depressants in individuals diagnosed with major depressive
disorder (MDD) (Undurraga et al., 2019). Evidence from
many observational studies and randomized controlled tri-
als also supports the antisuicidal effect of lithium (Cipriani
et al., 2013). Because of its narrow therapeutic index (ap-
proximately 2), regular plasma monitoring of lithium
concentration is essential. It should be administered
to reach a concentration of 0.5–1 mEq/L 10–14 hours
after the last administration (Malhi et al., 2020). Many
patients with BD show an excellent response to lith-
ium; however, the response may vary among patients
(Kessing et al., 2011; Fornaro et al., 2016a; Hui
et al., 2019; Lin et al., 2021; Stone et al., 2021).

Even though lithium is commonly employed in clini-
cal practice and is acknowledged for its effectiveness in
treating BD, the mechanism through which it produces
its effects remains largely unclear. The intricate impacts

of lithium can be investigated across various levels,
encompassing cellular and intracellular neuronal alter-
ations, neural networks, and neurocognition. As a
result, the clinical response to this treatment may
vary, leading to a heterogeneous outcome (Ikonomov
and Manji, 1999; Pasquali et al., 2010; Freland and
Beaulieu, 2012; Forlenza et al., 2014; Akkouh et al.,
2020; Puglisi-Allegra et al., 2021). The etiology of BD
remains incompletely understood, thought to arise from
an intricate interplay of elements that involve abnormal-
ities in neuroanatomical structure and function, dis-
rupted signaling pathways and gene expression,
impaired synaptic plasticity, and decreased brain cell
density (Carvalho et al., 2020). Additionally, lithium’s
neurotrophic effects have been suggested to potentially
mitigate some of these impairments (Puglisi-Allegra
et al., 2021). Recent advances in genetics and bioinfor-
matics illuminate lithium’s pharmacology and have
renewed the interest in its mechanism (Hou et al., 2016;
Cearns et al., 2022), together with a rediscovery of lith-
ium in clinical practice (Anmella et al., 2021).

This review will delve into the contemporary under-
standing and recent advancements concerning lith-
ium’s biologic functions and its roles in various brain
disorders. To be precise, we start with a perspective
on the clinical use of lithium in mood disorders. Next,
we discuss its molecular mechanisms and physiologic
roles in cellular processes, broadening the perspective
on new potential biologic underpinnings related to dif-
ferent clinical uses of lithium. Moreover, we present
limitations to the use of lithium through the explica-
tion of mechanisms implied in its toxicity, and we con-
clude our review with new perspectives and future
directions in lithium treatment and research.

II. Clinical Use in Mood Disorders

BD is a severe psychiatric disorder characterized by
recurring mood episodes of depression alternating with
episodes of euphoria (called manic/hypomanic episodes),
affecting approximately 2% of the general population
(Vieta et al., 2018). Despite the pharmacological guide-
lines for treatment being well established, most indi-
viduals still experience high rates of mood recurrences
or signiﬁcant residual symptoms while on medication
(Perlis et al., 2006). Lithium is considered a gold stan-
dard in treating all phases of BD, and it is recommended
in all different international treatment guidelines
(Fountoulakis et al., 2017; Malhi et al., 2020; Yatham
et al., 2018). The targeted lithium level, also known as
the therapeutic range, is the desired concentration of
lithium in the blood to achieve optimal treatment out-
comes in individuals with BD. The speciﬁc targeted lith-
ium levels can vary among countries and guidelines.
For example, the American Psychiatric Association
(Hirschfeld et al., 2003) or the Canadian Network for
Mood and Anxiety Treatments and International

326

Bortolozzi et al.

Society for Bipolar Disorders guidelines (Yatham
et al., 2018) recommend a range of 0.8–1.2 mEq/L for
acute mania and 0.6–1.0 mEq/L for maintenance treat-
ment. Similarly, the National Institute for Health and
Care Excellence [National Collaborating Centre for
Mental Health (UK), 2014] in the United Kingdom
suggests a range of 0.8–1.0 mEq/L for acute mania and
0.4–1.0 mEq/L for maintenance treatment. Monitoring
lithium levels and adhering to the recommended
ranges are essential to ensure the effectiveness of
treatment and minimize the risk of side effects. Sev-
eral guidelines also recommend the use of lithium for
treating patients with MDD or individuals with a
high risk of suicidality (Kennedy et al., 2016). In ad-
dition to its effectiveness in managing and preventing
mood disorder symptoms, there is a belief that lith-
ium has the potential to induce neurotrophic and
neuroprotective effects across a diverse array of cellular
pathways. Moreover, it may impact brain circuits associ-
ated with behavioral, cognitive, and motor-related func-
tions (Puglisi-Allegra et al., 2021). Indeed, it has been
recently reported that lithium might exert neuroprotec-
tion in stroke (Chen et al., 2022b), neurodegenerative
diseases such as dementia (Forlenza et al., 2014; Morris
and Berk, 2016; Velosa et al., 2020), spinal cord injury
(Yang et al., 2012), and other diseases involving the ner-
vous system, including BD (Bauer et al., 2003). Indeed,
the number of lifetime affective episodes in BD might
result in biologic insult, ultimately worsening the
course of the illness, which is conceptualized as
“neuroprogression.” For these reasons, lithium’s clinical
use and neuroprotective effect should be seen as inter-
twined entities since lithium might prevent neuroprog-
ression, and advanced neuroprogression might impact
lithium’s clinical response in BD (Bauer et al., 2017).

A. Acute Mania

A manic episode is marked by elevated or irritable
mood, increased energy levels, reduced need for sleep,
and diminished attention span, among other symptoms
that may include aggressive behavior and impulsiveness.
Lithium is one of the indicated ﬁrst-line treatments for
acute mania. It has proven to be more effective than
placebo and equal to other mood stabilizers or antipsy-
chotics in several studies (Cipriani et al., 2011; Hayes
et al., 2016; Bohlken et al., 2021). In addition, a recent
meta-analysis including 36 randomized controlled trials
showed that lithium was more effective than placebo at
inducing response (odds ratio, 2.13; 95% CI, 1.73–2.63)
or remission (odds ratio, 2.16; 95% CI, 1.73–2.69) in
acute mania (McKnight et al., 2019). However, it is often
administered as a combination therapy with atypical
antipsychotics, (e.g., olanzapine, aripiprazole, cariprazine,
and asenapine, among others) (Conus et al., 2015;
Kishi et al., 2022) to treat concomitant acute agita-
tion or aggressive behavior during manic states

(Chengappa et al., 2004; de Bartolomeis and Perugi, 2012;
Grande and Vieta, 2015, Kishi et al., 2022). Response
to lithium appears to be better in patients with classic
(euphoric) mania, whereas response rates are relatively
worse in mixed states (Swann et al., 1997; Sportiche
et al., 2017; Grunze et al., 2018) or rapid cycling
(Calabrese et al., 2005). Lithium is primarily used in
concentrations in the range of 0.8–1.2 mmol/L during
acute mania (Yatham et al., 2018).

B. Acute Depression

Despite the high rates of patients with BD experienc-
ing multiple depressive episodes during their life, with
a signiﬁcant impact on global functioning (Manning,
2005; Undurraga et al., 2012), few pharmacological op-
tions exist to treat acute depressive episodes (Nivoli
et al., 2011; Vieta and Valenti, 2013; Correia-Melo et al.,
2017). Lithium is not approved for treating depressive
episodes for bipolar type I or type II patients since evi-
dence of its efﬁcacy on acute depressive episodes in
monotherapy is less robust than that in acute manic
episodes (Manchia et al., 2019; Rakofsky et al., 2022).
Indeed, a recent meta-analysis showed no statistically
signiﬁcant differences between lithium versus antide-
pressants or placebo in patients with bipolar depression
(Rakofsky et al., 2022). It should be noted that lithium
might be the most studied drug in BD. Still, its effect on
acute bipolar depression remains underexplored, with
most studies having several methodological limitations
(Fountoulakis et al., 2022). Nevertheless, the use of lithium
for the treatment of acute bipolar depressive episodes is
every day and is also supported by clinical guidelines for
its antisuicidal properties and prophylactic effect against
affective recurrences, especially in combination with other
agents (Malhi et al., 2020).

Despite not being the ﬁrst-line option, lithium is
also prescribed to treat acute depression in patients
with MDD, often as adjunctive treatment to conven-
tional antidepressants (Undurraga et al., 2019). Lithium
monotherapy did not show superiority over citalopram
in unipolar depressed patients (Bschor et al., 2013) and
is not an established treatment of acute major depres-
sion. Two studies showed that lithium is superior to
antidepressants (Bauer et al., 2000) or electroconvul-
sive therapy (Lambrichts et al., 2021) in preventing
relapses in MDD, but these results should be replicated
in larger samples. Lithium’s role as an augmentation of
antidepressants in treatment-resistant major depressive
episodes is well clinically established and proven in sev-
eral clinical trials (Dold et al., 2018; V(cid:3)azquez et al., 2021).

C. Maintenance and Prophylaxis of Mood Episodes in
Bipolar Disorder

The maintenance treatment of BD represents a major
clinical challenge since the lifetime recurrence rate of

Potential Therapeutic Effects of Lithium

327

affective episodes of both polarities is 95%, with a major
impact on long-term disability and quality of life (Perlis
et al., 2006; V(cid:3)azquez et al., 2015; Etain et al., 2021).
Noteworthy, people with BD experience depression
more frequently than they experience mania or hypo-
mania (Kupka et al., 2007). This may encourage the
use of lithium in real-world clinical practice beyond
the sole FDA approval, also aiming at reducing the
odds of polypharmacy in BD (Fornaro et al., 2016b).
Lithium continues to be the preferred choice for
maintenance treatment in both types I and II of BD
(Hayes et al., 2016; Kessing, 2019). A network meta-
analysis comparing the efﬁcacy and tolerability of
various pharmacological treatments for bipolar dis-
order maintenance therapy demonstrated that lith-
ium was more effective than a placebo in preventing
mood relapses (Kishi et al., 2021). Furthermore, in a
multicenter, randomized, open-label trial involving
individuals with BD type I, it was found that both
combination therapy with lithium and valproate, as
well as lithium monotherapy, were more effective at
preventing relapses compared with valproate mono-
therapy (Geddes et al., 2010). In general, combina-
tion therapy with lithium proved superior to mood-
stabilizer monotherapy in preventing recurrence of
any type for up to 12 months (Kishi et al., 2021).

Among other mood stabilizers, lithium also demon-
strated a higher preventive effect for manic episodes
compared with depressive episodes (Nestsiarovich et al.,
2022). In the long-term treatment of BD, target serum
levels should generally be around 0.6–1 mmol/L to reach
optimal clinical efﬁcacy. There has been a recent proposal
suggesting a dose-response relationship in which higher
serum lithium levels are associated with a reduced risk
of recurrence (Hsu et al., 2022).

D. Antisuicidal Effect

Lithium has been associated with reduced suicide risk
in individuals with BD or MDD as well as in the general
population in diverse observational and randomized clin-
ical trials (Cipriani et al., 2013). The reduction of suicide
risk is up to 60% after long-term lithium treatment. A
rebound effect with increased rates of suicide with lith-
ium discontinuation or in patients with poor treatment
adherence has also been reported (Gonzalez-Pinto et al.,
2006). Lithium concentrations in drinking water might
also inﬂuence suicide risk, although the evidence is con-
troversial (Del Matto et al., 2020; Rybakowski, 2022). In
the Systematic Treatment Enhancement Program for
Bipolar Disorder study, the presence of suicidal ideation
was found to be similar among patients with BD receiv-
ing lithium treatment and those not receiving it
(Goldberg and Chengappa, 2009). Moreover, the study
revealed no signiﬁcant relationship between lithium
use and suicide attempts or completions as well as
for other mood-stabilizing medications (Marangell
et al., 2008). Interestingly, one recent randomized clinical

trial reported no signiﬁcant difference between lithium
and placebo in preventing suicide among veterans
(Katz et al., 2022). However, this study reported off-
therapeutic ranges of lithium levels (between 0.54 and
0.46 mmol/L) and had other critical methodological limi-
tations (Manchia et al., 2022). Contrasting results about
the antisuicidal effect of lithium have been reported re-
cently (Nabi et al., 2022), but the reasons for the discrep-
ancy between these ﬁndings and previous meta-analyses
may depend on the seemingly arbitrary inclusion and
exclusion of randomized controlled trials and an un-
satisfactory reinterpretation of data compared with the
original publications (Bschor et al. 2022). The putative
mechanism by which lithium exerts its antisuicidal ef-
fect is mainly attributed to the mood-stabilizing proprie-
ties in patients with mood disorders but also to some of
its intrinsic characteristics in reducing impulsive or
aggressive behavior (M€uller-Oerlinghausen and Lew-
itzka, 2010).

E. Neuroprotective and Neurotrophic Effects of Lithium

Extensive evidence shows that lithium exerts a neu-
roprotective effect through several biologic mechanisms.
These include the reduction of oxidative stress and
inﬂammation, up-regulation of mitochondrial function,
and activation of neurotrophic response (Diniz, et al.,
2013; Rybakowski et al., 2018). BD is a chronic disease
characterized by recurrent affective episodes associ-
ated with related structural, functional, and the afore-
mentioned neurochemical brain changes in an illness-
related process conceptualized as “neuroprogression”
(Berk, 2009). The biologic underpinnings of BD neuro-
progression are thought to include different pathways,
encompassing regulation of neurogenesis and apopto-
sis to inﬂammation and redox stress-related pathways
and epigenetic modiﬁcations (Berk, 2009). The changes
affecting brain structure and function differ from those
observed at the onset of the disease and become more
evident with illness’ chronicity, which is linked to a
high number of depressive or manic episodes. Indeed,
the neuroprogression construct suggests that each
mood episode might cause a biologic insult and conse-
quent neural damage, therefore increasing brain vulner-
ability to developing future illness episodes (Berk, 2009).
Neuroprogression inﬂuences the prognosis of BD,
linked to a poorer response to treatment, including
lithium (Fico et al., 2021), atypical antipsychotics (Berk
et al., 2011) and psychotherapy, cognitive and functional
decline, and a higher tendency to relapse (Bauer et al.,
2017). However, neuroprogression is probably only evi-
dent in a subgroup of patients with BD (Martino et al.,
2017). Because of the progressive nature of BD, it is
essential to commence disease-modifying treatments
as early as possible. Lithium has been shown to prevent
structural and cognitive change after the ﬁrst episode of
mania (Berk et al., 2017; Daglas et al., 2017). Indeed,
good lithium responders also seem to show lower levels

328

Bortolozzi et al.

of deterioration during follow-up (Bergh€ofer et al., 2013).
Thus, lithium’s unique neuroprotective proprieties might
be key in targeting neurobiological alterations during neu-
roprogression in BD (Rybakowski and Suwalska, 2010;
Squassina et al., 2017; Vecchio et al., 2020) as well as in
other neurodegenerative diseases (Forlenza et al., 2014).
Lithium’s neuroprotective effect may be reﬂected in in-
creased cerebral gray matter in healthy subjects and pa-
tients with BD (Moore et al., 2000; Berk et al., 2017; Hozer
et al., 2021). Also, lithium might ameliorate cellular signal
transduction pathways, mood regulation, and neurocogni-
tive function in BD (Puglisi-Allegra et al., 2021). Whether
the proposed preventive effects of lithium are exerted
on the systems mentioned above to prevent changes
and, thus, cognitive decline in BD is unknown to date.
A better understanding of lithium’s impact on neu-
roprogression and its underlying biologic pathways
affecting mood regulation and neurocognitive func-
tions might help to disentangle the etiology of BD.

III. Mechanism of action

A. Inositol Monophosphatase, Posphoglucomutase,
and Glycogen Synthase Kinase-3 Inhibition

The therapeutic and mood-stabilizing effects of lithium
are thought to involve neurotrophic and neuroprotective

mechanisms (Malhi et al., 2013; Malhi and Outhred,
2016; Won and Kim, 2017). Lithium is pleiotropic, and it
regulates a variety of proteins/cellular regulatory path-
ways impacting different structural and functional levels
of the brain, from molecular and cellular elements to
synaptic plasticity, neurotransmission, and brain circuits.
Hence, it is unclear if the agent has a single mechanism
of action or works through a combination of synergistic
mechanisms (Fig. 1) (Alda, 2015; Anand et al., 2020;
Kavalali and Monteggia, 2020, Haggarty et al., 2021;
Ochoa, 2022).

Earlier studies have highlighted the primary criteria
for conﬁrming the direct molecular targets of lithium,
which include 1) the inhibition of the target protein’s
activity at lithium concentrations that are therapeuti-
cally signiﬁcant (0.62–1.2 mM) both in vitro and in vivo
procedures, 2) comparable outcomes by employing inhib-
itors of the suggested target that are chemically distinct
from lithium, 3) that the mimicking of lithium’s effect is
achieved by impairing the function of the proposed tar-
get gene, and 4) restoring of target function or a down-
stream effector that revers the effect of lithium (Phiel
and Klein, 2001; O’Brien et al., 2011).

Speciﬁc lithium targets have been identiﬁed, including
enzymes such as inositol monophosphatase (IMPase) and
magnesium-dependent phosphomonoesterases, which are

Fig. 1. Lithium (Li1) modulates a number
of cellular pathways in the brain involved
in neuroplasticity and neuroprotection. In-
hibition of GSK3 is clearly central to its
therapeutic mechanisms. Recent research
has elucidated the direct and indirect effects
of lithium on neurotrophic response, ER
stress, UPR, autophagy, oxidative stress,
inﬂammation, and mitochondrial function,
mechanisms modulated by lithium that
facilitate cell viability. Lithium elicits ho-
meostatic synaptic plasticity that is de-
pendent on AMPAR expression on the cell
surface and requires BDNF/TrkB signal-
ing. Structural imaging studies indicate
that lithium may lead to neuroprotection
by increasing gray matter volumes in the
amygdala, hippocampus, and prefrontal
cortex. Conversely, ﬁndings from neuro-
psychological and functional magnetic
resonance imaging studies suggest that
the overall inﬂuence of lithium on cogni-
tion leans toward potential cognitive im-
pairment. Different biologic pathways
might be targeted during affective epi-
sodes: neurotransmitter modulation, in-
hibition of GSK-3 and dopamine regulation
in mania, enhancement of neuroplasticity
and neurotransmitter modulation in depres-
sion and cAMP signaling, and glutamate
and GABA regulation during maintenance
phases. MARCKS, myristoylated alanine-
rich C kinase substrate.

Potential Therapeutic Effects of Lithium

329

structurally related (Hallcher and Sherman, 1980).
These enzymes, which encompass inositol polyphos-
phate 1-phosphatase (IPPase), fructose 1,6-bisphos-
phatase (FBPase), and bisphosphate 30-nucleotidases
(BPntase), possess a shared metal ion-binding consen-
sus sequence. Additionally, phosphoglucomutase (PGM),
responsible for converting glucose-1-phosphate (G1P) to
glucose-6-phosphate (G6P), requires magnesium and is
directly inhibited by lithium (York et al., 1995, 2001;
Phiel and Klein, 2001). Additionally, lithium directly
inhibits glycogen synthase kinase-3 (GSK3), a crucial
enzyme in glycogen metabolism that is now known to
regulate various cell functions (Klein and Melton, 1996;
Cohen and Frame, 2001; Beurel et al., 2015).

Despite their structural differences, all three classes
of lithium targets—IMPase, PGM, and GSK3—rely on
magnesium for their function. In each instance, lithium
competes to occupy a magnesium-binding site (Snitow
et al., 2021). It is noteworthy that the identiﬁed primary
targets of lithium are intricately linked to the regulation
of glucose metabolism or the control of phosphoglucose
levels. Speciﬁcally, PGM catalyzes the isomerization of
G6P to G1P, IMPase plays a crucial role in gluconeogene-
sis, and GSK3 acts to inhibit the incorporation of glucose
into glycogen.

Indeed, the risk of type 2 diabetes is up to 3 times
higher in patients with BD than in healthy controls of
similar age and sex. Over half of BD patients have im-
paired glucose metabolism, including insulin resistance,
impaired glucose tolerance, or type 2 diabetes (Calkin
et al., 2015; Vancampfort et al., 2016; Gim(cid:3)enez-Palomo
et al., 2022). Interestingly, improvement in insulin resis-
tance with metformin is associated with improved symp-
toms of BD (Calkin et al., 2022). Furthermore, lithium
treatment also affects downstream effectors, including
adenylate cyclase, the phosphoinositol cascade, and the
metabolism of arachidonic acid. (Gould et al., 2004;
Quiroz et al., 2004; Rao and Rapoport, 2009; Chiu et al.,
2013). Since lithium affects other magnesium-dependent
proteins, it has been estimated that there are >3000
human proteins whose function may be modiﬁed by
lithium treatment (Davies et al., 2000, Piovesan et al.,
2012; Puglisi-Allegra et al., 2021). Lithium’s capacity to
interact with a wide range of molecules grants it signiﬁ-
cant potency as a pharmacological tool and makes it a
valuable asset in both clinical and preclinical research
(Fig. 2).

GSK3 is a serine/threonine protein kinase (PK) with
two isoforms, GSK3a and GSK3b. Although both iso-
forms are expressed at comparable levels in the mouse
brain (Yao et al., 2002), in the human brain, the b iso-
zyme predominates (Lau et al., 1999), highlighting its
critical role in the functioning of the human central ner-
vous system. Furthermore, GSK3 plays a pivotal role in
numerous cellular processes and diseases (Harwood,
2001; Jope and Johnson, 2004; Beurel et al., 2015).

Several mechanisms are involved in the control of GSK3
actions, including phosphorylation, protein complex for-
mation, and subcellular distribution. In addition, GSK3
has many unique properties, such as constitutive activity
in cells and inhibition by extracellular stimuli, unlike
other kinases, that are usually activated by extracellu-
lar stimuli. Phosphorylation on a serine residue of N-
terminal GSK3 (serine 21 in GSK3a and serine 9 in
GSK3b) leads to activity inhibition of GSK3. There are
several protein kinases, including serine/threonine
kinase (Akt; previously known as protein kinase B),
protein kinase A, and protein kinase C (PKC), known to
phosphorylate GSK3 to inhibit its function (Fang et al.,
2000). GSK3 activity is also negatively regulated through
growth factor stimulation of mitogen-activated protein
kinases (MAPKs) and mammalian target of rapamycin
(mTOR) (Doble and Woodgett, 2003; Kirshenboim et al.,
2004).

GSK3 maintains cellular homeostasis by interact-
ing with numerous substrates, such as transcription
factors, glycolytic enzymes, pro- and antiapoptotic
factors, mitochondrial channels, membrane receptors,
and cytoskeleton-associated proteins (Duda et al., 2018).
The dysregulation of GSK3 is associated with numerous
prevalent and frequently comorbid diseases, such as
diabetes and/or insulin resistance, Alzheimer disease
(AD), Parkinson disease (PD), schizophrenia, MDD and
BD, among others (Jope and Johnson, 2004; Beurel
et al., 2015). Studies in human post mortem brain and
peripheral cells have identiﬁed correlations between
alterations in GSK3 function and mood regulation,
suggesting that depression may be associated with
impaired inhibitory control of GSK3, and mania with
GSK3 hyperactivity (Karege et al., 2007; Diniz et al.,
2011; Jope, 2011; Iwahashi et al., 2014).

Consequently, a decline in serine phosphorylation of
GSK3 was observed in peripheral blood mononuclear
cells during the disease state, and its levels were found
to rise following lithium therapy (Li et al., 2010). Addi-
tionally, recent evidence indicates that BD exhibits a bi-
modal pattern of energy, with enhanced energy levels
during manic episodes and decreased energy levels dur-
ing depressive episodes. Notably, individuals experienc-
ing mania demonstrate heightened mitochondrial
respiration and ATP production as opposed to individu-
als during euthymia or depression, who display dimin-
ished mitochondrial function (Morris et al., 2017).

The notion that GSK3 represents the therapeutic
target of lithium is reinforced by preclinical research
involving genetic modiﬁcations of GSK3 or its down-
stream components. Downregulation of GSK3b mimics
the effects of lithium on behavior in mice, whereas
GSK3b overexpression reverts the lithium-induced
neurobehavioral effects in mice (O’Brien et al., 2004,
2011), indicating that GSK3 is a critical target of lith-
ium in mammalian behaviors. Moreover, in b-arrestin

330

Bortolozzi et al.

Fig. 2. Representative scheme of the main molecular and cellular targets modulated directly and indirectly by lithium (Li1). Lithium inhibits IMPase
(A), including inositol polyphosphate 1-phosphatase (IPPase), fructose 1,6-bisphosphatase (FBPase), and bisphosphate nucleotidases (BPntase). These enzymes
are part of the phosphatidylinositol 4,5-bisphosphate (PIP2) cycle, one of the signaling pathways underlying many cellular functions, such as G-coupled neuro-
transmitter receptors (GPCR) signaling, cytokinesis, endocytosis, and apoptosis. Phospholipase C (PLC) mediates the hydrolysis of PIP2 to the secondary mes-
sengers diacylglycerol (DAG) and IP3, which, in turn, activate downstream signaling pathways, including PKC and IP3 receptor (IP3R)/ER stress/ UPR.
Therefore, lithium inhibits ER stress (ERS), altered UPR signaling, and increased intracellular Ca21 levels through depletion of free inositol (B) and subsequent
lower IP3 levels and IP3R activation (C). ERS and abnormal UPR result in the buildup of misfolded or unfolded proteins, faulty autophagy, and cell death via
apoptosis. Lithium acts to counter these effects through the IP3/IP3R mechanism (C). Lithium directly inhibits GSK3 and facilitates the phosphorylation of
GSK3 at the N-terminal serine (D). Lithium also acts by inhibiting PKC (D) through an intricate myristoylated alanine-rich C kinase substrate (MARCKS)
pathway initiated by its inhibition of GSK3 (D). Inhibition of PKC and GSK3 by lithium prevents the potentially harmful effects of downstream activation of these
pathways. These include 1) oxidative stress pathway (E) due to accumulation of reactive oxygen species (ROS) scavenged from damaged mitochondria and downre-
gulation of the transcriptional nuclear factor (erythroid-derived 2)-like 2 (Nrf2); 2) impaired transcription of neurotrophic, neuroprotective, and antioxidant genes
(F), such as BDNF, vascular endothelial growth neurotrophic (VEGF), IGF, Bcl-2, and Nrf2, which is reversed by lithium through inhibition of GSK3 (D) and acti-
vation of the CREB transcription factor placed downstream of GPCRs (F); 3) activation of the inﬂammasome, production of proinﬂammatory cytokines underlying
activation of the STAT/interferon-c (INFc)/NF-kB pathway (G); and 4) accumulation of hyperphosphorylated s, which is concurrent to cytoskeletal altera-
tions and autophagy impairment (H). The anti-inﬂammatory effects of lithium are also produced by suppressing TLR4 signaling (G). Lithium also modi-
ﬁes the expression of miRNAs and their targeted mRNA, suggesting that they could play a role in modulating lithium’s clinical efﬁcacy (I). Modiﬁed from
Puglisi-Allegra et al. (2021). eIF2a, eukaryotic translation initiation factor 2a.

2 knockout mice, lithium administration fails to impact
Akt/GSK3 signaling but still induces behavioral changes
associated with GSK3 inhibition, resembling the effects
observed in wild-type mice. Correspondingly, speciﬁc
GSK3 inhibitory peptides reproduce the behavioral
outcomes of lithium in mice (Gould et al., 2004;
Kaidanovich-Beilin et al., 2004; Beaulieu et al.,
2004, 2008). Thus, lithium inhibits GSK3 signaling by
binding directly to the magnesium-sensitive site of the
enzyme and indirectly by increasing the phosphoryla-
tion of this kinase at speciﬁc serine21/9 residues.
Valproate, in addition to antidepressants (including
the rapid-acting antidepressant ketamine) and antipsy-
chotics, indirectly suppresses GSK3 activity through
the phosphorylation of serine21/9. This suggests a com-
mon mechanism involving GSK3 across these treat-
ments (Beurel et al., 2011; Zarate and Machado-Vieira,
2016; Snitow et al., 2021). Nevertheless, a recent study
using selective GSK3b inhibitors, such as AZ1080 and
compound A, showed that GSK3b inhibition alone
does not replicate the lithium-induced behavioral

and cellular effects in rats (Georgievska et al., 2013).
Additionally, GSK3b inhibition alone did not increase
brain-derived neurotrophic factor (BDNF) levels. In
contrast, lithium administration did (Caberlotto et al.,
2013), indicating that other mechanisms/pathways may
be involved in the therapeutic responses to lithium
(Fig. 2).

However, the mechanisms underlying GSK3 lithium-
induced inhibition and how it contributes to both anti-
manic and antidepressant effects remain uncertain.
Recent research suggests that mood stabilizers work
by blocking GSK3, which, in turn, makes cells more
responsive to natural extracellular signals, like neuro-
trophins and neurotransmitters. These signals typically
activate Akt, leading to the phosphorylation and deacti-
vation of GSK3 inactivation (Puglisi-Allegra et al., 2021;
Snitow et al., 2021) (Fig. 3). However, GSK3 opposes its
phosphorylation through two mechanisms: one involving
the inhibition of Akt through a b-arrestin complex and
the other involving the activation of protein phosphatase
1 (PP1) by GSK3, which is inhibited by protein

Potential Therapeutic Effects of Lithium

331

[see Kleandrova and Speck-Planche (2020), Vignaux
et al. (2020), Zhu et al. (2020), and Reilley et al.
(2021) for more details].

B. Protein Kinase C and Myristoylated Alanine-Rich
C Kinase Substrate Inhibition

PKC is a family of enzymes involved in mood regu-
lation, relying on calcium and phospholipids for acti-
vation. The conventional PKC isoforms (a, bI, bII, c)
necessitate both calcium and diacylglycerol for activa-
tion, whereas the newer PKC isoforms (d, e, g, h, l)
can be activated solely by diacylglycerol (Zarate and
Manji, 2009). The conventional PKC isoforms are the
prevailing variants and are prominently present in mul-
tiple brain regions, with a notable presence at presyn-
aptic terminals, including those in the prefrontal cortex,
amygdala, and hippocampus (Naik et al., 2000; Zarate
and Manji, 2009). PKC signaling is involved in several
intracellular pathways regulating neuronal excitability,
neurotransmitter release, glutamate signaling, and neu-
roplasticity (Zarate et al., 2003, 2006a; Chu et al., 2014;
Pahl et al., 2014) and underlies many of the patho-
logic mechanisms, including neuroinﬂammation and
mitochondrial dysfunction related to oxidative stress
and apoptosis (Jun et al., 2014; Nam et al., 2015).

Accumulating evidence from both human and animal
studies strongly supports the substantial role played by
this enzyme group in BD. Inhibiting PKC has been
shown to effectively reduce manic-like behaviors and
mitigate hippocampal cell degeneration in rat models of
mania induced by sleep deprivation (Abrial et al., 2013).
Individuals with BD show increased PKC activity in
both central (cortical) and peripheral (platelet) regions
when compared with healthy controls (Wang and Fried-
man 1996; Wang et al., 1999). Finally, a meta-analysis
involving 8700 patients with unipolar and bipolar de-
pression has identiﬁed a signiﬁcant correlation between
PKCe genetic locus and suicidality (Saxena et al., 2017).
Furthermore, genomic investigations have established
correlations between speciﬁc loci and lithium respon-
siveness, indicating a potential shared genetic predis-
position for both the disease and the response to
treatment (Turecki et al., 2001; Khayachi et al., 2021).
In this context, research has shown that long-term
lithium treatment leads to a reduction in PKC levels
in the platelets of individuals with BD (Soares et al.,
2000). Additionally, both lithium and valproic acid have
shown the ability to inhibit PKC activity in vitro and
in vivo (Chen et al., 1994, 2000a; Zarate and Manji
2009), which has led to the study of PKC as a potential
therapeutic drug target.

Remarkably, the prolonged use of quercetin, which is
a nonspeciﬁc PKC inhibitor, has been observed to block
methylphenidate-induced hyperlocomotion and lipid per-
oxidation in mice (Kanazawa et al., 2017). Furthermore,
tamoxifen, another potent PKC inhibitor, has shown efﬁ-
cacy in the treatment of acute manic or mixed episodes

Fig. 3. Positive feedback mechanisms regulating GSK3. (A) GSK3 is phos-
phorylated and inhibited by AKT in response to upstream signals. PP1 de-
phosphorylates and activates GSK3. GSK-3 inhibits AKT and activates PP1,
thereby potentiating its activity. (B) Lithium, directly and indirectly, inhibits
GSK3 and disrupts both feedback loops. Disruption of these feedback loops
by lithium may leave an increased response of endogenous ligands (e.g., neu-
rotransmitters such as glutamate, dopamine, and serotonin) that signal
through AKT and whose synaptic levels are affected in BD. Modiﬁed from
Snitow et al. (2021).

phosphatase-1/inhibitor-2 complex (I-2). Deactivation of
Akt hinders the phosphorylation and suppression of
GSK3. Lithium and other GSK3 inhibitors interfere
with this process by disrupting the complex, enabling
Akt to stay active and continue phosphorylating GSK3
(Beaulieu et al., 2004; O’Brien et al., 2011). The phos-
phorylation of GSK3 at I-2 prompts its detachment
from PP1, which subsequently leads to the dephosphor-
ylation of GSK-3 and the restoration of its activity. Lith-
ium and other GSK3 inhibitors block the process by
which PP1 dephosphorylates GSK3 in an I-2–dependent
manner (Zhang et al., 2003; Freland and Beaulieu, 2012;
Snitow et al., 2021).

As a result, when GSK3 is pharmacologically inhib-
ited, it lowers the threshold for endogenous signals to
deactivate cellular GSK3 clusters. This means that
even relatively weak signals can generate a consistent
response due to the increased inhibition of GSK3. This
mechanism may explain how lithium sensitizes cells to
endogenous neurotransmitters or other signals that may
be diminished in BD, and it may account for the effec-
tiveness of lithium treatment as an adjunct to antide-
pressants in treatment-resistant depression (Snitow
et al., 2021).

Lithium shows efﬁcacy in treating both manic and de-
pressive episodes in BD and is a potential drug for neu-
rodegenerative diseases. Unfortunately, lithium suffers
from signiﬁcant drawbacks, mainly a narrow therapeutic
window and renal toxicity (Davis et al., 2018). Undoubtedly,
among the many molecular targets of lithium, GSK3b
may be in part responsible for its therapeutic effects,
so the development of selective inhibitors of this kinase
could inﬂuence the side effects of lithium. Although
beyond the scope of this review, in recent years, the
application of machine learning is accelerating the
discovery of potential drugs with GSK3b inhibitory
activity that can be repurposed as therapeutics for
mood disorders and/or neurodegenerative disorders

332

Bortolozzi et al.

in BD (Yildiz et al., 2008, 2016; Amrollahi et al., 2011;
Kulkarni et al., 2014; Talaei et al., 2016). It is worth
noting that despite its promising antimanic proper-
ties (Talaei et al., 2016; Palacios et al., 2019; Novick
et al., 2020), the FDA has not granted its approval
for the treatment of manic episodes. However, a new
PKC inhibitor called endoxifen has received approval
in India (Ahmad et al., 2021).

C. Enhancement of Trophic Factors

Putative mechanisms for the therapeutic effects of
lithium also include the upregulation of trophic factors
and activation of their receptors (Hashimoto et al.,
2004, Seelan et al., 2008; Gideons et al., 2017; Haupt
et al., 2021). In addition to being the ﬁrst choice in the
treatment of BD, recent reports point to lithium having
beneﬁcial effects on Alzheimer disease (Nelson et al.,
2014; Damri et al., 2020), and there are suggestions that
lithium may help individuals with PD (Guttuso et al.,
2019). At least part of the reason that lithium has bene-
ﬁts in these pathologic conditions is probably due to its
effects on BDNF levels.

BDNF, acting via the tropomyosin receptor kinase
B (TrkB) receptor to promote cortical development, syn-
aptic plasticity, neurogenesis, and neuronal viability, is
recognized for its signiﬁcant contribution to BD and
other psychiatric disorders (Fernandes et al., 2011; Autry
and Monteggia, 2012; Malhi et al., 2013; Scola and An-
dreazza, 2015; Rowland et al., 2018). Six separate meta-
analyses consistently demonstrated that in BD, BDNF
plasma levels were signiﬁcantly lower than those in
healthy controls, schizophrenia, or unipolar depression
(Molendijk et al., 2014; Fernandes et al., 2015; Rowland
et al., 2018). Moreover, BDNF levels are reduced in ma-
nia or depression but not during euthymia (Tunca et al.,
2014; Fernandes et al., 2015; Rowland et al., 2018). Fur-
thermore, in individuals with BD, BDNF mRNA levels
in white blood cells are also lower in individuals with BD
compared with unaffected individuals (D’Addario et al.,
2012). Post mortem analysis of hippocampal tissue has
also revealed reduced BDNF protein levels in patients
with BD (Knable et al., 2004). Manic (Frey et al., 2006;
Jornada et al., 2010; Fries et al., 2015) and depressive-
like behavioral animal models (Tsankova et al., 2006;
Bj€orkholm and Monteggia, 2016; Koo et al., 2019) have
also shown a decrease in both BDNF mRNA and protein
levels in the hippocampus. Conversely, lithium treatment
has been associated with increased BDNF protein levels
(Cunha et al., 2006; Tramontina et al., 2009; de Sousa
et al., 2011) and increased BDNF mRNA and protein
expression in the hippocampus, cortex, and amygdala
in rodent models and in cultured cortical neurons
(Fukumoto et al., 2001; Yasuda et al., 2009; Jornada
et al., 2010). Lithium treatment also increases TrkB
activity in neuronal cultures and enhances BDNF-
TrkB signaling (Hashimoto et al., 2002).

The potential mechanisms for how lithium increases
BDNF levels are complex. Lithium affects adenyl cy-
clase enzymes, increasing and stabilizing the production
of cyclic adenosine monophosphate (cAMP) (Manji and
Lenox, 2000). Increased cAMP levels increase protein ki-
nase A activity, an enzyme that phosphorylates and acti-
vates numerous other molecules and enzymes, including
the transcription factor cAMP response element binding
protein (CREB). When activated through phosphoryla-
tion, CREB increases BDNF transcription and produc-
tion (Zheng et al., 2011). Promoter exons are regions of a
gene that promote its transcription to produce more of a
targeted protein. The BDNF gene has several promoter
exons, and studies in animal models suggest that lith-
ium upregulates the function of promoter exon IV.
When exposed to therapeutic concentrations of lithium,
cultured rat cortical neurons exhibited elevated levels
of BDNF mRNA containing exon IV and an enhanced
activity of BDNF promoter IV (Yasuda et al., 2009;
Dwivedi and Zhang, 2015). Through increased BDNF
production, lithium may enhance neurogenesis, nerve
cell growth and survival, and neural plasticity. These
effects explain at least part of the therapeutic effects
seen with its use. More recently, Gideons et al. (2017)
have highlighted the necessity of BDNF-TrkB signaling
in the lithium-induced antimanic-like response, whereas
this mechanism does not appear to be involved in the
antidepressant-like effects of lithium. Furthermore, they
have identiﬁed a direct impact of lithium treatment on
the trafﬁcking of a-amino-3-hydroxy-5-methyl-4-isoxazole
propionic acid receptors (AMPARs), wherein there is a
decrease in the cell surface expression of AMPARs due
to a sustained increase in dynamin-mediated AMPAR
endocytosis. This process is reliant on the proper func-
tioning of BDNF-TrkB, offering valuable mechanistic in-
sights into the actions of lithium that may underpin its
therapeutic efﬁcacy in the treatment of BD. Further-
more, alterations in BDNF levels induced by lithium
alone can effectively inhibit the activity of GSK3b (Ma-
chado-Vieira et al., 2009). It’s worth noting that BDNF
not only acts as a mediator for gene expression linked
to synaptic plasticity through PKC signaling (Arevalo
and Wu, 2006) but also plays a role as a regulator of
PKC itself, inﬂuencing BDNF and other neurotrophins’
expression (Xu et al., 2013, 2015b). The intricate inter-
play between these pathways underscores the complex
role that neurotrophins play in regulating a wide range
of neuronal signaling mechanisms, rendering them sig-
niﬁcant molecular targets of lithium.

Other trophic factors have been identiﬁed as molecu-
lar targets of lithium, such as glial cell line–derived neu-
rotrophic factor (GDNF), vascular endothelial growth
factor, and insulin-like growth factor (IGF). However,
the mechanisms involved are less understood than those
of BDNF (Scola and Andreazza, 2015). GDNF levels in-
crease with lithium treatment in astrocyte cultures

Potential Therapeutic Effects of Lithium

333

(Emamghoreishi et al., 2015). Hence, it is plausible
that the neuroprotective beneﬁts of lithium may not be
restricted solely to neurons but could also encompass as-
trocytes. Several ﬁndings on the effects of GDNF in BD
reveal that different stages of the disorder and pharmaco-
logical treatment with lithium may alter GDNF expres-
sion in BD. However, there is some controversy about the
possibility of considering GDNF as a nonspeciﬁc periph-
eral factor marker that may respond to lithium treatment
(Scola and Andreazza, 2015). Lithium may increase vas-
cular endothelial growth factor expression through phos-
phatidylinositol 3-kinase (PI3K)/GSK3b–dependent and -
independent pathways in brain endothelium and astro-
cytes, contributing to lithium’s ability to promote neuro-
vascular remodeling after stroke (Guo et al., 2009).

Furthermore, genetic investigations have indicated
the involvement of IGF in BD as its gene is situated in
the chromosomal region 12q23.2, a region associated
with BD pathophysiology (Curtis et al., 2003; Pereira
et al., 2011). Interestingly, the mRNA expression of IGF-
binding protein-2, a protein with high afﬁnity for IGF-1
or IGF-2, used to transport these factors to other tissues
or organs, was found to be reduced in the prefrontal cor-
tex of individuals with BD (Bezchlibnyk et al., 2007).
Moreover, patients with BD exhibited lower blood lev-
els of IGF-1 compared with those with schizophrenia
(Palomino et al., 2013). Intriguingly, IGF-1 was observed
to be upregulated in lymphoblastoid cells derived from
lithium-responsive BD patients (Squassina et al., 2013),
suggesting that one potential mechanism of lithium’s
action might involve the regulation of IGF-1 secretion,
a known cell survival factor that prevents apoptosis
(Fidaleo et al., 2017).

D. Factors Affecting Apoptotic Signaling

Apoptosis, the process of programmed cell death driven
by signal transduction, has been a subject of extensive
research. Seminal studies have revealed that lithium has
several remarkable effects: 1) it elevates the expression
of the B-cell lymphoma (Bcl-2) protein, a key regulator of
programmed cell death; 2) it reduces the expression of
proapoptotic proteins such as p53 and Bax; and 3) it
hinders the release of cytochrome c from mitochondria
induced by glutamate in cultured neurons (Chen and
Chuang, 1999). In addition to its impact on neurons,
chronic lithium administration also increases Bcl-2
protein levels in astrocytes, which are crucial for neu-
ronal survival (Keshavarz et al., 2013). It is noteworthy
that differences in Bcl-2 gene expression may serve as a
distinguishing factor between lithium responders and
nonresponders (Beech et al., 2014), suggesting that the
effectiveness of lithium treatment might be linked to the
preservation of neurons and their supporting cellular
structures. Furthermore, valproate also exhibits antia-
poptotic properties, hinting at a potential shared mech-
anism where mood stabilization coincides with the
reduction of apoptotic pathways (Gupta et al., 2012).

When cells face harmful insults, lithium plays a protective
role by preserving mitochondrial function, by reducing re-
active oxygen species, thus preventing cell apoptosis (Hou
et al., 2015).

Consistent with these ﬁndings, recent research
afﬁrms (conﬁrms) that lithium protects the hippocam-
pus from apoptosis by engaging neuroprotective and
anti-inﬂammatory pathways (Liechti et al., 2014; Dwivedi
and Zhang, 2015). Indeed, lithium decreased the expres-
sion of proapoptotic genes Bad, Bax, and caspase 3. Inter-
estingly, a clinical study showed that BD patients who
respond to lithium showed an increased ratio of anti- to
proapoptotic genes in blood cells. In contrast, patients
who do not respond to lithium had no signiﬁcant effect
(Lowthert et al., 2012). Thus, effects on pro- and antia-
poptotic genes might underpin lithium action in clinical
response to BD. There are several possibilities whereby
lithium modulates the transcription of pro- and antiapop-
totic genes. One could be that BDNF-induced activation
of extracellular signal-regulated kinase (ERK) signal-
ing may lead to increased expression of these genes. For
example, the Bcl-2 gene contains binding sites for CREB,
a transcription factor activated by ERK1/2.

Interestingly, lithium has earlier been shown to upre-
gulate ERK expression in cultured cells and rats’ frontal
cortex and hippocampus (Chen and Manji, 2006). Fur-
thermore, lithium also upregulates the expression of
BAG-1, a gene that binds to and increases the activity
of Bcl-2 (Zhou et al., 2005). Thus, the effect of lithium on
Bcl-2 could be associated with increased expression of
BAG-1 (Dwivedi and Zhang, 2015).

E. Intracellular Signaling Cascades

1. PI3K/Akt Pathway. As stated above, BDNF in-
duction is an early and essential step in the neuro-
plasticity and neuroprotection activity of lithium as
demonstrated using different animal models of trau-
matic brain injury (TBI) (Ciftci et al., 2020), cerebral
ischemia (Fan et al., 2015; Ates et al., 2022), and
many others (Dou et al., 2005; Nowicki et al., 2008). It
has been suggested that neuroprotection may originate
from activating the PI3K/Akt signal transduction path-
way (Kilic et al., 2017). Additionally, the trophic inﬂu-
ence of BDNF is intricately connected to the activation
induced by lithium in cell survival pathways, speciﬁ-
cally the PI3K/Akt and MEK/ERK (also known as the
Ras-Raf-MEK-ERK) pathways (Chiu et al., 2013).

Akt, a serine/threonine kinase regulated by PI3K,
experiences activation through phosphorylation at
Thr308 and Ser473 residues (Jacinto et al., 2006).
Notably, lithium has been shown to induce the phosphor-
ylation of Akt at Ser473 (Tian et al., 2014; Fan et al.,
2015). Early studies conducted with cultured rat cerebel-
lar granule cells revealed that lithium rapidly counter-
acted Akt-glutamate–induced inactivation by stimulating
PI3K, leading to increased phosphorylation of Akt at its
Ser473 residue. This Akt activation triggers alterations

334

Bortolozzi et al.

in Bcl-2–associated death promoter, CREB, members
of the forkhead family, and procaspase-9, which are
antiapoptotic targets (Chiu et al., 2013). Similarly, in cul-
tured human neuroblastoma cells,
lithium treatment
demonstrated an inhibitory effect on caspase-3 activation
induced by neurotoxins mimicking the neurochemical
changes associated with PD. This inhibition occurred in
a manner dependent on PI3K (King et al., 2001). More
recently, Ates et al. (2022) reported that, in a mouse
model of brain ischemia, the phosphorylation of Akt at
Thr308 was signiﬁcantly higher than that at the Ser473
residue following the administration of a therapeutic
dose of 2 mmol/kg lithium. This ﬁnding suggests that
the PI3K/Akt pathway plays a major role in lithium’s
neuroprotective activity.

2. MEK/ERK Pathway. Genetic studies of BD and
molecular studies of lithium’s mechanism have previ-
ously pointed to MEK/ERK pathways. Reduced phos-
phorylation of ERK1/2 has been observed in post mortem
samples collected from the prefrontal cortex of patients
with BD (Yuan et al., 2010) and in both the prefrontal
cortex and hippocampus of individuals who died by sui-
cide (Dwivedi et al., 2009). Preclinical studies showed
that lithium might engage ERK to alter the expression
of PER2 by activating the transcription factor egr-1 (Kim
et al., 2013). Furthermore, U0126, both a K252a and the
MEK inhibitor, inhibits the antidepressant-like effects
induced by BDNF (Shirayama et al., 2002), supporting
the notion of TrkB’s involvement in activating the
MEK/ERK pathway. ERK, in turn, regulates several
downstream effector systems, including the transcrip-
tion factor nuclear factor j-light-chain-enhancer of acti-
vated B cells (NF-kB) and ribosomal S6 kinase (RSK).
Additionally, ERK inhibits GSK3b and activates CREB
(Steelman et al., 2004). CREB functions as a shared down-
stream effector for both the PI3K/Akt and MEK/ERK
signaling pathways. When it is activated through phos-
phorylation, it assumes a pivotal role in bolstering cell
survival by upregulating the expression of cell-protective
proteins, like BDNF and Bcl-2 (Finkbeiner, 2000). Inter-
estingly, treatment with lithium enhances ERK phos-
phorylation; however, the lithium-induced enhancements
in BrdU-positive cells and cognitive function were hin-
dered by the administration of U0126 (Yan et al., 2007a).
In addition, more recently ERK was identiﬁed as a regu-
lator of lithium’s effect on circadian rhythm amplitude in
ﬁbroblasts from BD patients and demonstrated that
p-ERK1/2 is decreased in BD cells (McCarthy et al.,
2013; 2016).

3. Wnt/b-Catenin Pathway. Lithium serves multi-
ple essential functions in maintaining the proper func-
tioning of the nervous system, including its role in
enhancing neurogenesis, synaptic plasticity, and cell sur-
vival (Chen et al., 2000b; Schloesser et al., 2008; Kim
and Thayer, 2009). Neurogenesis, a critical process for
hippocampal plasticity, continues throughout adulthood

in the mammalian brain. Furthermore, lithium contrib-
utes to learning and memory processes. Recent neuroim-
aging research underscores the signiﬁcance of
the
hippocampus as a key target for the effects of lithium.
Studies in mice and humans show an accumulation of
lithium in the hippocampal regions of the brain after re-
peated oral administration (Zanni et al., 2017; Stout
et al., 2020; Palmos et al., 2021). In addition, large mega-
analyses from the ENIGMA neuroimaging consortium
suggest that smaller hippocampal volumes are a common
feature among psychiatric disorder patients (Hibar et al.,
2016; van Erp et al., 2016; Logue et al., 2018). Neverthe-
less, individuals with bipolar disorder who are on long-
term lithium treatment display larger hippocampal
volumes compared with their nonmedicated counter-
parts within the BD patient group (Hajek et al., 2012).
This indicates that lithium therapy could potentially
mitigate the reductions in hippocampal volume typically
observed in individuals with psychiatric disorders, either
through the preservation of existing neurons or the stim-
ulation of neurogenesis.

These data align with preclinical research indicating
that mice treated with lithium experience increased
neurogenesis, which is associated with the activation
of Wnt signaling. This activation is evident through
enhanced nuclear b-catenin staining in newly formed
neurons (Fiorentini et al., 2010; Valvezan and Klein,
2012). The inhibition of GSK3 by Wnt canonical signal-
ing allows the translocation of b-catenin to the nucleus
and facilitates activation of b-catenin/TCF-LEF target
genes critical for synapse plasticity and neurogenesis
(Valvezan and Klein, 2012). Moreover, lithium’s impact
extends to suppressing astrogliogenesis through non–
lithium
GSK3-mediated mechanisms. Consequently,
appears to enhance the neuronal differentiation of neural
stem cells through a dual mechanism, promoting neuro-
genesis while curtailing astrogliogenesis (Zhu et al.,
2011; Kerr et al., 2018). However, recent in vitro ﬁndings
have suggested that high-dose lithium treatment at
2.25-mM levels can increase the generation of neuro-
blasts, neurons, and glial cells in human hippocampal
progenitors. This treatment also inﬂuences the expres-
sion of genes responsible for regulating the molecular
layer’s volume in the dentate gyrus (Palmos et al., 2021).
These ﬁndings support the idea that adult hippocampal
neurogenesis and gliogenesis are mechanisms that could
help explain the therapeutic effects of lithium.

4. Calcium/Calmodulin-Dependent Protein Kinase II/
CREB Pathway and Calcium Channels. Lithium treat-
ment not only exerts a neuroprotective action through
Akt activation but also through calcium/calmodulin-
dependent protein kinase II (CaMKII) activation and
calcium mobilization, respectively, leaving an inhibi-
tion of apoptosis signaling (Kang et al., 2003). Indeed,
activation of these kinases leaves a lithium-induced

Potential Therapeutic Effects of Lithium

335

neuroprotective function in a rat model of ischemia-
induced brain injury (Sasaki et al., 2006).

CaMKII plays a critical role in neurotransmission,
synaptic plasticity,
learning, and memory. In post
mortem brain samples from patients with BD, lower
levels of CaMKII mRNA expression were reported in
different laminae of Brodmann’s area nine and area
46 compared with control subjects (Xing et al., 2002).
These early observations suggested that decreased
CaMKII expression/function in patients with BD seems
to be associated with some of the affective and cognitive
alterations reported in BD. Preclinical studies in rats
conﬁrmed that CAMKII-CREB signaling pathway acti-
vation in the hippocampus and prefrontal cortex are im-
plicated in memory consolidation of inhibitory avoidance
learning (Ghasemzadeh and Rezayof 2016; Amiri et al.,
2020). Furthermore, Amiri et al. (2020) also reported
that glutamate NMDA receptors are involved in the
interactive effects of lithium and olanzapine on mem-
ory consolidation through the CAMKII-CREB signal-
ing pathway.

Recent ﬁndings also focus on the role of calcium,
calcium channels, and neuronal calcium sensor pro-
tein 1 (NCS-1) in the etiology of BD (D’Onofrio et al.,
2017; Garcia-Rill et al., 2019). In the manic or mixed
state, patients with BD display reduced auditory elec-
troencephalogram synchronization in the b/c band
during a click train paradigm (O’Donnell et al., 2004).
c band oscillations are essential to information proc-
essing during states of arousal, such as sensory percep-
tion and motor behavior, and are thought to be involved
in memory formation (Kann et al., 2014, Mably and
Colgin, 2018). Therefore, a decrease in high-frequency
c band activity may underlie many of the symptoms of
BD, such as sleep disturbances, emotional dysregula-
tion, attention and memory deﬁcits, and impairments
in ﬁne motor skills (Goldberg and Chengappa, 2009).
Importantly, the reticular activating system, especially
the pedunculopontine nucleus, generates c oscillations
via calcium channels, pointing to roles for the reticular
activating system and calcium in the disease progression
(D’Onofrio et al., 2017; Byrum et al., 2019). Human post
mortem studies reported increased expression of NCS-1
in the brains of patients with BD and schizophrenia
(Koh et al., 2003). Lithium appears to act by inhib-
iting the interaction between NCS-1 and inositol
1,4,5-triphosphate (IP3) receptor (Schlecker et al., 2006),
preventing the action of excess NCS-1 and restoring in-
tracellular pathways that mediate normal c oscillations.
Although low levels of NCS-1 allow high-threshold cal-
cium channels to mediate intrinsic membrane oscillations,
high levels of NCS-1 inhibit the oscillations. Therefore,
optimal concentrations of lithium reduce the effects of
NCS-1 overexpression by normalizing c band activity.

F. Oxidative Stress Pathways and Mitochondrial
Dysfunction

A growing body of evidence points to disrupted mito-
chondrial function in psychiatric conditions, including
BD, as well as in neurodegenerative diseases that mani-
fest psychiatric symptoms. In fact, various mitochondrial
abnormalities have been documented in psychiatric dis-
orders, encompassing reduced expression of peroxisome
proliferator-activated receptor c (PPARc), diminished
mitochondrial respiration, imbalances in proinﬂamma-
tory and apoptotic responses, and impaired mitochon-
drial motility (Pei and Wallace, 2018, Preston et al.,
2018; Galts et al., 2019; Kolar et al., 2021; van Rensburg
et al., 2022). BD is hypothesized as being a biphasic dys-
regulation of mitochondrial biogenesis, decreased in
depression and increased in mania (Morris et al., 2017).
Although exploring signaling pathways and mechanisms
related to mitochondrial dysfunction exceeds the scope
of this review, we will brieﬂy report evidence indicating
the involvement of oxidative stress pathways in several
central nervous system disorders as well as their regula-
tion by lithium.

Research involving individuals with bipolar disorder
has indicated that lithium reduces levels of lipid peroxi-
dation and enhances mitochondrial function, effectively
countering the impacts of oxidative stress (Khairova
et al., 2012; De Sousa et al., 2014, 2015). Using different
animal models of cerebral ischemia or neurotoxicity
induced by 3-nitro propionic acid or kainic acid, lith-
ium was found to prevent neuronal sensitivity to oxi-
dative damage (Rojo et al., 2008; Castro et al., 2009;
Khan et al., 2015; Chen et al., 2016). The protective
effects of lithium against oxidative damage are evident
through several indicators, including reduced levels of
lipid peroxidation, as measured by thiobarbituric acid
reactive substances (TBARS) or 4-hydroxynonenal
(4-HNE), decreased protein carbonylation, and a decrease
in the production of reactive oxygen species (Shao et al.,
2005; Rojo et al., 2008; Castro et al., 2009). Further-
more, lithium treatment has been shown to boost the
expression of antioxidant enzymes such as catalase
(Khan et al., 2015), heme-oxygenase-1 (HO-1) (Khan
et al., 2015; Chen et al., 2016), and NAD(P)H quinone
oxidoreductase-1 (NQ01) (Chen et al., 2016) as well as
restoring levels of glutathione and glutathione-trans-
ferases (GstD1, GstD2), crucial mediators of neuronal
defense against oxidative damage (Kerr et al., 2017).

Moreover, the inhibition of GSK3 mirrors many of
these antioxidant properties of lithium. This has been
shown in studies utilizing GSK3 antisense oligonucleoti-
des, short-interfering RNAs, and speciﬁc GSK3 inhibi-
tors (e.g., SB216763, TDZD-8) in rat models of cerebral
ischemia and in the SAMP8 mouse model, which simu-
lates aging-associated AD (Rojo et al., 2008; Chen et al.,
2016). In this context, the transcription factor nuclear
factor (erythroid-derived 2)-like 2 (Nrf2) has emerged

336

Bortolozzi et al.

as a pivotal molecular mediator responsible for trans-
mitting lithium’s antioxidant effects following GSK3
activation. Nrf2 operates by upregulating the expression
of a variety of genes containing antioxidant response
elements, thus effectively mitigating oxidative dam-
age (Kerr et al., 2018).

G. Protein Quality Control Mechanisms

1. Ubiquitin-Proteasome System and Autophagy. Pro-
tein homeostasis is the equilibrium between the synthe-
sis and breakdown of proteins. For neurons, where the
removal of impaired components cannot be accomplished
via cellular division, qualitative adjustments to the prote-
ome and the prompt removal of damaged and misfolded
proteins are crucial processes (Douglas and Dillin, 2010;
Balchin et al., 2016; Kerr et al., 2018). Intriguingly,
lithium inﬂuences proteostasis by diminishing protein
synthesis and augmenting protein degradation, thus
regulating proteasomal activity and autophagy. These
effects may hold promise for addressing a range of neu-
rodegenerative diseases, such as AD, PD, and various
forms of dementia. This potential beneﬁt can be attrib-
uted to its ability to either enhance the clearance of ab-
normal protein aggregates, a common hallmark of these
disorders, or maintain protein homeostasis for the proper
function of neuronal cells. Furthermore, lithium pro-
motes the breakdown of proteins prone to forming ag-
gregates, including mutated huntingtin, phosphorylated
s, and a-synuclein (Motoi et al., 2014).

Although rapamycin is the most widely used phar-
macological agent to induce autophagy through inhibi-
tion of the mTOR pathway, the mechanism by which
lithium acts as an autophagy enhancer appears to be
independent of the mTOR pathway. Several studies
have identiﬁed the ability of lithium to deplete free
inositol and subsequently lower IP3 levels, through in-
hibition of IMPase and inositol transporters, as an
mTOR-independent pathway to induce autophagy
(Sarkar and Rubinsztein, 2006; Chiu et al., 2013). The
lithium-caused “inositol depletion” has a positive feed-
back mechanism, in which the incremental effect of lith-
ium is greater the higher the concentration of the IMP-
IMPase complex (Harwood, 2005; Yu and Greenberg,
2016). This evidence led to the hypothesis that lithium
may exert its therapeutic effect through inositol deple-
tion, which mediates the autophagy effect. Lithium’s
ability to induce autophagy has mainly been showcased
through animal models of neurodegenerative disorders
characterized by the accumulation of misfolded pro-
teins (Cuervo et al., 2004; Levine and Kroemer, 2008;
Rubinsztein et al., 2012). More recent studies indicate
the possible involvement of aberrant autophagy in
schizophrenia as altered autophagy markers, e.g., beclin1
and microtubule-associated protein one light chain 3
(LC39), among others, have been identiﬁed in post
mortem brain samples from patients with schizophrenia
as well as in perinatal animal models of phencyclidine-

induced schizophrenia-like behavior (Yuan et al., 2015;
Jevtic et al., 2016). Interestingly, although the search for
studies linking autophagy to BD yields very few direct re-
sults, evidence points to mitochondrial dysfunction in BD
because of impaired autophagy and, especially, to the role
of mood stabilizers in its prevention (Toker and Agam
2015; Scaini et al., 2016; Bar-Yosef et al., 2019). Con-
sidering the robust therapeutic effects of lithium on
mood disorders, autophagy may occupy a central place in
its antimanic and antidepressant action. It is worth not-
ing that the mood-stabilizing effects observed with cer-
tain drugs that induce autophagy, like valproate and
rapamycin, are not unexpected. These medications are
originally prescribed for different therapeutic purposes
but have shown additional mood-stabilizing properties
(Puglisi-Allegra et al., 2021).

2. Endoplasmic Reticulum Stress and Unfolded Protein
Response Pathway. The endoplasmic reticulum (ER)
serves as the main site for protein synthesis, folding,
and trafﬁcking within cells. Additionally, it functions as
an intracellular calcium store and is extremely suscepti-
ble to disruptions in its internal environment, leading
to ER stress. To ensure cell survival, the unfolded protein
response (UPR) is activated as an adaptive reaction to
ER stress. Both ER stress and abnormal UPR have sig-
niﬁcant implications in the development of various neu-
ropsychiatric and neurodegenerative disorders, playing
a central role in their pathogenesis. (Bengesser et al.,
2016; Limanaqi et al., 2019). Numerous investigations
have proposed that the UPR pathway might be in-
volved in the pathophysiology of BD. Additionally, it
has been suggested that mood stabilizers could poten-
tially exert their therapeutic effects by triggering the
activation of the UPR (Chen et al., 2000a; Kakiuchi
et al., 2003; Shao et al., 2006; Kim et al., 2009; Pfaffen-
seller et al., 2014; Bengesser et al., 2016).

Evidence for altered UPR in BD comes from studies
reporting an abnormal response to ER stress inducers.
When stimulated with thapsigargin and tunicamycin,
individuals with BD displayed either an unresponsive
or reduced expression of UPR markers, including eIF2a,
GRP78 (Bip), GRP94, XBP1, and CHOP (Hayashi et al.,
2009; Pfaffenseller et al., 2014). Remarkably, altera-
tions in these markers appear to have predictive value
for lithium responsiveness in BD (Breen et al., 2016).
Lithium increases the expression of UPR chaperones
(i.e., GRP78, GRP94, and calreticulin) in rats in both
brain tissue and cultured cells (Shao et al., 2006). How-
ever, it is worth noting that some studies have reported
that mood stabilizers have no signiﬁcant impact on the
UPR pathway. For instance, valproate led to increased
GRP78 protein levels in HEK293 cells, but neither val-
proate nor lithium had a substantial effect GRP78
expression in Neuro-2a cells (Kakiuchi et al., 2003,
2009). Additionally, valproate and lithium did not in-
duce changes in XBP1SH-SY5Y and lymphoblastoid

Potential Therapeutic Effects of Lithium

337

cells. (Kakiuchi et al., 2003). Despite these discrepan-
cies, a substantial body of research in mammals strongly
supports an induced activation of UPR by mood stabil-
izers. Several mechanisms have been proposed as poten-
tial contributors to potentially underlie the activation of
the UPR by these mood stabilizers. These mechanisms
include histone deacetylases inhibition, upregulation of
the wolframin gene (WFS1), and myoinositol depletion
(Shi et al., 2007; Kakiuchi et al., 2009; Jadhav et al.,
2016), although these mechanisms have been de-
scribed primarily for valproate (Sulliman et al.,
2021).

H. Immunomodulatory Role of Lithium

New evidence indicates a correlation between an
increased susceptibility to mood disorders and the
inﬂammatory responses of the immune system, along-
side alterations in the phenotype of macrophages trig-
gered by the activation of microglia. Changes in the
activation of microglia and the presence of inﬂamma-
tory factors are also an early characteristic seen in
individuals with dementia (Calsolaro and Edison,
2016; Sakrajda and Szczepankiewicz, 2021). There is
also evidence revealing that mitochondrial dysfunc-
tion plays a crucial role in the development of neuro-
degenerative diseases, including AD, PD, Huntington
disease (HD), amyotrophic lateral sclerosis (ALS), or
multiple sclerosis, by increasing innate and adaptive
immune responses that result in neuroinﬂammation
(Garabadu et al., 2019; Zang et al., 2022). In addition,
mitochondrial dysfunction and impaired energy me-
tabolism are also involved in the pathophysiology of
mood disorders (Kato, 2006; Cikankova et al., 2017;
Allen et al., 2018; Culmsee et al., 2019). The mito-
chondrial hypothesis proposes a reciprocal relationship
between changes in cell energy metabolism and in-
ﬂammation. It suggests that disturbances in energy
metabolism can activate the inﬂammasome, leading to
elevated cytokine production and eventual apoptotic
cell death. Conversely, inﬂammation can also impact the
generation of energy within the cell (Ghosh et al., 2018;
Kerr et al., 2018; Sakrajda and Szczepankiewicz, 2021;
Tang et al., 2021). In this review, we will emphasize the
pharmacological role of lithium as an immunomodula-
tory agent.

Previous research has indicated that lithium can re-
duce the levels of proinﬂammatory cytokines, both in
peripheral tissues and within the central nervous sys-
tem, and these changes have been linked to its efﬁcacy
(Bouﬁdou et al., 2004; Beurel and Jope, 2014). Lithium’s
most well known mechanism of action is the inhibition
of GSK3, which can impact various transcription fac-
tors, including NF-jB. NF-jB plays a critical role in the
innate immune response and regulates the production
of cytokines (Jope et al., 2007). The reduction in NF-jB’s
transcriptional activity, induced by lithium’s inhibition of
GSK3b, results in decreased production of proinﬂammatory

mediators such as interleukin (IL)-1b, interferon-c, IL-6,
and MCP1, which are associated with M1 macrophages.
Conversely, it increases the production of anti-inﬂamma-
tory cytokines (Martin et al., 2005).

Another potential downstream target of GSK3 is a sig-
nal transducer and activator of the transcription (STAT)
family. There are seven members of the STAT protein
family in mammals. Among them, STAT3 was discovered
as a component of the IL-6–activated acute phase
response factor (APRF) complex, which has a crucial role
in stimulating the expression of innate immune media-
tors (Hillmer et a., 2016). Furthermore, GSK3 phosphor-
ylates and activates STAT3 by facilitating its interaction
with the proinﬂammatory interferon-c receptor as dem-
onstrated in primary astrocytes from mice. Treatments
with lithium or GSK3 inhibitor TDZD-8 treatment blocks
these effects (Beurel and Jope, 2009; Rowse et al., 2012).
In addition, molecular mediators of the anti-inﬂam-
matory effects of lithium also correlate with Toll-like
receptor 4 (TLR4) pathways (Kerr et al., 2018). TLR4
serves as a pattern-recognition receptor responsible for
detecting speciﬁc pathogen-associated molecular pat-
terns, such as lipopolysaccharide, along with cytokines.
After binding to its ligand, TLR4 recruits signaling
adaptors and initiates a series of signaling cascades
that result in the activation of NF-jB and the release
of inﬂammatory cytokines (Lien et al., 2000; Cheong
et al., 2011). The anti-inﬂammatory effects of lithium
via suppression of microglial activation and attenuation
of overexpression of proinﬂammatory cytokines and che-
mokines are thought to be dependent on TLR4 signaling.
Indeed, lithium inhibited lipopolysaccharide-induced
TLR4 expression and microglial activation through
the PI3K/Akt/FoxO1 signaling pathway (Dong et al.,
2014). Furthermore, changes in the levels of TLR4
expression and its associated transcription factor
NF-jB were found to be associated with lithium’s
ability to alleviate memory deﬁcits in elderly rats.
This improvement in memory was connected to reduc-
tions in the levels of TNF-a and IL-1b in the hippocam-
pus (Lu et al., 2015, Cheng et al., 2016). Taken together,
these data suggest that lithium’s anti-inﬂammatory and
neuroprotective effects may be mediated independently
of GSK3 inhibition through modulation of TLR4, NF-jB,
and STAT3 signaling.

IV. Ketamine, Lithium, and the Targeting of
Homeostatic Synaptic Plasticity

Recent studies indicate that ketamine and lithium
target the same synaptic process, i.e., elicit functional
synaptic plasticity (Kavalali and Monteggia, 2020; Price
et al., 2021), albeit their targets are widely divergent,
and their mechanisms are different. Therefore, com-
bined lithium and ketamine treatment may enhance
antidepressant responses by promoting molecular sig-
naling cascades and bioenergetic pathways essential to

338

Bortolozzi et al.

enable synaptic processes. Over the last 10 years, clini-
cal research has shown that administering a low dose
of ketamine intravenously leads to a swift and effective
antidepressant response in individuals with depression,
including those with treatment-resistant depression and
bipolar depression (Berman et al., 2000; Zarate et al.,
2006b; Price et al., 2009; Daly et al., 2018; Wilkowska
et al., 2020). Ketamine is recognized as a noncompetitive
antagonist of the glutamatergic N-methyl-D-aspartate
receptor (NMDAR), and several initial targets for its ac-
tions have been proposed in the literature. These targets
include NMDARs on GABA interneurons (Homayoun
and Moghaddam 2007; Quirk et al., 2009) and NMDAR
and AMPAR on pyramidal neurons (Zanos et al., 2016;
Artigas et al., 2018). Similar to other rapid-acting anti-
depressant treatments (Duman et al., 2016; Jim(cid:3)enez-
S(cid:3)anchez et al., 2016), ketamine’s mechanism of action
involves the activation of AMPARs. This effect may
result from the blockade of NMDARs in speciﬁc sub-
sets of GABA neurons or direct activation of AMPARs.
Studies utilizing [1H]-magnetic resonance spectroscopy
have revealed that ketamine increases the levels of
glutamine, which serves as a marker for glutamatergic
transmission, in the anterior cingulate cortex of healthy
individuals (Rowland et al., 2005). Similarly, research
employing [13C]-NMR in rats has shown that ketamine
increases cortical labeling of glutamate, glutamine, and
GABA (Chowdhury et al., 2012). These ﬁndings align
with previous observations of increased glutamate efﬂux
using microdialysis procedures (Adams and Moghaddam,
2001). Nevertheless, the antidepressant effects of keta-
mine can be blocked by opioid receptor antagonists
(Williams et al., 2018). These observations indicate that
ketamine, at least in part, enhances presynaptic gluta-
matergic neurotransmission, leading to rapid upregula-
tion of AMPAR and BDNF/TrkB activation to promote
neurotrophic signaling through mTOR activation
(Li et al., 2010) and GSK3b inhibition (Beurel et al.,
2011). These molecular cascades, in turn, have been
shown to functionally promote the development of new
synaptic connections to enhance connectivity between
mood-related brain regions (Duman and Aghajanian,
2012; Costemale-Lacoste et al., 2016; Gerhard et al.,
2016; Zarate and Machado-Vieira, 2016; Fullana
et al., 2022).

Lithium activates neurotrophic and neuroprotective
cellular cascades (Quiroz et al., 2004, 2010; Sinha et al.,
2005; Dwivedi and Zhang, 2015; Costemale-Lacoste
et al., 2016), including the stimulation of neurotrophic
molecular pathways (i.e., BDNF/TrkB and mTOR acti-
vation, GSK3 inhibition) (Machado-Vieira et al., 2009;
Gideons et al., 2017), direct modulation of bioenergetic
factors (i.e., increased IGF expression) (Fidaleo et al.,
2017; Price et al., 2021), and protection of mitochondrial
health, cellular energy metabolism, and antioxidant de-
fense (Rojo et al., 2008; Castro et al., 2009; Kerr et al.,

2018). Certainly, some of the most consistently observed
ﬁndings in this context involve the inhibition of GSK3,
the upregulation of neurotrophins, and shifts in AMPAR
expression (Hashimoto et al., 2002; Pisanu et al., 2016;
Kavalali and Monteggia, 2020; Price et al., 2021). Recent
investigations into the synaptic mechanisms inﬂu-
enced by lithium have unveiled a signiﬁcant reduction
in AMPAR-mediated miniature excitatory postsynaptic
current amplitudes. This reduction is contingent on
BDNF and its TrkB receptor (Gideons et al., 2017).
Such an effect on glutamatergic neurotransmission
may play a role in counterbalancing the heightened
glutamatergic signaling observed in individuals with BD
during manic episodes (Ong€ur et al., 2008; Lan et al.,
2009). Furthermore, these ﬁndings align with additional
evidence gathered from post mortem brain tissue of indi-
viduals with BD (Hashimoto et al., 2007; Eastwood and
Harrison, 2010). Electrophysiological recordings in hu-
man neurons derived from induced pluripotent stem
cells of patients with BD have also indicated molecular
and functional alterations associated with increased
glutamatergic neurotransmission (Mertens et al., 2015).
Notably, the decrease in cell surface AMPAR expression
is contingent on BDNF/TrkB signaling (Gideons et al.,
2017). Consequently, although lithium elevates BDNF
expression and diminishes AMPAR function, ketamine
also increases BDNF levels, leading to enhanced AMPAR
responses. Further research is essential to unravel the
intricate mechanisms through which BDNF/TrkB sig-
naling, inﬂuenced by either ketamine or lithium, can
evoke such diverse effects at both synaptic and behav-
ioral levels.

Downstream of these mechanisms, both lithium and
ketamine initiate neurotrophic cascades through activa-
tion of MEK/ERK and CREB pathways, which provide
bioenergetics stimuli for neuronal and synaptic plasticity,
and play a critical role in antidepressant responses (Kim
et al., 2013; McCarthy et al., 2016; R(cid:3)eus et al., 2016).
Consequently, lithium is a promising candidate for
adjunctive treatment to ketamine and has shown po-
tential as a boosting agent for other antidepressant
approaches for treatment-resistant depression and
bipolar depression (Nelson et al., 2014; Costi et al.,
2019; Caldiroli et al., 2021). For example, in a rodent
model of treatment-resistant depression, augmentation
of imipramine with lithium was shown to promote cen-
tral and peripheral insulin signaling, which directly cor-
related with the antidepressant behavioral response
(Walker et al., 2019). In addition, lithium has been
shown to potentiate the synaptogenic and antidepres-
sant effects of subthreshold doses of ketamine in naıve
rats (Liu et al., 2013). Similarly, lithium was found to
enhance the antidepressant response to ketamine in
antidepressant-unresponsive animals, along with pe-
ripheral insulin efﬂux and region-speciﬁc prefrontal cor-
tex insulin signaling (Price et al., 2021). However, Xu

Potential Therapeutic Effects of Lithium

339

et al. (2015a) reported that therapeutic doses of lithium
(0.79 ± 0.15 mEq/L in serum) did not correlate with an
improvement in antidepressant efﬁcacy of ketamine at a
dose of 0.5 mg/kg in treatment-resistant bipolar depres-
sion. Some considerations should be taken into account
for a plausible explanation of the differences obtained be-
tween preclinical and clinical studies on the lithium ef-
fects as an enhancer of the antidepressant ketamine
action (Liu et al., 2013; Xu et al., 2015a). These include
1) the difference in the experimental design of the
studies; 2) the small number of patients included (n 5
23 subjects), not sufﬁcient for statistical power; 3) the
use of subtherapeutic doses of lithium and ketamine in
the animal model, whereas patients received stable
therapeutic levels of lithium for 4 weeks prior to keta-
mine infusion; and 4) treatment-refractory patients
versus an untreated rat model as well as other varia-
bles directly related to differential metabolism between
humans and rodents. In any case, further studies
are needed to determine the appropriate timing of
administration of lithium or selective GSK-3 inhibi-
tors to enhance the synaptic and antidepressant ef-
fects of ketamine. Based on the broad pharmacology
of ketamine and lithium, these data support that es-
sential synaptic plasticity may provide new insights and
targets for advancing the treatment of mood disorders.

V. Biology of Lithium’s Response

Clinical response to lithium when used as a mood-
stabilizer agent varies considerably, with half of the pa-
tients showing an incomplete response. Family studies
showed a pattern of heritability of response to lithium
among generations (Grof et al., 2002). Both heterogene-
ity and familiar transmission of the response could be
explained on genetic bases. Candidate-gene studies
were able to identify a large number of genes coding
for GSK3b, BDNF, and the serotonin transporter as-
sociated with lithium response (Pisanu et al., 2018).
However, the mild effect of these variants suggested
the hypothesis of a polygenic nature of lithium re-
sponse. Genome-wide association studies (GWAS) are
ideal to study complex traits or diseases since they
test the association between millions of common ge-
netic variants distributed across the human genome
with a speciﬁc phenotype on large populations (Tam
et al., 2019). Results of GWAS studies on lithium re-
sponse are, to date, contrasting, with several studies
failing to ﬁnd genome-wide associations replicating
previous results (Perlis et al., 2009, Squassina et al.,
2011). A study that used a formal deﬁnition of clinical
response to lithium (i.e., using the Alda Scale) (Manchia
et al., 2013) identiﬁes two signiﬁcant single nucleo-
tide polymorphisms (SNPs) located in the glutamate-
decarboxylase-like protein 1 (GADL1) associated with
lithium response (Chen et al., 2014). These results might

support the importance of the glutamatergic system in
lithium response (McCarthy et al., 2010).

Despite GWAS providing insights into the genetics of
lithium response, they face several limitations. These in-
clude small sample sizes, challenges in replicating re-
sults across diverse ancestries or populations, and the
use of heterogeneous deﬁnitions for clinical response to
lithium. To overcome these limitations, the ConLiGen
collaboratory consortium was established in 2008 to facil-
itate high-quality, well powered analysis of lithium treat-
ment response data (Schulze et al., 2010).

In a GWAS from the ConLiGen consortium on 2563
patients with BD, a single locus for four linked SNPs on
chromosome 21 was associated with lithium response
(Hou et al., 2016).

Individuals carrying these alleles linked to treat-
ment response exhibited a reduced relapse rate in an
independent prospective study involving 73 patients
receiving lithium monotherapy. The identiﬁed region en-
compasses two long noncoding RNA genes (AL157359.3
and AL157359.4), implying their potential role as regula-
tors of gene expression in the central nervous system
(Hou et al., 2016).

GWAS, despite their limitations, can nowadays be
used to calculate the polygenic risk score (PRS), which is
a numerical score that quantiﬁes an individual’s genetic
risk for a particular trait (as for example lithium
response) or disease based on the cumulative effect of
multiple genetic variants, typically SNPs scattered
across the genome. Although GWAS on lithium response
failed to generate good estimates to calculate the lithium
response-PRS due to lack of statistical powers, PRSs of
other phenotypes have been used to predict lithium re-
sponse in BD. Indeed, higher schizophrenia and major
depression PRSs were associated with poorer response to
lithium, whereas BD-PRS showed no such association
(Schubert et al., 2021). In a multiethnic study, individu-
als with higher PRS for major depressive disorder were
less likely to respond to lithium treatment compared
with those with lower scores in the multiethnic sample
and in the European sample, though no signiﬁcant asso-
ciation was observed in the Asian sample (Amare et al.,
2021). In another sample, a higher PRS for attention-
deﬁcit/hyperactivity disorder or major depression was
associated with a poorer response to lithium (Coombes
et al., 2021). As for GWAS, the effect size estimate for
PRS is modest as well as the generalizability of the re-
sults. Nevertheless, PRS with clinical variables and using
machine-learning models might signiﬁcantly improve the
prediction of lithium response (Cearns et al., 2022).

In a ﬂow-cytometric study, the expression levels of
28 intracellular proteins in CD41 lymphocytes and
monocytes were analyzed before and after 16 weeks
of lithium treatment in patients with BD, divided accord-
ing to lithium response. Results showed that lithium in-
duced divergent changes in protein expression depending

340

Bortolozzi et al.

on an individual’s response to treatment (Gao et al.,
2023).

Furthermore, a network-based integrative analysis of
transcriptomic and genomic data revealed 41 differen-
tially expressed genes in lithium responders versus non-
responders, and post-GWAS gene prioritization identiﬁed
1119 candidate genes. Functional enrichment highlighted
focal adhesion and the extracellular matrix (ECM) as the
most signiﬁcant functions, emphasizing the importance
of dysregulation in these pathways in understanding
lithium response and underlying BD mechanisms
(Niemsiri et al., 2023).

Induced pluripotent stem cells (iPSCs) have emerged
as a valuable tool in BD research in disease modeling,
drug screening, and personalized medicine. iPSCs are
somatic adult cells that have been reprogrammed to
exhibit pluripotent characteristics, meaning they can
differentiate into any cell type in the human body,
including neurons. In a recent study, an iPSC model
for BD was created, identifying mitochondrial abnormal-
ities and hyperactive action-potential ﬁring in young
neurons derived from patients with BD. The hyperexcit-
ability phenotype was selectively reversed by lithium
treatment in neurons from responsive patients, suggest-
ing that iPSC models may aid in the development of tar-
geted therapies for BD (Mertens et al., 2015). Indeed,
circadian rhythms in neuronal precursor cells (NPCs)
and reprogrammed glutamatergic neurons were dis-
rupted to a greater extent in samples obtained from
lithium nonresponders as compared with lithium res-
ponders (Mishra et al., 2021). Furthermore, in iPSC
models, lithium increases mitochondrial respiration
capacity only in lithium responders, suggesting involve-
ment of mitochondrial functions in the mechanisms of
mood stabilizers (Osete et al., 2021). iPSC-derived brain
organoids have also been studied to model BD. One
study explored the effects of long-term lithium treatment
on iPSC-derived human cortical spheroids from healthy
controls and patients with BD (Osete et al., 2023). BD
human cortical spheroids displayed altered neuronal
characteristics compared with controls, and lithium
treatment exerted opposite effects on neuronal excit-
ability between BD and controls. Also, 132 lithium-
associated differentially expressed genes related to so-
dium ion homeostasis and kidney-related pathways were
identiﬁed in the same study, highlighting the potential of
iPSC-derived three-dimensional brain models for preci-
sion medicine in psychiatry (Osete et al., 2023). Although
these studies are intriguing, their connection with the
individual genomic load of each patient concerning
lithium response has yet to be established.

VI. Lithium-Modified microRNA Pathways

MicroRNAs (miRNAs) have arisen as regulators of
gene expression post-transcriptionally, albeit they are
not classiﬁed as part of the epigenetic machinery. Their

involvement extends across nearly all biologic pro-
cesses, encompassing cell proliferation, development,
differentiation, and programmed cell death. The identi-
ﬁcation of over 1500 miRNA genes highlights their piv-
otal role, with each miRNA having the potential to
target multiple mRNAs. Highlighted by their multiface-
ted role, miRNAs hold considerable importance in shap-
ing cellular states and outcomes (Lin and Gregory, 2015)
given their ability to either inhibit the translation of tar-
get mRNA or expedite its degradation. Moreover, they
can serve as enhancers of translation or even impact
transcription by binding to gene promoters. Considering
the intricate nature of the nervous system at both the
cellular and transcriptional levels, it is not surprising
that approximately 75% of annotated miRNAs ﬁnd ex-
pression within the brain (Kosik, 2006, Artigas et al.,
2018; Bortolozzi et al., 2021). Intriguingly, miRNAs can
be released from the brain and enter circulatory bio-ﬂu-
ids, where they remain remarkably stable (Cheng et al.,
2014; _Zurawek and Turecki, 2021; Clausen et al., 2022).
Alterations in the miRNA levels have been reported in
brain tissue as well as in blood from patients with mood
disorders, including BD (Forstner et al., 2015; Mafﬁoletti
et al., 2016; Fries et al., 2018; Clausen et al., 2022).
Interestingly, several studies have shown that lithium
modiﬁes the expression of miRNAs and their targeted
mRNA (Chen et al., 2009; Hunsberger et al., 2015;
Reinbold et al., 2018; Pisanu et al., 2019; Marie-Claire
et al., 2021), suggesting that they could play a role in
modulating lithium’s clinical efﬁcacy.

Here, we summarize translational studies showing the
involvement of miRNAs in lithium’s actions (Table 1).
Previous studies have identiﬁed several miRNAs and
their predicted mRNA effectors in the rat hippocampus
as targets for the action of mood stabilizers (Zhou et al.,
2009). Some of these miRNAs, such as miR-221 and
miR-34a, have been shown to be inﬂuenced by lithium
treatment in lymphoblastoid cell lines derived from
patients with BD (Chen et al., 2009). Although certain
miRNAs, like miRNA-134, have been linked to treat-
ment response in bipolar mania, (Rong et al., 2011), the
majority of available data suggests that lithium’s impact
on miRNA levels is largely independent of its clinical ef-
ﬁcacy. A recent study compared miRNA and targeted
mRNA expression proﬁling of lymphoblastoid cell lines
before and after in vitro lithium treatment to identify
networks of miRNAs and their targets involved in lith-
ium response (Hunsberger et al., 2015). The lympho-
blastoid cell lines used in the study were obtained from
both lithium-responsive and nonresponsive BD patients.
The results indicated that in vitro lithium treatment
led to the downregulation of the Let-7 family of miRNAs
in both groups. Furthermore, a genome-wide analysis of
miRNAs in 2563 patients, categorized by their response
to lithium, identiﬁed 15 miRNAs signiﬁcantly associated

Potential Therapeutic Effects of Lithium

341

9
0
0
2

,
.
l
a

t
e

u
o
h
Z

1
1
0
2

,
.
l
a

t
e

g
n
o
R

d
n
a

,
a
5
1
-
R
m

i

,
2
5
1
-
R
m

i

d
e
s
a
e
r
c
e
d

d
n
a

5
5
1
-
R
m

i

s
l
e
v
e
l

4
9
4
-
R
m

i

d
e
s
a
e
r
c
n
i

m
u
i
h
t
i
L

:
6
1

y
a
D

,
2
5
1
-
R
m

i

,
1
2
2
-
R
m

i

s
l
e
v
e
l

i

a
4
3
-
R
m
d
n
a

5
5
1
-
R
m

i

,
b
7
-
t
e
l

f
o

s
l
e
v
e
l

d
e
c
u
d
e
R

,
a
4
2
-
R
m

i

,
a
8
2
1
-
R
m

i

,
c
7
-
t
e
l

d
n
a

,
a
4
3
-
R
m

i

,
c
0
3
-
R
m

i

d
e
s
a
e
r
c
n
i

d
n
a

,
1
2
2
-
R
m

i

s
l
e
v
e
l

4
4
1
-
R
m

i

r
e
t
f
a

i

4
3
1
-
R
m
d
e
s
a
e
r
c
n
I

d
e
n
i
b
m
o
c

f
o

s
k
e
e
w
4

s
c
i
t
o
h
c
y
s
p
i
t
n
a

h
t
i

w

t
n
e
m
t
a
e
r
t

m
u
i
h
t
i
l
(

s
r
e
z
i
l
i
b
a
t
s

d
o
o
m
d
n
a

)
e
t
a
o
r
p
l
a
v

d
n
a

3
1
0
2

,
.
l
a

t
e

r
e
g
r
e
b
s
n
u
H

,
7
4
1
-
R
m

i

i

,
2
8
1
-
R
m
d
e
s
a
e
r
c
n
I

e
h
t

g
n
i
w
o
l
l
o
f

i

2
2
2
-
R
m
d
n
a

h
t
i

w

t
n
e
m
t
a
e
r
t

n
o
i
t
a
n
i
b
m
o
c

a
4
3
-
R
m

i

.
e
t
a
o
r
p
l
a
v
1
m
u
i
h
t
i
l

5
1
0
2

,
.
l
a

t
e

r
e
g
r
e
b
s
n
u
H

7
1
0
2

,
.
l
a

t
e

r
e
n
p
p
e
o
D

8
1
0
2

,
.
l
a

t
e

d
l
o
b
n
i
e
R

9
1
0
2

,
.
l
a

t
e

u
n
a
s
i
P

)
d
e
u
n
i
t
n
o
c
(

0
2
0
2

,
.
l
a

t
e

a
n
i
s
s
a
u
q
S

n
w
o
h
s

h
t
o
b

e
r
e
w
5
9
4
-
R
m
d
n
a

i

g
n
i
w
o
l
l
o
f

d
e
t
a
l
u
g
e
r
n
w
o
d

e
b

o
t

.
t
n
e
m
t
a
e
r
t

n
o
i
t
a
n
i
b
m
o
c

y
l
t
n
e
t
s
i
s
n
o
c

s
i

y
l
i

m
a
f

7
-
t
e
L

n
i

m
u
i
h
t
i
l

y
b

d
e
t
a
l
u
g
e
r
n
w
o
d

s
i
h
t

e
r
e
h
w

,
s
p
u
o
r
g

h
t
o
b

n
e
e
b

s
a
h

y
l
i

m
a
f

A
N
R
m

i

n
i

d
e
t
a
c
i
l
p
m

i

l
l
e
c

,

n
o
i
t
a
r
e
n
e
g
e
d
o
r
u
e
n

c
i
t
p
a
n
y
s

d
n
a

,
l
a
v
i
v
r
u
s

t
n
e
m
p
o
l
e
v
e
d

-

i

R
m
d
e
s
a
e
r
c
n
i

m
u
i
h
t
i
L

n
o
i
s
s
e
r
p
x
e

4
2
1

d
e
t
a
i
c
o
s
s
a

i

s
A
N
R
m
n
e
e
t
f
i
F

g
n
o
m
a

,
e
s
n
o
p
s
e
r
m
u
i
h
t
i
l

h
t
i

w

a

d
e
w
o
h
s

i

a
9
9
4
-
R
m
m
e
h
t

h
t
i

w
n
o
i
t
a
i
c
o
s
s
a

t
s
u
b
o
r

e
s
n
o
p
s
e
r
m
u
i
h
t
i
l

i

e
r
e
w
s
A
N
R
m
e
n
o
-
y
t
r
i
h
T

R
E
n
i

d
e
s
s
e
r
p
x
e

y
l
l
a
i
t
n
e
r
e
f
f
i
d

y
l
e
s
r
e
v
n
i

d
n
a
R
N
s
u
s
r
e
v

s
e
n
e
g

8
1
4

h
t
i

w
d
e
t
a
l
e
r
r
o
c

d
e
s
s
e
r
p
x
e

y
l
l
a
i
t
n
e
r
e
f
f
i
d

.
s
p
u
o
r
g

o
w

t

e
h
t

n
e
e
w
t
e
b

.

n
a
c
S
t
e
g
r
a
T

r
o

a
d
n
a
R
m
y
b

i

,
1
S
2
P
A

,
1
A
2
P
A

(

s
e
n
e
g

e
v
i
F

e
r
e
w

)

L
C
V
d
n
a

,
1
F
I
E

,

P
A
2
D
C

d
n
a

d
e
h
c
i
r
n
e

y
l
t
n
a
c
ﬁ
i
n
g
i
s

,
s
e
s
s
e
c
o
r
p

c
i
g
o
l
o
i
b

o
t

d
e
k
n
i
l

r
a
l
u
c
e
l
o
m
o
r
c
a
m
x
e
l
p
m
o
c

,
.
e
.
i

n
i
e
t
o
r
p

,
y
l
b
m
e
s
s
a

d
n
a

,
y
l
b
m
e
s
s
a

x
e
l
p
m
o
c

y
l
b
m
e
s
s
a

t
n
e
n
o
p
m
o
c

r
a
l
u
l
l
e
c

:
s
t
e
g
r
a
t
-
A
N
R
m
d
e
t
c
i
d
e
r
P

i

,

K
R
E

,
e
c
n
a
d
i
u
g

l
a
n
o
x
a

,

N
E
T
P

d
n
a

,

n
i
n
e
t
a
c
-
b
/
t
n
W

g
n
i
l
a
n
g
i
s

c
i
g
r
e
n
e
r
d
a
-
b

s
y
a
w
h
t
a
p

d
e
t
r
o
p
e
r

t
o
N

:
s
t
e
g
r
a
t
-
A
N
R
m
d
e
t
c
i
d
e
r
P

i

G
G
E
K

,
g
n
i
l
a
n
g
i
s

b
-

F
G
T

s
y
a
w
h
t
a
p

r
e
h
t
o

d
n
a

,
y
a
w
h
t
a
p

,
e
c
n
a
d
i
u
g

l
a
n
o
x
a

g
n
i
d
u
l
c
n
i

n
i
t
c
a

,

n
o
i
s
e
h
d
a

l
a
c
o
f

d
n
a

,

n
o
i
t
a
l
u
g
e
r

l
a
t
e
l
e
k
s
o
t
y
c

n
o
i
t
a
i
t
n
e
t
o
p
m
r
e
t
-
g
n
o
l

:
s
t
e
g
r
a
t
-
A
N
R
m
d
e
t
c
i
d
e
r
P

i

n
e
e
b

s
a
h

y
l
i

m
a
f

i

A
N
R
m
7
-
t
e
L

n
i

d
e
t
a
c
i
l
p
m

i

l
l
e
c

,

n
o
i
t
a
r
e
n
e
g
e
d
o
r
u
e
n

c
i
t
p
a
n
y
s

d
n
a

,
l
a
v
i
v
r
u
s

t
n
e
m
p
o
l
e
v
e
d

g
n
i
c
n
e
l
i
s
-
1
E
R

:
t
e
g
r
a
t

4
2
1
-
R
m

i

,

T
S
E
R

(

r
o
t
c
a
f

n
o
i
t
p
i
r
c
s
n
a
r
t

)

F
S
R
N
s
a

n
w
o
n
k

o
s
l
a

d
e
t
r
o
p
e
r

t
o
N

:
s
t
e
g
r
a
t
-
A
N
R
m
d
e
t
a
d
i
l
a
V

i

1

t
i
n
u
b
u
s

l
l
a
m
s

n
i
a
p
l
a
c

G

f
o

r
o
t
a
l
u
g
e
r

,
)
1
S
N
P
A
C

(

,
)
6
1
S
G
R

(

6
1

g
n
i
l
a
n
g
i
s

n
i
e
t
o
r
p

)
4
p
S
(

4
P
S

r
o
t
c
a
f

n
o
i
t
p
i
r
c
s
n
a
r
t

)
4
P
S

d
n
a

a
0
2
3
-
R
m

i

(

s
r
e
d
r
o
s
i
d

e
c
n
e
r
e
f
e
R

s
t
c
e
f
f

E
m
u
i
h
t
i
L

s
e
n
e
G

t
e
g
r
a
T

9
0
0
2

,
.
l
a

t
e

n
e
h
C

i

,
1
2
2
-
R
m
d
e
s
a
e
r
c
n
I

:
4

y
a
D

d
e
t
c
i
d
e
r
p

e
r
e
w
s
t
e
g
r
a
t
-
A
N
R
m

i

-

T
R
d
n
a

y
a
r
r
a
o
r
c
i

M

R
C
P
q

;
s
t
a
r

r
a
t
s
i

W
o
t
o
y
K

;
s
e
l
p
m
a
s

s
u
p
m
a
c
o
p
p
i
h

k
e
e
w
1

r
o
f

g
k
/
g

2
.
1

3
O
C
2
i
L

d
n
a

4

r
o
f

M
m
1

s
y
a
d

t
a

6
1

t
n
e
m
t
a
e
r
t

R
C
P
q
-
T
R

D
B
e
e
r
f
-
g
u
r
d

,
a
m
s
a
l
p

n
a
m
u
H

)
1
2
5
n
(

s
t
n
e
i
t
a
p

d
o
h
t
e
M

R
C
P
q
-
T
R

l

C
L

i

d
i
o
t
s
a
l
b
o
h
p
m
y
L

;
)
0
2
5
n
(

D
B

;
s
e
n
i
l

l
l
e
c

,
a
5
1
-
R
m

i

,
2
5
1
-
R
m

i

,
1
2
2
-
R
m

i

,
a
4
3
-
R
m

i

,
c
1
8
1
-
R
m

i

,
5
5
1
-
R
m

i

,
4
9
4
-
R
m

i

,

p
3
-
7
1
-
R
m

i

,
5
0
6
-
R
m

i

,

C
0
0
2
-
R
m

i

,
a
8
4
1
R
m

i

3
1
5
-
R
m

i

,
b
1
8
1
-
R
m

i

,
5
0
1
-
R
m

i

,
c
7
-
t
e
l

,
b
7
-
t
e
L

,
4
2
-
R
m

i

,
a
8
2
1
-
R
m

i

,
4
4
1
-
R
m

i

,
1
2
2
-
R
m

i

,
a
4
3
R
m

i

,
c
0
3
-
R
m

i

6
3
1
-
R
m

4
3
1
-
R
m

i

s
e
l
p
m
a
S

s
A
N
R
m

i

,

p
i
h
C
e
n
e
G
x
i
r
t
e
m
y
f
f

A

r
a
l
l
e
b
e
r
e
c

t
a
R

R
C
P
q
-
T
R

r
o
f

M
m
3

l

C
L

i

;
s
l
l
e
c

e
l
u
n
a
r
g

,
2
8
1
-
R
m

i

,
7
4
1
-
R
m

i

,
a
4
3
-
R
m

i

d
n
a

,
5
9
4
-
R
m

i

,
2
2
2
-
R
m

i

s
y
a
d

6

0
9
6
-
R
m

i

E
T
I
N
A
R
G

g
n
i
r
a
p
m
o
c

y
d
u
t
s

o
r
t
i
v

n
I

m
u
i
h
t
i
l

c
i
n
o
r
h
c

s
u
s
r
e
v

e
l
c
i
h
e
v

d
e
v
i
r
e
d
-
t
n
e
i
t
a
p

n
i

t
n
e
m
t
a
e
r
t

m
o
r
f

s
l
l
e
c

d
i
o
t
s
a
l
b
o
h
p
m
y
l

i

A
N
R
m
7
-
t
e
L

-
n
o
n

r
o

s
r
e
d
n
o
p
s
e
r

r
e
h
t
i
e

)
8
5
n
(

s
r
e
d
n
o
p
s
e
r

R
C
P
q
-
T
R

l
a
r
b
e
r
e
c

l
a
c
o
f

f
o

l
e
d
o
m
e
s
u
o
M

s
u
l
o
b

g
k
/
g
m
1

l

C
L

i

;
a
i
m
e
h
c
s
i

4
2
1
-
R
m

i

S
A
W
G
n
e
G
L
n
o
C

i

t
e
s
a
t
a
d

y
a
d

7

r
o
f

y
a
d
/
g
k
/
g
m
2

n
e
h
t

)
3
6
5
.
2
5
n
(

D
B

d
e
t
s
e
t

e
r
e
w
s
A
N
R
m
2
9
6
.
1

i

-

T
R
d
n
a

y
a
r
r
a
o
r
c
i

M

R
C
P
q

m
o
r
f

d
n
a

)
2
1
5
n
(

s
e
n
i
l

l
l
e
c

m
u
i
h
t
i
l

o
t

)
2
1
5
n
(

R
N

R
E
s
t
n
e
i
t
a
p
D
B

e
r
e
w
s
e
n
e
g

t
e
g
r
a
t

r
i
e
h
t

d
e
t
a
d
i
l
a
v

d
i
o
t
s
a
l
b
o
h
p
m
y
L

d
n
a

,

i

p
3
-
5
5
1
-
R
m
a
0
2
3
-
R
m

i

1
E
L
B
A
T

n
o
i
s
s
e
r
p
x
e
A
N
R
m
n
o
m
u
i
h
t
i
l

i

f
o

s
t
c
e
f
f
e

e
h
t

g
n
i
t
r
o
p
e
r

s
e
i
d
u
t
S

342

Bortolozzi et al.

d
e
u
n
i
t
n
o
C
—
1
E
L
B
A
T

e
c
n
e
r
e
f
e
R

s
t
c
e
f
f

E
m
u
i
h
t
i
L

s
e
n
e
G

t
e
g
r
a
T

d
o
h
t
e
M

s
e
l
p
m
a
S

s
A
N
R
m

i

6
8
2
4
-
r
i

M

.

C
H
h
t
i

w
d
e
r
a
p
m
o
c

e
n
i
l
e
s
a
b

t
a

i

s
A
N
R
m
o
w
T

d
n
a

)
p
3
–
7
3
3
-
R
m

i

,
6
8
2
4
-
R
m

i

(

h
t
i

w
d
e
t
a
e
r
t

s
e
n
i
l

l
l
e
c
-
n
i

e
e
r
h
t

,

p
5
–
6
8
1
-
R
m

i

,
6
8
2
4
-
R
m

i

(

l

C
L

i

e
r
e
w

)
p
5
–
3
2
4
-
R
m

i

d
e
s
s
e
r
p
x
e

y
l
l
a
i
t
n
e
r
e
f
f
i
d

6
8
2
4
-
R
m

i

.

R
L

d
n
a
C
S

n
e
e
w
t
e
b

d
e
r
a
p
m
o
c
C
S

n
i

d
e
s
a
e
r
c
n
i

s
a
w

s
a
e
r
e
h
w

,
e
n
i
l
e
s
a
b

t
a
R
L

h
t
i

w

n
i

d
e
s
a
e
r
c
e
d

s
a
w
p
5
–
6
8
1
-
R
m

i

C
S
m
o
r
f

s
L
C
L

d
e
t
a
e
r
t
-

m
u
i
h
t
i
l

e
h
t

f
o

t
r
a
p

s
t
e
g
r
a
t

6
8
2
4
-
R
m

i

y
a
w
h
t
a
p

e
c
n
a
t
s
i
s
e
r

n
i
l
u
s
n
i

i

A
N
R
m
r
e
t
n
u
o
C
n

y
a
s
s
A
n
o
i
s
s
e
r
p
x
e

d
n
a

g
n
i
r
t
s
o
n
a
N

(

R
C
P
q
-
T
R

D
B
h
t
i

w
s
t
n
e
i
t
a
p
m
o
r
f

s
L
C
L

,

C
S
(

e
d
i
c
i
u
s

y
b

d
e
i
d

f
o

k
s
i
r
w
o
l

a

.
)
1
1
5
n

h
t
i

w
d
n
a

,

R
L
(

e
d
i
c
i
u
s

o
h
w

)
7
5
n

s
n
o
i
t
a
r
t
n
e
c
n
o
c

c
i
t
u
e
p
a
r
e
h
T

e
e
r
f
-
g
u
r
d

r
o

l

C
L

i

f
o

)

M
m
1
(

.

d
e
t
a
u
l
a
v
e

e
r
e
w

p
5
–
3
2
4
–
R
m

i

,

p
5
–
6
8
1
–
R
m

i

p
3
–
7
3
3
-
R
m

i

,
6
8
2
4
-
R
m

i

e
h
t

n
i

d
e
s
a
e
r
c
n
i

o
s
l
a

s
a
w

s
L
C
L

d
e
t
a
e
r
t
-

m
u
i
h
t
i
l

-
i
u
s

f
o

k
s
i
r
w
o
l

,

R
L

;
e
n
i
l

l
l
e
c

d
i
o
t
s
a
l
b
o
h
p
m
y
l

,

L
C
L

;
s
e
m
o
n
e
G
d
n
a

s
e
n
e
G

f
o

a
i
d
e
p
o
l
c
y
c
n
E
o
t
o
y
K

,

G
G
E
K

;
t
n
e
m
n
o
r
i
v
n
E

l
o
o
T

l
a
n
o
i
t
a
g
i
t
s
e
v
n
I

s
k
r
o
w
t
e
N

f
o

s
i
s
y
l
a
n
A
y
r
o
t
a
l
u
g
e
R
c
i
t
e
n
e
G

,

E
T
I
N
A
R
G

;

m
u
i
h
t
i
l

.
l
a
d
i
c
i
u
s

,

C
S

;

n
o
i
t
c
a
e
r

n
i
a
h
c

e
s
a
r
e
m
y
l
o
p

n
o
i
t
p
i
r
c
s
n
a
r
t
-
e
s
r
e
v
e
r

e
v
i
t
a
t
i
t
n
a
u
q

,

R
C
P
q
-
T
R

;

m
u
i
h
t
i
l

o
t

o
t

r
e
d
n
o
p
s
e
r

t
n
e
l
l
e
c
x
e

,

R
E

r
e
d
n
o
p
s
e
r
-
n
o
n

,

R
N

;
e
d
i
c

with two lithium response phenotypes (Reinbold et al.,
2018).

Furthermore, Pisanu et al. (2019) reported differential
expression levels of 31 miRNAs in lymphoblastoid cell
lines from individuals who exhibited excellent responses
to lithium compared with nonresponders. Notably,
changes in miRNA levels showed an inverse correla-
tion with 418 differentially expressed genes in the two
groups. Overall, these data provided new insights into
the molecular processes involved in lithium effects
that may help us ﬁll the gap between molecular func-
tions and the clinical efﬁcacy of mood stabilizers.

VII. Repurposing Lithium for Brain Disorders
Beyond Bipolar Disorder

In addition to effectively treating BD, lithium is cur-
rently under active investigation for a broad array of
neuropsychiatric (i.e., treatment-resistant depression,
suicidal behavior, post-traumatic stress disorder, schizo-
phrenia, and autism spectrum disorder) and neurologic
and neurodegenerative (i.e., PD, HD, AD and frontotem-
poral dementia, ALS, TBI, and stroke) disorders as well
as gastrointestinal disease, cardiovascular disease,
and neoplasia, among other conditions. In addition,
as of July 2022, the US National Institutes of Health
lists 191 planned, recruiting, or active clinical trials
for lithium effects on several disorders (http://www.
clinicaltrials.gov). In this section, we will present a sum-
mary of promising translational research and provide a
concise overview of the current knowledge regarding the
mechanism responsible for lithium-induced neuroplas-
ticity and neuroprotection in neurologic and neurode-
generative disorders.

A. Parkinson Disease

Several studies have provided evidence of lithium’s
neuroprotective properties in cellular and animal models
of PD (Kim et al., 2011; Lieu et al., 2014; Hou et al.,
2015; Lazzara and Kim, 2015; Guttuso et al., 2019, Zhao
et al., 2019; Vall(cid:3)ee et al., 2021). Accumulation and ag-
gregation of the a-synuclein protein, one of the main
histopathological features of PD, may lead to dysfunc-
tional autophagy and lysosomal processes (Cuervo
et al., 2004). Lithium treatment reduces a-synuclein
aggregation by targeting autophagy through the Akt/
mTOR pathway (Motoi et al., 2014). Furthermore, mito-
chondrial complex I inhibitors like 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP) and rotenone are
commonly used neurotoxins to induce PD-like symptoms
in animal models (Cannon et al., 2009). Notably, lithium
treatment has been found to alleviate rotenone-induced
toxicity in human neuroblastoma SH-SY5Y cells. This
protective effect is characterized by reduced nuclear frag-
mentation and apoptosis, accompanied by an increase
in autophagy markers (Xiong et al., 2011). Further-
more, in an MPTP mouse model treated with lithium,

Potential Therapeutic Effects of Lithium

343

researchers observed a decline in mitochondrial mem-
brane potential, decreased generation of reactive oxygen
species, and an enhanced presence of lysosomes and au-
tophagy vacuolar organelles (Li et al., 2013). Likewise,
lithium administration protects against oxidative stress
in a transgenic mouse model with overexpression of
mutant A53T a-synuclein (Kim et al., 2011). Other pre-
clinical studies reported that transplantation of stem
cells preincubated with lithium in rodents with PD im-
proves cognitive functions and motor coordination in
these animals through the regulation of the Wnt/b-
catenin signaling pathway (Qi et al., 2017). Currently,
an active phase 1 clinical trial (clinicaltrials.gov identi-
ﬁer: NCT04273932) is investigating lithium therapy as
a potential disease-modifying therapy in PD (McFarthing
et al., 2022).

B. Huntington Disease

Previous preclinical studies reported that lithium
treatment induces considerable protection against neu-
rodegeneration in an HD-like ﬂy model by inhibiting
IMPase and reducing inositol and IP3 levels (Sarkar
et al., 2008). In addition, other studies showed that
1–10 mM lithium enhances the autophagy of trans-
fected mutant huntingtin in COS-7, SKNSH, PC12, and
mouse embryonic ﬁbroblast cells. Lithium has mixed ef-
improving it by downregulating
fects on autophagy,
GSK-3b, inositol species, and cytoplasmic transcription
factor p53 or, at higher lithium doses, reducing autoph-
agy by activating mTOR through GSK-3b inhibition
(Chiu et al., 2011; Lauterbach, 2013). In addition, early
studies on lithium reported its neuroprotective effects
against apoptotic processes at clinically relevant concen-
trations using various striatal cell culture models of HD,
i.e., striatal medium spiny neurons from YAC128 trans-
genic mice, striatal cells exposed to mutant huntingtin,
or excitotoxic quinoline (Senatorov et al., 2004). Simi-
larly, lithium exhibits neuroprotective properties in the
quinoline injection model, not solely by inhibiting apo-
ptosis but also by promoting the proliferation of neuro-
nal and astroglial progenitors within the striatum or
facilitating their migration from the subventricular zone
(Senatorov et al., 2004). Low-dose lithium (20–40 mg/kg
per day per rectal mucosal absorption) reversed BDNF
deﬁcits in the YAC128 HD transgenic mouse (Pouladi
et al., 2012). Decades ago, lithium’s clinical application
in patients with HD was investigated before its neu-
roprotective properties were recognized. Remarkably,
lithium demonstrated a signiﬁcant reduction in cho-
rea and remarkable improvement in voluntary move-
ments and motor function in patients with HD.
Individuals in the initial phases of the disease ap-
peared to derive greater beneﬁt from lithium treatment,
experiencing advantageous mood and temperament sta-
bilization (Chiu et al., 2013). Conversely, other clinical
studies showed that lithium did not yield any favorable
effects in individuals with HD (Chiu et al., 2013).

Currently, there are no ongoing clinical trials for
lithium and HD. The latest one (clinicaltrials.gov
identiﬁer: NCT00095355) was designed to examine
whether lithium, given alone or with divalproex, in-
creases BDNF levels in the cerebrospinal ﬂuid of HD
patients.

C. Alzheimer Disease

Lithium has been proposed as a potential therapy
for dementia as positive effects have been described in
cellular and animal models of dementia (Tsaltas et al.,
2009; Forlenza et al., 2012; Hampel et al., 2019). There
is evidence for its neuroprotective effects from experi-
mental research and clinical studies using brain im-
aging (Kessing et al., 2010; Puglisi-Allegra et al.,
2021; Chen et al., 2022b). Two meta-analyses (Matsu-
naga et al., 2015; Velosa et al., 2020) and a subsequent
randomized controlled trial (Forlenza et al., 2019) have
suggested that lithium has beneﬁcial effects on cogni-
tion in mild cognitive impairment and AD. Lithium
has the capacity to intervene at various points in the
biochemical processes associated with the onset and
progression of AD. This includes enhancing autophagy,
exerting antiapoptotic effects, and initiating neurotro-
phic cascades. For example, several preclinical studies
showed that therapeutic doses of lithium leave a de-
crease in sprotein hyperphosphorylation through inhibi-
tion of GSK3b, resulting in a reduction of cognitive
impairment in rodents (Phiel et al., 2003; Nakashima
et al., 2005; Engel et al., 2006; Sudduth et al., 2012).

Accumulation of autophagy vacuoles has been demon-
strated in post mortem brain tissue from AD patients,
possibly due to altered autophagy vacuole clearance, but
it may also reﬂect a ﬂawed process of downstream lyso-
somal degradation (Boland et al., 2008; Barnett and
Brewer, 2011). Once more, it is worth noting that lith-
ium-induced autophagy might act in opposition to the
anticipated autophagy suppression observed in AD. This
suppression is attributed to the gradual rise in mTOR
activity throughout the progression of the disease
(Tramutola et al., 2015; Damri et al., 2020).

In addition, lithium favors synthesizing and releasing
neurotrophic factors such as BDNF, whose increased
availability promotes cell survival, stimulates hippocam-
pal neurogenesis, and increases synaptic plasticity (Kerr
et al., 2018; Forlenza et al., 2019). Indeed, accumulation
of b-amyloid (Ab) in the brain is associated with memory
decline in healthy individuals as a prelude to AD.
BDNF polymorphisms have been identiﬁed as potential
moderators of Ab-related cognitive decline in preclinical
AD (Lim et al., 2015). Moreover, BDNF has been shown
to reduce Ab production within the brain (Nigam et al.,
2017). However, BDNF therapeutic potential is hindered
by its short half-life and its inability to penetrate the
blood-brain barrier (Wurzelmann et al., 2017). Lithium
can effectively activate the molecular pathway that in-
creases BDNF synthesis. Recently, a new microdose

344

Bortolozzi et al.

formulation of lithium, NP03, has been reported to be
effective in amyloid pathology after the onset of Ab
plaques by increasing BDNF levels and reducing
markers of neuroinﬂammation and cellular oxidative
stress (Wilson et al., 2020; Kok et al., 2022). Addition-
ally, although the precise molecular mechanisms respon-
sible for lithium’s anti-inﬂammatory effects in dementia
models remain unclear, there is correlational evidence
implicating the involvement of GSK3, STAT, and NFkB
pathways in playing a causative role (Jope et al., 2017;
Kerr et al., 2018). Lastly, there is epidemiology evidence
that levels of lithium in drinking water are associated
with the risk for dementia (McGrath and Berk, 2017).
Taken together, these preclinical data support that lith-
ium has a crucial role in AD, encouraging clinical stud-
ies in patients to evaluate the efﬁcacy of lithium in
contrasting Ab and s pathology (Velosa et al., 2020). Sev-
eral clinical trials are currently in progress focusing on
the effect of lithium as a treatment to prevent impair-
ment of cognition in elders (clinicaltrials.gov identiﬁer:
NCT03185208) as well as in the treatment of psycho-
sis and agitation in AD (clinicaltrials.gov identiﬁer:
NCT02129348).

D. Amyotrophic Lateral Sclerosis

The pathogenesis of ALS involves interconnected
processes, including altered proteostasis, ER stress, ab-
normal UPR signaling, mitochondrial dysfunction, and
impaired autophagy. Interestingly, lithium treatment
has demonstrated efﬁcacy in ALS patients who possess
genetic variations in the UNC13 presynaptic protein.
These genetic variations are linked not only to ALS
spectrum disorders but also to psychiatric conditions
(Lipstein et al., 2017; Nakamura et al., 2018; Limanaqi
et al., 2019). Lithium’s neuroprotective and neurotro-
phic effects on motor function are achieved by targeting
processes associated with UPR signaling, excitotoxicity,
and autophagy dysfunction, whether at synapses or in
cell bodies.

Markers of ER stress and UPR are increased in the
blood and the spinal cord in both ALS patients and
ALS-like mouse models. Notably, the activation of XBP1
represents an early pathologic event in motor neuron
disease (Ilieva et al., 2007; Hetz et al., 2009; Ito et al.,
2009; Montibeller and de Belleroche, 2018; Vats et al.,
2018). Studies conducted in vitro suggest that lithium
can alleviate ER stress by inhibiting GSK3b (Song
et al., 2002; Takadera et al., 2007) and modulatin gene
transcription via the PKC-GSK3b (Chen et al., 2000a;
Hiroi et al., 2005). Lithium also has the potential to mit-
igate ER stress and aberrant UPR signaling by stimu-
lating autophagy. In fact, the administration of lithium
resulted in reduced levels of ER stress-related proteins,
including GRP78, ATF-6, and CHOP, while simulta-
neously enhancing the autophagy process to safeguard
motor neurons in the spinal cord (He et al., 2017; Tong
et al., 2018). Similarly, lithium provides neuroprotective

effects, postpones the onset and duration of the disease,
and extends the lifespan in G93A SOD-1 mice—muta-
tions in copper-zinc superoxide dismutase 1 (SOD1) are
a known genetic cause of ALS, and the SOD1 G93A
mouse has been used extensively to investigate molecular
mechanisms in ALS (Kreilaus et al., 2020)—by triggering
autophagy, promoting the generation of mitochondria,
and inhibiting reactive astrogliosis (Fornai et al., 2008).
In recent studies, it has been discovered that lithium
exerts neuroprotective effects by suppressing the upre-
gulation of Notch signaling and postsynaptic protein
Homer1b/c in the spinal cord of G93A SOD-1 mice. This
mechanism leads to an increase in the Bcl-2/Bax ratio,
contributing to the neuroprotective properties of lithium
in this context (Wang et al., 2015; Jiang et al., 2016).

Moreover, a clinical study showed signiﬁcant beneﬁts
in ALS patients who received riluzole plus lithium for 15
months compared with those who received riluzole alone.
Lithium delayed disease progression in ALS patients as
assessed by quantitative measures of muscle strength
and preservation of lung function (Fornai et al., 2008).
Similarly, the combined administration of lithium and
valproate signiﬁcantly extended the survival of ALS
patients and provided neuroprotection by elevating the
levels of antioxidant defense markers. These changes
were assessed at baseline, 5 months, and 9 months
through the analysis of plasma samples. However, the
clinical trial was prematurely terminated at 21 months
owing to the occurrence of treatment-related adverse
events (Boll et al., 2014). Findings derived from three
randomized trials revealed that although lithium did
not improve the overall 12-month survival rate in the
general ALS population, it signiﬁcantly raised the
12-month survival probability from 40.1% to 69.7%
among individuals carrying the UNC13A variant (van
Eijk et al., 2017). Further investigations delving into the
molecular mechanisms by which lithium operates with
respect to ER stress, UPR, and autophagy may unveil
potential neurobiological processes at play in the early
stages of ALS, potentially leading to the identiﬁcation of
preventive or therapeutic targets.

E. Traumatic Brain Injury

TBI consists of an initial primary injury that causes
mechanical damage to neurons, glia, and blood ves-
sels. This primary injury is frequently succeeded by a
sequence of secondary injuries that commence hours
or even days following the initial trauma and that can
lead to neurodegeneration as well as cognitive and mo-
tor impairments. TBI is also recognized as a potential
contributor to the onset of neurodegenerative conditions
such as AD. In fact, tauopathy and Ab plaques are
known to be the key pathologic markers of TBI, which
contribute to the progressive deterioration associated
with chronic traumatic encephalopathy and AD (Leeds
et al., 2014; Shim and Stutzmann, 2016). Its pathophysi-
ology requires pharmacologic agents that act coordinated

Potential Therapeutic Effects of Lithium

345

to increase cell survival and decrease cell death path-
ways. In this context, there is growing evidence to sup-
port the idea that lithium could potentially alleviate the
neurologic impairments resulting from TBI by acting as
an inhibitor of GSK3-mediated signaling (Leeds et al.,
2014; Welling et al., 2017). Using murine models of TBI,
lithium was reported to attenuate hippocampal neurode-
generation, IL-1b expression, and brain edema. It also
inhibits microglia activation, matrix metallopeptidase-9
expression, and cyclooxygenase-2 induction (Reis et al.,
2015; Dell’Osso et al., 2016). In addition, low doses of
combined lithium and valproate were more helpful in at-
tenuating TBI than either agent used alone, leading to a
reduction in neurodegeneration and neuroinﬂammation
associated with improved behavioral outcomes (Yu et al.,
2013). Zhu et al. (2010) achieved comparable outcomes,
demonstrating that the administration of lithium led to
a decrease in tissue damage while enhancing memory
performance and spatial learning abilities. In addition,
these data were associated with a decreased proinﬂam-
matory IL-1b expression (Zhu et al., 2010). Likewise,
lithium treatment was reported to reduce depressive-
like behavior in mice after cold-induced TBI (Ciftci
et al., 2020). Although not strictly a traumatic brain
injury, lithium has been shown to be neuroprotective
in people with cancer receiving chemotherapy or radio-
therapy (Khasraw et al., 2012).

These discoveries suggest the potential repurposing
of mood stabilizers like lithium and valproate, whether
used individually or in combination, as viable pharma-
ceutical options for addressing neurologic disorders char-
acterized by excitotoxic components, the best example of
which is TBI. Currently, a phase 3 study (clinicaltrials.
gov identiﬁer: NCT05126238) examines the hypothesis
that preoperative lithium administration may reduce
brain damage during carotid artery surgery.

F. Stroke

Ischemic stroke is a severe life-threatening disease
that causes degeneration and death of neurons, leading
to the loss of motor function and frequent occurrence of
cognitive impairment and depression (Pendlebury and
Rothwell, 2009; Brown et al., 2012; Makin et al., 2013).
The intricate pathophysiology of this condition encom-
passes an initial acute stage, during which neuronal loss
is induced by a combination of hypoxia and nutrient
deprivation. These factors set in motion mechanisms
that ultimately give rise to neuroinﬂammation and
apoptosis. The subsequent phase, marked by delayed
brain injury, is further compounded by the subse-
quent restoration of blood vessel perfusion. Improv-
ing neurologic outcomes after an ischemic stroke is a
major clinical priority. However, most neuroprotec-
tants for stroke effective in rodent research have not
been efﬁcacious in clinical practice (Haupt et al., 2021;
Chen et al., 2022a). Therefore, repurposing market-
approved neuroprotective drugs, such as lithium, for

treating cerebral ischemia represents a viable strat-
egy. In this context, previous studies using rodent
models of stroke showed that lithium treatment in-
duces antiapoptotic mechanisms, leading to decreased
caspase-3 activity, reductions in activated protein one
and proapoptotic p53 expression, and increases in anti-
apoptotic Bcl-2 and heat shock protein 70 (HSP70) lev-
els (Xu et al., 2003; Bian et al., 2007). Furthermore,
lithium enhanced hippocampal neurogenesis in a pre-
clinical model of global cerebral ischemia. The effects,
as mentioned earlier, are not both dependent on the
GSK3b pathway and involve other signaling pathways,
such as prosurvival MAPK/ERK1/2 (Yan et al., 2007a,b;
Sawe et al., 2008).

Further research endeavors were undertaken to
explore the therapeutic potential of administering lithium
following a stroke event. In a rat ischemia/reperfusion
model, poststroke lithium treatment demonstrated a no-
table reduction in infarct volume and a corresponding de-
crease in neurologic deﬁcits (Ren et al., 2003). Moreover,
this neuroprotective effect was correlated with a decrease
in apoptosis levels and an elevation in HSP70 levels
(Ren et al., 2003). In addition, lithium administration
led to improved spatial learning and memory perfor-
mance in mice subjected to ischemia-reperfusion (Fan
et al., 2015). Although the precise mechanisms govern-
ing how lithium regulates inﬂammation, apoptosis, and
neuroplasticity after a stroke are still largely shrouded
in mystery, emerging evidence hints at the possibility
that lithium may exert its inﬂuence not only within the
brain parenchyma but also directly on the endothelium
itself (Bosche et al., 2016). Consistent with this observa-
tion, Haupt et al., (2020) reported that lithium-induced
impact on endothelium cells could reverse early blood-
brain barrier breakdown after stroke, resulting in a con-
trolled modulation of leukocyte inﬁltration into the brain
parenchyma. In addition to preclinical
investigations,
there is data from two clinical trials. One assessed retro-
spective risk in patients treated with lithium (Lan et al.,
2015), and the other examined the prospective motor re-
covery of stroke patients undergoing lithium treatment
(Mohammadianinejad et al., 2014). Thus, a randomized
clinical trial on the effects of lithium in stroke patients
demonstrated enhanced motor recovery after early
treatment with low-dose lithium (Mohammadianinejad
et al., 2014). More recently, however, evidence-based
guidelines from the European Academy of Neurology
and the European Federation of Neurorehabilitation So-
cieties do not recommend lithium intervention for early
motor rehabilitation after acute ischemic stroke due to
safety and tolerability concerns (Beghi et al., 2021). Cur-
rently, some clinical trials (e.g., clinicaltrials.gov identiﬁer:
NCT05126238) aim to examine a lithium-based medi-
cation to improve neurologic outcomes after carotid ar-
tery surgery.

346

Bortolozzi et al.

VIII. Limitations for Lithium Treatment

Despite its widely proven efﬁcacy, lithium use is some-
times limited due to its narrow therapeutic index requiring
routine monitoring of serum concentrations, possible nega-
tive effects on endocrine and renal function, or teratogenic-
ity (McKnight et al., 2012).

A. Renal Funcion

Nephrogenic diabetes insipidus is the most common
renal side effect of lithium therapy, characterized by
loss of the ability of the kidney to concentrate urine
due to resistance to vasopressin (Garofeanu et al.,
2005). Rarely, when nephrogenic diabetes insipidus is
uncontrolled, it may result in distal renal tubular aci-
dosis (Weiner et al., 2014). Polyuria may rapidly occur
during lithium treatment but is usually resolved once
lithium is interrupted (Garofeanu et al., 2005). Long-
term lithium treatment occasionally causes nephrotoxi-
city, characterized by kidney dysfunction and interstitial
nephritis with microcyst formation and, occasionally,
focal segmental glomerulosclerosis (Gr€unfeld and Rossier,
2009). In a longitudinal recent study on a large popula-
tion of patients treated with lithium or valproate, results
showed that lithium was meaningfully associated with
adverse kidney outcomes, but the absolute risks did not
signiﬁcantly differ from those observed with valproate
therapy (Bosi et al., 2023). However, the risk of chronic
kidney disease increased with lithium levels >1 mmol/L
(Bosi et al., 2023). In line with this evidence, another
study showed that long-term lithium therapy was not
linked to nephrotoxicity in the absence of acute intoxi-
cation episodes (Clos et al., 2015) nor to increased
rates of chronic kidney disease (Kessing et al., 2015).

Although the biologic underpinnings of nephrotoxicity
are complex and poorly understood, several molecular
mechanisms might be implicated, including the suppres-
sion of phosphatidylinositol (3,4,5)-trisphosphate (PIP3)
signaling, inhibition of GSK3a, competition with magne-
sium ions, and overactivity of cyclooxygenase-2 (Gong
et al., 2016).

B. Thyroid and Parathyroyd Function

Thyroid (Kibirige et al., 2013) and parathyroid
(Meehan et al., 2018) abnormalities affect up to 25%
of patients receiving lithium treatment. Lithium is
highly concentrated in the thyroid glands and inhibits
iodine uptake, iodothyrosine coupling, and thyroxine
secretion and modiﬁes thyroglobulin structure (P(cid:3)erez-
Castro et al., 2021). Lithium competes for the iodide
transport in thyroid glands, ultimately leading to
reduced iodine reuptake (Shopsin et al., 1973). Lithium
may also increase the thyroid-stimulating hormone se-
cretion in response to the inhibitory effect on thyroxine
(T4) availability, which leads to the inhibition of cAMP
and alteration of tubulin polymerization (Lazarus, 1998).
The alteration of thyroglobulin structure might be

caused by the effect of lithium on protein conformation
and subsequent iodotyrosine coupling defects (Lazarus,
1998). These molecular alterations result in clinical
manifestations such as hypothyroidism, goitre, or
hyperthyroidism (P(cid:3)erez-Castro et al., 2021). The risk
of developing hypothyroidism and subclinical hypothy-
roidism in long-term treated patients is 6 times higher
than in the general population (McKnight et al., 2012).
Lithium-induced hyperthyroidism is less frequent and is
characterized by transient and painless thyroiditis. The
risk of developing primary hyperparathyroidism during
lithium treatment is relatively high, and it is probably
caused by the inactivation of the calcium-sensing recep-
tor and interference with intracellular second messenger
signaling, with a subsequent increase in parathyroid
hormone and blood calcium levels (Szalat et al., 2009).
Therefore, both thyroid and parathyroid function should
be monitored in clinical practice by baseline blood tests
of thyroid-stimulating hormone and calcium and regular
yearly follow-ups (Malhi et al., 2017).

C. Lithium and Pregnancy

Clinical concerns have been raised regarding the risk
of lithium during pregnancy. A recent meta-analysis
showed that lithium-exposed women had higher odds
of any congenital anomaly or cardiac malformations
compared with nonexposed ones (Fornaro et al., 2020).
However, the risk of congenital malformations at any
time during pregnancy was globally low, being higher
for the ﬁrst trimester or with higher lithium doses.
Also, there are no signiﬁcant differences in obstetric out-
comes in women with BD that take lithium during preg-
nancy compared with those not treated with lithium except
for an impact on newborn Apgar scores (Sagu(cid:3)e-Vilavella
et al., 2022). However, although lithium treatment in the
peripartum period is considered safe, attention should be
paid during the ﬁrst trimester in particular, always priori-
tizing the lowest effective dose (Clark et al., 2022).

D. Metabolic Effects

Weight gain is a distressing adverse effect that has
been previously associated with lithium treatment
(Gitlin, 2016). Lithium might have an insulin-like effect
on increasing glucose uptake and glycogen production in
animal models (de Groot et al., 2017; Jung et al., 2021).
In humans, the administration of lithium induces insulin-
like hypoglycemia (Shah et al., 1986). Likewise, lithium
induces the suppression of GSK3, a key regulator of glyco-
gen metabolism cell proliferation on differentiation
(Snitow et al., 2021). However, a recent meta-analysis
did not show a signiﬁcant increase in weight in pa-
tients taking lithium compared with the ones without
lithium or against placebo (Gomes-da-Costa et al.,
2022). Indeed, patients with BD have a higher risk
compared with the general population of developing
weight-related conditions, including metabolic syndrome,
diabetes, or obesity, independently of lithium treatment

Potential Therapeutic Effects of Lithium

347

(Prillo et al., 2021). A combination treatment with lith-
ium antipsychotics is often used both in the acute and
maintenance phases of BD. Antipsychotics, in particular
olanzapine and clozapine,
induce more pronounced
metabolic side effects compared with lithium, includ-
ing weight gain (Pillinger et al., 2020). Aripriprazole
showed no signiﬁcant differences in the long-term use
compared with lithium in terms of metabolic parame-
ters in patients with BD type I (McIntyre et al.,
2011). When used in combination with antipsychotics,
lithium showed to improve manic symptoms but also
increase the risk of metabolic syndrome (K€ohler-Fors-
berg et al., 2023).

E. Skin and Hair Disorders

There is conﬂicting evidence on the risk of skin and
hair disorders with lithium treatment. Mechanisms
involved in lithium-related skin disorders might involve
cAMP cascade or the inhibition of the synthesis of pros-
taglandins, which ultimately stimulates neutrophil func-
tion (Jafferany, 2008). Although recent meta-analyses do
not point to an increased rate of adverse skin reactions,
clinicians should not overlook cutaneous symptoms dur-
ing lithium treatment (Pinna et al., 2017).

F. Cognitive Effects

Concerns regarding cognitive impairment in patients
treated with lithium have been raised (Wingo et al.,
2009). Accumulating evidence is somewhat contrasting,
suggesting that the cognitive effects of lithium are nu-
anced or showing a positive effect of lithium on cognitive
performance. Some studies have indicated that lithium
treatment may not only preserve but potentially improve
certain aspects of neurocognitive function in individuals
with BD (Burdick et al., 2020). Notably, cognitive domains
such as verbal learning, memory recall, and executive
functions (Rybakowski et al., 2009) have been found to
exhibit positive responses to lithium therapy. However,
individual responses may vary, and some patients may
report subjective experiences of cognitive numbness
(Grandjean and Aubry, 2009). Despite these reports,
lithium’s overall cognitive effects seem to lean toward
beneﬁting neurocognitive functioning in patients with
BD, further supporting its continued use as a valuable
treatment option with careful monitoring and manage-
ment of side effects.

G. Toxicity in Overdose

Lithium is dangerous in overdose, and clinical signs
of toxicity might be seen at lithium serum concentra-
tions equal to or more than 1.5 mEq/L (Oruch et al.,
2014). Symptoms and signs of lithium toxicity may
involve different systems, such as the gastrointestinal
(nausea, vomiting, diarrhea), neurologic (confusion, leth-
argy, seizures, and coma, named syndrome of irrevers-
ible Lithium-Effected Neurotoxicity and attributed to
cerebellar dysfunction), musculoskeletal (tremor or muscle

twitching), renal (renal failure), cardiovascular (T wave
inversion, conduction disturbances, arrhythmias, atrio-
ventricular node dissociations, cardiovascular collapse),
and hematologic (leukocytosis) systems. Indeed, clinical
guidelines suggest monitoring serum lithium concentra-
tions regularly to avoid lithium overdose (Malhi et al.,
2017).

Lithium’s adverse effect and toxicity proﬁle might
be one of the causes of its decreased clinical usage
during the last decade. The majority of side effects
under lithium treatment are not life-threatening and
can be easily managed.

IX. Conclusions and Future Directions

In this review, we focused on the multiple functions
of lithium that demonstrate its exceptional pharmacol-
ogy and therapeutic effects to highlight common mecha-
nisms of action in different brain disorders. As the
complex therapeutic mechanisms of lithium are unrav-
eled, valuable information is provided to better under-
stand the pathophysiology of the diseases in which it is
implicated and point to possible new therapeutic devel-
opments. Converging evidence from preclinical and clin-
ical models ﬁrmly supports the concept that lithium
exerts regulatory effects on diverse cellular pathways
within the brain that are crucial for neuroplasticity and
neuroprotection. These include neurotrophic response,
ER stress, UPR, autophagy, oxidative stress, mitochon-
drial function, and inﬂammation. This wide range of in-
tracellular responses may be secondary to two key
effects: inhibition of GSK3 and IMPase by lithium, in
which dysregulation has been implicated in diverse
neuropathological conditions. Therefore, a more pro-
found and precise understanding of the speciﬁc thera-
peutic mechanisms of lithium will aid us in establishing
a better understanding of the complex mechanisms
underlying the pathophysiology of BD.

Although the promotion of autophagy is widely recog-
nized as the primary molecular mechanism explaining
lithium’s protective effects in neurodegenerative diseases,
there is still a lack of understanding regarding how lith-
ium’s ability to enhance autophagy might contribute to
therapeutic beneﬁts for patients with neuropsychiatric
disorders, including BD. An inability to effectively clear
misfolded proteins through autophagy can result in the
accumulation of these substrates within cells. Conse-
quently, a shared pathogenic factor implicated in neu-
rodegenerative disorders is the inhibition of autophagy,
often stemming from mTOR activation. However, the
signaling pathway of lithium as an autophagy enhancer
might be an mTOR-independent pathway involving IP3
signaling. Indeed, although the pathophysiology of neu-
rodegenerative diseases is clearly different from mood
disorders, cognitive impairment and functional decline
are present in many bipolar patients, and neuroimaging
ﬁndings conﬁrm decreased neuroplasticity and its anatomic

348

Bortolozzi et al.

correlates, particularly concerning gray matter loss (Vieta
et al., 2018).

Although lithium unquestionably demonstrates efﬁ-
cacy in both treating and preventing BD, it is worth
noting that certain subtypes of the disorder exhibit a
reduced responsiveness to lithium, and not all individ-
uals experience the therapeutic advantages it offers.
The crucial task of pinpointing biologic indicators that
can predict a patient’s response to lithium remains a
signiﬁcant stride toward advancing personalized medi-
cine in the treatment of BD (Salagre and Vieta, 2021).
With contemporary neuroimaging methodologies at
our disposal to explore the fundamental neurobiological
processes involved in BD, as well as the neuroprotective
and neurotrophic impacts of lithium, there is a hopeful
expectation that forthcoming research in neuroimaging
will expedite the discovery and exploration of biologic in-
dicators for predicting the response to lithium treat-
ment. The development of more robust and personalized
predictive models remains an important area of future
research. Integrating multiomics data, such as genomics,
transcriptomics, proteomics, and metabolomics with clini-
cal characteristics, and other relevant factors through
machine learning and artiﬁcial intelligence algorithms
could signiﬁcantly enhance the accuracy and speciﬁcity
of such models. Also, innovation in molecular technolo-
gies, such as organ-on-a-chip systems and iPSC-derived
three-dimensional organoids, can provide novel experi-
mental models to study lithium’s effects on human brain
cells with greater precision and relevance. International
collaborative consortiums involving different populations
will be fundamental in generating comprehensive data-
sets for training and validating these models, therefore
increasing their reliability.

The fact that lithium has withstood several tests,
including concerns about its potential lethal toxicity
and difﬁculty of use, and has remained steadfast as
the treatment of choice for BD for more than six dec-
ades demonstrates that lithium is an essential thera-
peutic agent and an extraordinary tool in neuroscience
research.

Data Availability

The authors declare that all the data supporting the ﬁndings

of this study are contained within the paper.

Authorship Contributions

Wrote or contributed to the writing of the manuscript: Bortolozzi,
Fico, Berk, Solmi, Fornaro, Quevedo, Zarate, Kessing, Vieta, Carvalho.

References
Abrial E, Etievant A, B(cid:3)etry C, Scarna H, Lucas G, Haddjeri N, and Lamb(cid:3)as-Se~nas L
(2013) Protein kinase C regulates mood-related behaviors and adult hippocampal
cell proliferation in rats. Prog Neuropsychopharmacol Biol Psychiatry 43:40–48.

Adams BW and Moghaddam B (2001) Effect of clozapine, haloperidol, or M100907 on
phencyclidine-activated glutamate efﬂux in the prefrontal cortex. Biol Psychiatry
50:750–757.

Ahmad A, Sheikh S, Khan MA, Chaturvedi A, Patel P, Patel R, Buch BC, Anand
RS, Shah TC, Vora VN, et al. (2021) Endoxifen: A new, protein kinase C inhibitor
to treat acute and mixed mania associated with bipolar I disorder. Bipolar Disord
23:595–603.

Akkouh IA, Skrede S, Holmgren A, Ersland KM, Hansson L, Bahrami S,
Andreassen OA, Steen VM, Djurovic S, and Hughes T (2020) Exploring lithium’s
transcriptional mechanisms of action in bipolar disorder: a multi-step study.
Neuropsychopharmacology 45:947–955.

Alda M (2015) Lithium in the treatment of bipolar disorder: pharmacology and

pharmacogenetics. Mol Psychiatry 20:661–670.

Allen J, Romay-Tallon R, Brymer KJ, Caruncho HJ, and Kalynchuk LE (2018)
Mitochondria and Mood: Mitochondrial Dysfunction as a Key Player in the
Manifestation of Depression. Front Neurosci 12:386.

Amare AT, Schubert KO, Hou L, Clark SR, Papiol S, Cearns M, Heilbronner U,
Degenhardt F, Tekola-Ayele F, Hsu YH, et al. (2021) Association of polygenic
score for major depression with response to lithium in patients with bipolar
disorder. Molecular psychiatry 26:2457–2470.

Amiri S, Jafari-Sabet M, Keyhanfar F, Falak R, Shabani M, and Rezayof A (2020)
Hippocampal and prefrontal cortical NMDA receptors mediate the interactive
effects of olanzapine and lithium in memory retention in rats: the involvement of
CAMKII-CREB signaling pathways. Psychopharmacology (Berl) 237:1383–1396.
Amrollahi Z, Rezaei F, Salehi B, Modabbernia AH, Marouﬁ A, Esfandiari GR, Naderi
M, Ghebleh F, Ahmadi-Abhari SA, Sadeghi M, et al. (2011) Double-blind, randomized,
placebo-controlled 6-week study on the efﬁcacy and safety of the tamoxifen adjunctive
to lithium in acute bipolar mania. J Affect Disord 129:327–331.

Anand A, Nakamura K, Spielberg JM, Cha J, Karne H, and Hu B (2020)
Integrative analysis of lithium treatment associated effects on brain structure
and peripheral gene expression reveals novel molecular insights into mechanism
of action. Transl Psychiatry 10:103.

Anmella G, Vieta E, and Hidalgo-Mazzei D (2021) Commentary on: “Make lithium

great again!”. Bipolar Disord 23:90–91.

Ar(cid:3)evalo JC and Wu SH (2006) Neurotrophin signaling: many exciting surprises!

Cell Mol Life Sci 63:1523–1537.

Artigas F, Celada P, and Bortolozzi A (2018) Can we increase the speed and efﬁcacy
of antidepressant treatments? Part II. Glutamatergic and RNA interference
strategies. Eur Neuropsychopharmacol 28:457–482.

Ates N, Caglayan A, Balcikanli Z, Sertel E, Beker MC, Dilsiz P, Caglayan AB, Celik
S, Dasdelen MF, Caglayan B, et al. (2022) Phosphorylation of PI3K/Akt at Thr308,
but not phosphorylation of MAPK kinase, mediates lithium-induced neuroprotection
against cerebral ischemia in mice. Exp Neurol 351:113996.

Autry AE and Monteggia LM (2012) Brain-derived neurotrophic factor and

neuropsychiatric disorders. Pharmacol Rev 64:238–258.

Balchin D, Hayer-Hartl M, and Hartl FU (2016) In vivo aspects of protein folding

and quality control. Science 353:aac4354.

Barnett A and Brewer GJ (2011) Autophagy in aging and Alzheimer’s disease:

pathologic or protective? J Alzheimers Dis 25:385–394.

Bar-Yosef T, Damri O, and Agam G (2019) Dual Role of Autophagy in Diseases of

the Central Nervous System. Front Cell Neurosci 13:196.

Bauer M, Alda M, Priller J, and Young LT; International Group For The Study Of
Lithium Treated Patients (IGSLI) (2003) Implications of the neuroprotective
effects of lithium for the treatment of bipolar and neurodegenerative disorders.
Pharmacopsychiatry 36 (Suppl 3):S250–S254.

Bauer IE, Soares JC, Selek S, and Meyer TD (2017) The Link between Refractoriness
and Neuroprogression in Treatment-Resistant Bipolar Disorder. Mod Trends
Pharmacopsychiatry 31:10–26.

Bauer M, Bschor T, Kunz D, Bergh€ofer A, Str€ohle A, and M€uller-Oerlinghausen B
(2000) Double-blind, placebo-controlled trial of the use of lithium to augment
antidepressant medication in continuation treatment of unipolar major depression.
Am J Psychiatry 157:1429–1435.

Bauer M (2022) Lithium: What can we do to overcome the discrepancies between
evidence, guideline recommendations and clinical practice? Eur Neuropsychopharmacol
60:1–3.

Beaulieu JM, Sotnikova TD, Yao WD, Kockeritz L, Woodgett JR, Gainetdinov RR,
and Caron MG (2004) Lithium antagonizes dopamine-dependent behaviors
mediated by an AKT/glycogen synthase kinase 3 signaling cascade. Proc Natl
Acad Sci USA 101:5099–5104.

Beaulieu JM, Marion S, Rodriguiz RM, Medvedev IO, Sotnikova TD, Ghisi V,
Wetsel WC, Lefkowitz RJ, Gainetdinov RR, and Caron MG (2008) A beta-arrestin
2 signaling complex mediates lithium action on behavior. Cell 132:125–136.

Beech RD, Leffert JJ, Lin A, Sylvia LG, Umlauf S, Mane S, Zhao H, Bowden C,
Calabrese JR, Friedman ES, et al. (2014) Gene-expression differences in peripheral
blood between lithium responders and non-responders in the Lithium Treatment-
Moderate dose Use Study (LiTMUS). Pharmacogenomics J 14:182–191.

Beghi E, Binder H, Birle C, Bornstein N, Diserens K, Groppa S, Homberg V, Lisnic V,
Pugliatti M, Randall G, et al. (2021) European Academy of Neurology and European
Federation of Neurorehabilitation Societies guideline on pharmacological support in
early motor rehabilitation after acute ischaemic stroke. Eur J Neurol 28:2831–2845.
Bengesser SA, Fuchs R, Lackner N, Birner A, Reininghaus B, Meier-Allard N,
Stracke A, Kapfhammer HP, Reininghaus EZ, and Wallner-Liebmann S (2016)
Endoplasmic Reticulum Stress and Bipolar Disorder - Almost Forgotten Therapeutic
Drug Targets in the Unfolded Protein Response Pathway Revisited. CNS Neurol
Disord Drug Targets 15:403–413.

Bergh€ofer A, Alda M, Adli M, Baethge C, Bauer M, Bschor T, Grof P, M€uller-
Oerlinghausen B, Rybakowski JK, Suwalska A, et al. (2013) Stability of lithium
treatment in bipolar disorder - long-term follow-up of 346 patients. Int J Bipolar
Disord 1:11.

Berk M, Ichim L, and Brook S (1999) Olanzapine compared to lithium in mania: a
double-blind randomized controlled trial. Int Clin Psychopharmacol 14:339–343.
Berk M (2009) Neuroprogression: pathways to progressive brain changes in bipolar

disorder. Int J Neuropsychopharmacol 12:441–445.

Berk M, Brnabic A, Dodd S, Kelin K, Tohen M, Malhi GS, Berk L, Conus P, and
McGorry PD (2011) Does stage of illness impact treatment response in bipolar
disorder? Empirical treatment data and their implication for the staging model
and early intervention. Bipolar Disord 13:87–98.

Potential Therapeutic Effects of Lithium

349

Berk M, Dandash O, Daglas R, Cotton SM, Allott K, Fornito A, Suo C, Klauser P,
Liberg B, Henry L, et al. (2017) Neuroprotection after a ﬁrst episode of mania: a
randomized controlled maintenance trial comparing the effects of lithium and
quetiapine on grey and white matter volume. Transl Psychiatry 7:e1011.

Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, and
Krystal JH (2000) Antidepressant effects of ketamine in depressed patients. Biol
Psychiatry 47:351–354.

Beurel E and Jope RS (2009) Lipopolysaccharide-induced interleukin-6 production
is controlled by glycogen synthase kinase-3 and STAT3 in the brain. J
Neuroinﬂammation 6:9.

Beurel E, Song L, and Jope RS (2011) Inhibition of glycogen synthase kinase-3 is
necessary for the rapid antidepressant effect of ketamine in mice. Mol Psychiatry
16:1068–1070.

Beurel E and Jope RS (2014) Inﬂammation and lithium: clues to mechanisms

contributing to suicide-linked traits. Transl Psychiatry 4:e488.

Beurel E, Grieco SF, and Jope RS (2015) Glycogen synthase kinase-3 (GSK3):

regulation, actions, and diseases. Pharmacol Ther 148:114–131.

Bezchlibnyk YB, Xu L, Wang JF, and Young LT (2007) Decreased expression of
insulin-like growth factor binding protein 2 in the prefrontal cortex of subjects with
bipolar disorder and its regulation by lithium treatment. Brain Res 1147:213–217.
Bian Q, Shi T, Chuang DM, and Qian Y (2007) Lithium reduces ischemia-induced
hippocampal CA1 damage and behavioral deﬁcits in gerbils. Brain Res 1184:270–276.
Bj€orkholm C and Monteggia LM (2016) BDNF - a key transducer of antidepressant

effects. Neuropharmacology 102:72–79.

Bohlken J, Riedel-Heller S, Bauer M, and Kostev K (2021) Bipolar Disorder and
Outcomes of Monotherapy with Lithium, Valproate, Quetiapine, Olanzapine,
Venlafaxine, and Citalopram. Pharmacopsychiatry 54:126–130.

Boland B, Kumar A, Lee S, Platt FM, Wegiel J, Yu WH, and Nixon RA (2008)
Autophagy induction and autophagosome clearance in neurons: relationship to
autophagic pathology in Alzheimer’s disease. J Neurosci 28:6926–6937.

Boll MC, Bayliss L, Vargas-Ca~nas S, Burgos J, Montes S, Pe~naloza-Solano G, Rios C,
and Alcaraz-Zubeldia M (2014) Clinical and biological changes under treatment
with lithium carbonate and valproic acid in sporadic amyotrophic lateral sclerosis. J
Neurol Sci 340:103–108.

Bortolozzi A, Manashirov S, Chen A, and Artigas F (2021) Oligonucleotides as
therapeutic tools for brain disorders: Focus on major depressive disorder and
Parkinson’s disease. Pharmacol Ther 227:107873.

Bosche B, Molcanyi M, Noll T, Rej S, Zatschler B, Doeppner TR, Hescheler J, M€uller
DJ, Macdonald RL, and H€artel FV (2016) A differential impact of lithium on
endothelium-dependent but not on endothelium-independent vessel relaxation. Prog
Neuropsychopharmacol Biol Psychiatry 67:98–106.

Bosi A, Clase CM, Ceriani L, Sj€olander A, Fu EL, Runesson B, Chang Z, Land(cid:3)en M,
Bellocco R, Elinder CG, et al. (2023) Absolute and Relative Risks of Kidney
Outcomes Associated With Lithium vs Valproate Use in Sweden. JAMA Netw Open
6:e2322056.

Bouﬁdou F, Nikolaou C, Alevizos B, Liappas IA, and Christodoulou GN (2004)
Cytokine production in bipolar affective disorder patients under lithium treatment.
J Affect Disord 82:309–313.

Breen MS, White CH, Shekhtman T, Lin K, Looney D, Woelk CH, and Kelsoe JR
(2016) Lithium-responsive genes and gene networks in bipolar disorder patient-
derived lymphoblastoid cell lines. Pharmacogenomics J 16:446–453.

Brown C, Hasson H, Thyselius V, and Almborg AH (2012) Post-stroke depression

and functional independence: a conundrum. Acta Neurol Scand 126:45–51.

Bschor T, Uhr M, Baethge C, Lewitzka U, Ising M, Erbe S, Winkelmann P, and
Ritter D (2013) Acute antidepressive efﬁcacy of
lithium monotherapy, not
citalopram, depends on recurrent course of depression. J Clin Psychopharmacol
33:38–44.

Bschor T, Adli M, Alda M, Baethge C, Etain B, Glenn T, Grof P, Hajek T, Hayes J,
Manchia M, et al.; International Group for The Study of Lithium Treated
Patients (IGSLI) (2022) Letter of response to Nabi Z, Stansfeld J, Pl€oderl M,
Wood L, Moncrieff J. Effects of lithium on suicide and suicidal behaviour: a
systematic review and meta-analysis of randomised trials. Epidemiol Psychiatr
Sci 31:e84.

Burdick KE, Millett CE, Russo M, Alda M, Alliey-Rodriguez N, Anand A, Balaraman
Y, Berrettini W, Bertram H, Calabrese JR, et al. (2020) The association between
lithium use and neurocognitive performance in patients with bipolar disorder.
Neuropsychopharmacology 45:1743–1749.

Byrum SD, Washam CL, Tackett AJ, Garcia-Rill E, Bisagno V, and Urbano FJ

(2019) Proteomic measures of gamma oscillations. Heliyon 5:e02265.

Caberlotto L, Carboni L, Zanderigo F, Andreetta F, Andreoli M, Gentile G, and
Razzoli M (2013) Differential effects of glycogen synthase kinase 3 (GSK3)
inhibition by lithium or selective inhibitors in the central nervous system.
Naunyn Schmiedebergs Arch Pharmacol 386:893–903.

Cade JFJ (1949) Lithium salts in the treatment of psychotic excitement. Med

J Aust 2:349–352.

Calabrese JR, Rapport DJ, Youngstrom EA, Jackson K, Bilali S, and Findling RL
(2005) New data on the use of lithium, divalproate, and lamotrigine in rapid
cycling bipolar disorder. Eur Psychiatry 20:92–95.

Caldiroli A, Capuzzi E, Tagliabue I, Capellazzi M, Marcatili M, Mucci F, Colmegna
F, Clerici M, Buoli M, and Dakanalis A (2021) Augmentative pharmacological
strategies in treatment-resistant major depression: A comprehensive review. Int
J Mol Sci 22:13070.

Calkin CV, Ruzickova M, Uher R, Hajek T, Slaney CM, Garnham JS, O’Donovan
MC, and Alda M (2015) Insulin resistance and outcome in bipolar disorder. Br
J Psychiatry 206:52–57.

Calkin CV, Chengappa KNR, Cairns K, Cookey J, Gannon J, Alda M, O’Donovan C,
Reardon C, Sanches M, and R˚uzickov(cid:3)a M (2022) Treating Insulin Resistance
With Metformin as a Strategy to Improve Clinical Outcomes in Treatment-
Resistant Bipolar Depression (the TRIO-BD Study): A Randomized, Quadruple-
Masked, Placebo-Controlled Clinical Trial. J Clinl Psychiatry 83:21m14022.

Calsolaro V and Edison P (2016) Neuroinﬂammation in Alzheimer’s disease:

Current evidence and future directions. Alzheimers Dement 12:719–732.

Cannon JR, Tapias V, Na HM, Honick AS, Drolet RE, and Greenamyre JT (2009) A
highly reproducible rotenone model of Parkinson’s disease. Neurobiol Dis 34:279–290.
Carvalho AF, Quevedo J, McIntyre RS, Soeiro-de-Souza MG, Fountoulakis KN, Berk M,
Hyphantis TN, and Vieta E (2014) Treatment implications of predominant polarity
and the polarity index: a comprehensive review. Int J Neuropsychopharmacol
18:pyu079.

Carvalho AF, Firth J, and Vieta E (2020) Bipolar Disorder. N Engl J Med 383:58–66.
Carvalho AF, Solmi M, Husain MI, Berk M, and Vieta E (2021) The rebirth of

lithium as the archetypal mood stabilizer. Bipolar Disord 23:211–212.

Castro AA, Casagrande TS, Moretti M, Constantino L, Petronilho F, Guerra GC,
Calo’ G, Guerrini R, Dal-Pizzol F, Quevedo J, et al. (2009) Lithium attenuates
behavioral and biochemical effects of neuropeptide S in mice. Peptides
30:1914–1920.

Cearns M, Amare AT, Schubert KO, Thalamuthu A, Frank J, Streit F, Adli M,
Akula N, Akiyama K, Ardau R, et al.; Major Depressive Disorder Working Group
of the Psychiatric Genomics Consortium (2022) Using polygenic scores and
clinical data for bipolar disorder patient stratiﬁcation and lithium response
prediction: machine learning approach. Br J Psychiatry 28:1–10.

Chen G, Manji HK, Hawver DB, Wright CB, and Potter WZ (1994) Chronic sodium
valproate selectively decreases protein kinase C alpha and epsilon in vitro.
J Neurochem 63:2361–2364.

Chen G, Masana MI, and Manji HK (2000a) Lithium regulates PKC-mediated
intracellular cross-talk and gene expression in the CNS in vivo. Bipolar Disord
2:217–236.

Chen B, Wang JF, and Young LT (2000b) Chronic valproate treatment increases
expression of endoplasmic reticulum stress proteins in the rat cerebral cortex
and hippocampus. Biol Psychiatry 48:658–664.

Chen B, Zhang M, Ji M, Zhang D, Chen B, Gong W, Li X, Zhou Y, Dong C, Wen G,
et al. (2022a) The neuroprotective mechanism of lithium after ischaemic stroke.
Commun Biol 5:105.

Chen CH, Lee CS, Lee MT, Ouyang WC, Chen CC, Chong MY, Wu JY, Tan HK, Lee
YC, Chuo LJ, et al., Taiwan Bipolar Consortium (2014) Variant GADL1 and
response to lithium therapy in bipolar I disorder. The New England journal of
medicine 370:119–128.

Chen G and Manji HK (2006) The extracellular signal-regulated kinase pathway: an
emerging promising target for mood stabilizers. Curr Opin Psychiatry 19:313–323.
Chen G, Rajkowska G, Du F, Seraji-Bozorgzad N, and Manji HK (2000) Enhancement

of hippocampal neurogenesis by lithium. J Neurochem 75:1729–1734.

Chen H, Wang N, Burmeister M, and McInnis MG (2009) MicroRNA expression
lines in response to lithium treatment. Int

changes in lymphoblastoid cell
J Neuropsychopharmacol 12:975–981.

Chen RW and Chuang DM (1999) Long term lithium treatment suppresses p53 and
Bax expression but increases Bcl-2 expression. A prominent role in neuroprotection
against excitotoxicity. J Biol Chem 274:6039–6042.

Chen X, Liu Y, Zhu J, Lei S, Dong Y, Li L, Jiang B, Tan L, Wu J, Yu S, et al. (2016)
GSK-3b downregulates Nrf2 in cultured cortical neurons and in a rat model of
cerebral ischemia-reperfusion. Sci Rep 6:20196.

Chen S, Underwood BR, Jones PB, Lewis JR, and Cardinal RN (2022b) Association
between lithium use and the incidence of dementia and its subtypes: A
retrospective cohort study. PLoS Med 19:e1003941.

Cheng L, Sharples RA, Scicluna BJ, and Hill AF (2014) Exosomes provide a protective
and enriched source of miRNA for biomarker proﬁling compared to intracellular and
cell-free blood. J Extracell Vesicles 3:23743.

Cheng Y, Pardo M, Armini RS, Martinez A, Mouhsine H, Zagury JF, Jope RS, and
Beurel E (2016) Stress-induced neuroinﬂammation is mediated by GSK3-dependent
TLR4 signaling that promotes susceptibility to depression-like behavior. Brain
Behav Immun 53:207–222.

Chengappa KN, Suppes T, and Berk M (2004) Treatment of bipolar mania with

atypical antipsychotics. Expert Rev Neurother 4(Suppl 2)S17–S25.

Cheong MH, Lee SR, Yoo HS, Jeong JW, Kim GY, Kim WJ, Jung IC, and Choi YH
(2011) Anti-inﬂammatory effects of Polygala tenuifolia root through inhibition
of NF-jB activation in lipopolysaccharide-induced BV2 microglial cells.
J Ethnopharmacol 137:1402–1408.

Chiu CT, Liu G, Leeds P, and Chuang DM (2011) Combined treatment with the
mood stabilizers lithium and valproate produces multiple beneﬁcial effects in
transgenic mouse models of Huntington’s disease. Neuropsychopharmacology
36:2406–2421.

Chiu CT, Wang Z, Hunsberger JG, and Chuang DM (2013) Therapeutic potential of
mood stabilizers lithium and valproic acid: beyond bipolar disorder. Pharmacol
Rev 65:105–142.

Chowdhury GM, Behar KL, Cho W, Thomas MA, Rothman DL, and Sanacora G
(2012) 1H-[13C]-nuclear magnetic resonance spectroscopy measures of ketamine’s
effect on amino acid neurotransmitter metabolism. Biol Psychiatry 71:1022–1025.
Chu Y, Fioravante D, Leitges M, and Regehr WG (2014) Calcium-dependent PKC
isoforms have specialized roles in short-term synaptic plasticity. Neuron 82:859–871.
Ciftci E, Karacay R, Caglayan A, Altunay S, Ates N, Altintas MO, Doeppner TR,
Yulug B, and Kilic E (2020) Neuroprotective effect of lithium in cold- induced
traumatic brain injury in mice. Behav Brain Res 392:112719.

Cikankova T, Sigitova E, Zverova M, Fisar Z, Raboch J, and Hroudova J (2017)
Mitochondrial Dysfunctions in Bipolar Disorder: Effect of the Disease and
Pharmacotherapy. CNS Neurol Disord Drug Targets 16:176–186.

Cipriani A, Barbui C, Salanti G, Rendell J, Brown R, Stockton S, Purgato M,
Spineli LM, Goodwin GM, and Geddes JR (2011) Comparative efﬁcacy and
acceptability of antimanic drugs in acute mania: a multiple-treatments meta-
analysis. Lancet 378:1306–1315.

Cipriani A, Hawton K, Stockton S, and Geddes JR (2013) Lithium in the prevention of
suicide in mood disorders: updated systematic review and meta-analysis. BMJ
346:f3646.

350

Bortolozzi et al.

Clark CT, Newmark RL, Wisner KL, Stika C, and Avram MJ (2022) Lithium
Pharmacokinetics in the Perinatal Patient With Bipolar Disorder. J Clin Pharmacol
62:1385–1392.

Clausen AR, Durand S, Petersen RL, Staunstrup NH, and Qvist P (2022)
Circulating miRNAs as Potential Biomarkers for Patient Stratiﬁcation in Bipolar
Disorder: A Combined Review and Data Mining Approach. Genes (Basel)
13:1038.

Clos S, Rauchhaus P, Severn A, Cochrane L, and Donnan PT (2015) Long-term
effect of lithium maintenance therapy on estimated glomerular ﬁltration rate in
patients with affective disorders: a population-based cohort study. The lancet
Psychiatry 2:1075–1083.

Cohen P and Frame S (2001) The renaissance of GSK3. Nat Rev Mol Cell Biol

2:769–776.

Conus P, Berk M, Cotton SM, Kader L, Macneil C, Hasty MK, Hallam K, Lambert
M, Murphy BP, and McGorry PD (2015) Olanzapine or chlorpromazine plus
lithium in ﬁrst episode psychotic mania: An 8-week randomised controlled trial.
Eur Psychiatry 30:975–982.

Coombes BJ, Millischer V, Batzler A, Larrabee B, Hou L, Papiol S, Heilbronner U,
Adli M, Akiyama K, Akula N, et al. (2021) Association of Attention-Deﬁcit/
Hyperactivity Disorder and Depression Polygenic Scores with Lithium Response: A
Consortium for Lithium Genetics Study. Complex Psychiatry 7:80–89.

Correia-Melo FS, Argolo FC, Ara(cid:3)ujo-de-Freitas L, Leal GC, Kapczinski F, Lacerda AL,
and Quarantini LC (2017) Rapid infusion of esketamine for unipolar and bipolar
depression: a retrospective chart review. Neuropsychiatr Dis Treat 13:1627–1632.
Costemale-Lacoste JF, Guilloux JP, and Gaillard R (2016) The role of GSK-3 in
treatment-resistant depression and links with the pharmacological effects of
lithium and ketamine: A review of the literature. Encephale 42:156–164.

Costi S, Soleimani L, Glasgow A, Brallier J, Spivack J, Schwartz J, Levitch CF,
Richards S, Hoch M, Stade EC, et al. (2019) Lithium continuation therapy following
ketamine in patients with treatment resistant unipolar depression: a randomized
controlled trial. Neuropsychopharmacology 44:1812–1819.

Cuervo AM, Stefanis L, Fredenburg R, Lansbury PT, and Sulzer D (2004) Impaired
degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science
305:1292–1295.

Culmsee C, Michels S, Scheu S, Arolt V, Dannlowski U, and Alferink J (2019)
Mitochondria, Microglia, and the Immune System-How Are They Linked in Affective
Disorders? Front Psychiatry 9:739.

Cunha AB, Frey BN, Andreazza AC, Goi JD, Rosa AR, Gonc¸alves CA, Santin A,
and Kapczinski F (2006) Serum brain-derived neurotrophic factor is decreased in
bipolar disorder during depressive and manic episodes. Neurosci Lett 398:215–219.
Curtis D, Kalsi G, Brynjolfsson J, McInnis M, O’Neill J, Smyth C, Moloney E,
Murphy P, McQuillin A, Petursson H, et al. (2003) Genome scan of pedigrees
multiply affected with bipolar disorder provides further support for the presence
of a susceptibility locus on chromosome 12q23-q24, and suggests the presence of
additional loci on 1p and 1q. Psychiatr Genet 13:77–84.

D’Addario C, Dell’Osso B, Palazzo MC, Benatti B, Lietti L, Cattaneo E, Galimberti D,
Fenoglio C, Cortini F, Scarpini E, et al. (2012) Selective DNA methylation of BDNF
promoter in bipolar disorder: differences among patients with BDI and BDII.
Neuropsychopharmacology 37:1647–1655.

Daly EJ, Singh JB, Fedgchin M, Cooper K, Lim P, Shelton RC, Thase ME, Winokur
A, Van Nueten L, Manji H, et al. (2018) Efﬁcacy and Safety of Intranasal
Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant
Depression: A Randomized Clinical Trial. JAMA Psychiatry 75:139–148.

Daglas R, Allott K, Y€ucel M, Henry LP, Macneil CA, Hasty MK, Berk M, and Cotton
SM (2017) Cognitive functioning following stabilisation from ﬁrst episode mania. Int
J Bipolar Disord 5:39.

Damri O, Shemesh N, and Agam G (2020) Is There Justiﬁcation to Treat
Neurodegenerative Disorders by Repurposing Drugs? The Case of Alzheimer’s
Disease, Lithium, and Autophagy. Int J Mol Sci 22:189.

Davis JM and Fann WE (1971) Lithium. Annu Rev Pharmacol 11:285–302.
Davis J, Desmond M, and Berk M (2018) Lithium and nephrotoxicity: a literature
review of approaches to clinical management and risk stratiﬁcation. BMC Nephrol
19:305.

Davies SP, Reddy H, Caivano M, and Cohen P (2000) Speciﬁcity and mechanism of
action of some commonly used protein kinase inhibitors. Biochem J 351:95–105.
de Bartolomeis A and Perugi G (2012) Combination of aripiprazole with mood
stabilizers for the treatment of bipolar disorder: from acute mania to long-term
maintenance. Expert Opin Pharmacother 13:2027–2036.

de Groot T, Damen L, Kosse L, Alsady M, Doty R, Baumgarten R, Sheehan S, van
der Vlag J, Korstanje R, and Deen PMT (2017) Lithium reduces blood glucose
levels, but aggravates albuminuria in BTBR-ob/ob mice. PLoS One 12:e0189485.
de Laeter JR, B€ohlke JK, de Bi(cid:1)evre P, Hidaka H, Peiser HS, Rosman KJR, and Taylor
PDP (2003) Atomic weights of the elements: Review 2000 (IUPAC Technical Report).
Pure Appl Chem 75:683–800.

Dell’Osso L, Del Grande C, Gesi C, Carmassi C, and Musetti L (2016) A new look
at an old drug: neuroprotective effects and therapeutic potentials of lithium
salts. Neuropsychiatr Dis Treat 12:1687–1703.

Del Matto L, Muscas M, Murru A, Verdolini N, Anmella G, Fico G, Corponi F,
Carvalho AF, Samalin L, Carpiniello B, et al. (2020) Lithium and suicide prevention
in mood disorders and in the general population: A systematic review. Neurosci
Biobehav Rev 116:142–153.

de Sousa RT, van de Bilt MT, Diniz BS, Ladeira RB, Portela LV, Souza DO,
Forlenza OV, Gattaz WF, and Machado-Vieira R (2011) Lithium increases plasma
brain-derived neurotrophic factor in acute bipolar mania: a preliminary 4-week
study. Neurosci Lett 494:54–56.

de Sousa RT, Streck EL, Zanetti MV, Ferreira GK, Diniz BS, Brunoni AR, Busatto
GF, Gattaz WF, and Machado-Vieira R (2015) Lithium increases leukocyte
mitochondrial complex I activity in bipolar disorder during depressive episodes.
Psychopharmacology (Berl) 232:245–250.

de Sousa RT, Zarate Jr CA, Zanetti MV, Costa AC, Talib LL, Gattaz WF, and
Machado-Vieira R (2014) Oxidative stress in early stage Bipolar Disorder and the
association with response to lithium. J Psychiatr Res 50:36–41.

Diniz BS, Machado-Vieira R, and Forlenza OV (2013) Lithium and neuroprotection:
translational evidence and implications for the treatment of neuropsychiatric
disorders. Neuropsychiatr Dis Treat 9:493–500.

Diniz BS, Talib LL, Joaquim HP, de Paula VR, Gattaz WF, and Forlenza OV (2011)
Platelet GSK3B activity in patients with late-life depression: marker of depressive
episode severity and cognitive impairment? World J Biol Psychiatry 12:216–222.
Doble BW and Woodgett JR (2003) GSK-3: tricks of the trade for a multi-tasking

kinase. J Cell Sci 116:1175–1186.

Doeppner TR, Kaltwasser B, Sanchez-Mendoza EH, Caglayan AB, B€ahr M, and
Hermann DM (2017) Lithium-induced neuroprotection in stroke involves increased
miR-124 expression, reduced RE1-silencing transcription factor abundance and
decreased protein deubiquitination by GSK3b inhibition-independent pathways.
J Cereb Blood Flow Metab 37:914–926.

Dold M, Bartova L, Kautzky A, Serretti A, Porcelli S, Souery D, Mendlewicz J,
Montgomery S, Zohar J, and Kasper S (2018) Clinical factors associated with
augmentation treatment with second-generation antipsychotics and lithium
in major depression - Results from a European multicenter study. Eur
Neuropsychopharmacol 28:1305–1313.

Dong H, Zhang X, Dai X, Lu S, Gui B, Jin W, Zhang S, Zhang S, and Qian Y (2014)
Lithium ameliorates lipopolysaccharide-induced microglial activation via inhibition
of toll-like receptor 4 expression by activating the PI3K/Akt/FoxO1 pathway.
J Neuroinﬂammation 11:140.

D’Onofrio S, Mahaffey S, and Garcia-Rill E (2017) Role of calcium channels in

bipolar disorder. Curr Psychopharmacol 6:122–135.

Dou H, Ellison B, Bradley J, Kasiyanov A, Poluektova LY, Xiong H, Maggirwar S,
Dewhurst S, Gelbard HA, and Gendelman HE (2005) Neuroprotective mechanisms
of lithium in murine human immunodeﬁciency virus-1 encephalitis. J Neurosci
25:8375–8385.

Douglas PM and Dillin A (2010) Protein homeostasis and aging in neurodegeneration.

J Cell Biol 190:719–729.

Duda P, Wi(cid:3)sniewski J, W(cid:3)ojtowicz T, W(cid:3)ojcicka O, Ja(cid:3)skiewicz M, Drulis-Fajdasz D,
Rakus D, McCubrey JA, and Gizak A (2018) Targeting GSK3 signaling as a
potential therapy of neurodegenerative diseases and aging. Expert Opin Ther
Targets 22:833–848.

Duman RS and Aghajanian GK (2012) Synaptic dysfunction in depression: potential

therapeutic targets. Science 338:68–72.

Duman RS, Aghajanian GK, Sanacora G, and Krystal JH (2016) Synaptic plasticity
and depression: new insights from stress and rapid-acting antidepressants. Nat
Med 22:238–249.

Dwivedi T and Zhang H (2015) Lithium-induced neuroprotection is associated with
epigenetic modiﬁcation of speciﬁc BDNF gene promoter and altered expression of
apoptotic-regulatory proteins. Front Neurosci 8:457.

Dwivedi Y, Rizavi HS, Zhang H, Roberts RC, Conley RR, and Pandey GN (2009)
Aberrant extracellular signal-regulated kinase (ERK)1/2 signalling in suicide
brain: role of ERK kinase 1 (MEK1). Int J Neuropsychopharmacol 12:1337–1354.
Eastwood SL and Harrison PJ (2010) Markers of glutamate synaptic transmission
and plasticity are increased in the anterior cingulate cortex in bipolar disorder.
Biol Psychiatry 67:1010–1016.

Emamghoreishi M, Keshavarz M, and Nekooeian AA (2015) Acute and chronic effects
of lithium on BDNF and GDNF mRNA and protein levels in rat primary neuronal,
astroglial and neuroastroglia cultures. Iran J Basic Med Sci 18:240–246.

Engel T, Go~ni-Oliver P, Lucas JJ, Avila J, and Hern(cid:3)andez F (2006) Chronic lithium
administration to FTDP-17 tau and GSK-3beta overexpressing mice prevents tau
hyperphosphorylation and neuroﬁbrillary tangle formation, but pre-formed
neuroﬁbrillary tangles do not revert. J Neurochem 99:1445–1455.

Etain B, Bellivier F, Oli(cid:3)e E, Aouizerate B, Aubin V, Belzeaux R, Courtet P, Dubertret
C, Schwan R, Roux P, et al.; FondaMental Advanced Center of Expertise for Bipolar
Disorders (FACE-BD); FACE-BD Clinical Sites and Principal Collaborators in
France (2021) Clinical predictors of recurrences in bipolar disorders type 1 and 2: A
FACE-BD longitudinal study. J Psychiatr Res 134:129–137.

Fan M, Song C, Wang T, Li L, Dong Y, Jin W, and Lu P (2015) Protective effects of
lithium chloride treatment on repeated cerebral ischemia-reperfusion injury in mice.
Neurol Sci 36:315–321.

Fang X, Yu SX, Lu Y, Bast Jr RC, Woodgett JR, and Mills GB (2000) Phosphorylation
and inactivation of glycogen synthase kinase 3 by protein kinase A. Proc Natl Acad
Sci USA 97:11960–11965.

Fernandes BS, Gama CS, Ceres(cid:3)er KM, Yatham LN, Fries GR, Colpo G, de Lucena D,
Kunz M, Gomes FA, and Kapczinski F (2011) Brain-derived neurotrophic factor as
a state-marker of mood episodes in bipolar disorders: a systematic review and
meta-regression analysis. J Psychiatr Res 45:995–1004.

Fernandes BS, Molendijk ML, K€ohler CA, Soares JC, Leite CM, Machado-Vieira R,
Ribeiro TL, Silva JC, Sales PM, Quevedo J, et al. (2015) Peripheral brain-derived
neurotrophic factor (BDNF) as a biomarker in bipolar disorder: a meta-analysis
of 52 studies. BMC Med 13:289.

Fico G, Anmella G, Gomez-Ramiro M, de Miquel C, Hidalgo-Mazzei D, Manchia M,
Alda M, Gonzalez-Pinto A, Carvalho AF, Vieta E, et al. (2021) Duration of
untreated illness and bipolar disorder: time for a new deﬁnition? Results from a
cross-sectional study. J Affect Disord 294:513–520.

Fidaleo M, Cavallucci V, and Pani G (2017) Nutrients, neurogenesis and brain ageing:
From disease mechanisms to therapeutic opportunities. Biochem Pharmacol
141:63–76.

Finkbeiner S (2000) CREB couples neurotrophin signals to survival messages. Neuron

25:11–14.

Fiorentini A, Rosi MC, Grossi C, Luccarini I, and Casamenti F (2010) Lithium
improves hippocampal neurogenesis, neuropathology and cognitive functions in
APP mutant mice. PLoS One 5:e14382.

Potential Therapeutic Effects of Lithium

351

Forlenza OV, de Paula VJ, Machado-Vieira R, Diniz BS, and Gattaz WF (2012)

Does lithium prevent Alzheimer’s disease? Drugs Aging 29:335–342.

Forlenza OV, De-Paula VJ, and Diniz BS (2014) Neuroprotective effects of lithium:
implications for the treatment of Alzheimer’s disease and related neurodegenerative
disorders. ACS Chem Neurosci 5:443–450.

Forlenza OV, Radanovic M, Talib LL, and Gattaz WF (2019) Clinical and biological
long-term lithium treatment in older adults with amnestic mild

effects of
cognitive impairment: randomised clinical trial. Br J Psychiatry 215:668–674.
Fornai F, Longone P, Cafaro L, Kastsiuchenka O, Ferrucci M, Manca ML, Lazzeri
G, Spalloni A, Bellio N, Lenzi P, et al. (2008) Lithium delays progression of
amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 105:2052–2057.

Fornaro M, Stubbs B, De Berardis D, Iasevoli F, Solmi M, Veronese N, Carano A,
Perna G, and De Bartolomeis A (2016a) Does the “Silver Bullet” Lose its Shine
Over the Time? Assessment of Loss of Lithium Response in a Preliminary
Sample of Bipolar Disorder Outpatients. Clin Pract Epidemiol Ment Health
12:142–157.

Fornaro M, De Berardis D, Koshy AS, Perna G, Valchera A, Vancampfort D, and
Stubbs B (2016b) Prevalence and clinical features associated with bipolar disorder
polypharmacy: a systematic review. Neuropsychiatr Dis Treat 12:719–735.

Forstner AJ, Hofmann A, Maaser A, Sumer S, Khudayberdiev S, M€uhleisen TW,
Leber M, Schulze TG, Strohmaier J, Degenhardt F, et al. (2015) Genome-wide
analysis implicates microRNAs and their target genes in the development of
bipolar disorder. Transl Psychiatry 5:e678.

Fountoulakis KN, Grunze H, Vieta E, Young A, Yatham L, Blier P, Kasper S, and
Moeller HJ (2017) The International College of Neuro-Psychopharmacology
(CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017),
Part 3: The Clinical Guidelines. Int J Neuropsychopharmacol 20:180–195.

Fountoulakis KN, Tohen M, and Zarate Jr CA (2022) Lithium treatment of Bipolar
disorder in adults: A systematic review of randomized trials and meta-analyses.
Eur Neuropsychopharmacol 54:100–115.

Fornaro M, Maritan E, Ferranti R, Zaninotto L, Miola A, Anastasia A, Murru A,
Sol(cid:3)e E, Stubbs B, Carvalho AF, et al. (2020) Lithium Exposure During Pregnancy
and the Postpartum Period: A Systematic Review and Meta-Analysis of Safety
and Efﬁcacy Outcomes. Am J Psychiatry 177:76–92.

Freland L and Beaulieu JM (2012) Inhibition of GSK3 by lithium, from single

molecules to signaling networks. Front Mol Neurosci 5:14.

Frey BN, Andreazza AC, Ceres(cid:3)er KM, Martins MR, Valvassori SS, R(cid:3)eus GZ,
Quevedo J, and Kapczinski F (2006) Effects of mood stabilizers on hippocampus
BDNF levels in an animal model of mania. Life Sci 79:281–286.

Fries GR, Carvalho AF, and Quevedo J (2018) The miRNome of bipolar disorder.

J Affect Disord 233:110–116.

Fries GR, Valvassori SS, Bock H, Stertz L, Magalh~aes PV, Mariot E, Varela RB,
Kauer-Sant’Anna M, Quevedo J, Kapczinski F, et al. (2015) Memory and brain-
derived neurotrophic factor after subchronic or chronic amphetamine treatment
in an animal model of mania. J Psychiatr Res 68:329–336.

Fukumoto T, Morinobu S, Okamoto Y, Kagaya A, and Yamawaki S (2001) Chronic
lithium treatment increases the expression of brain-derived neurotrophic factor
in the rat brain. Psychopharmacology (Berl) 158:100–106.

Fullana MN, Paz V, Artigas F, and Bortolozzi A (2022) Ketamine triggers rapid
antidepressant effects by modulating synaptic plasticity in a new depressive-like
mouse model based on astrocyte glutamate transporter GLT-1 knockdown in
infralimbic cortex. Rev Psiquiatr Salud Ment (Engl Ed) 15:94–100.

Gao K, Kaye NM, Ayati M, Koyuturk M, Calabrese JR, Christian E, Lazarus HM,
and Kaplan D (2023) Divergent Directionality of Immune Cell-Speciﬁc Protein
Expression between Bipolar Lithium Responders and Non-Responders Revealed
by Enhanced Flow Cytometry. Medicina (Kaunas) 59:120.

Galts CPC, Bettio LEB, Jewett DC, Yang CC, Brocardo PS, Rodrigues ALS, Thacker
JS, and Gil-Mohapel J (2019) Depression in neurodegenerative diseases: Common
mechanisms and current treatment options. Neurosci Biobehav Rev 102:56–84.

Garabadu D, Agrawal N, Sharma A, and Sharma S (2019) Mitochondrial metabolism: a
common link between neuroinﬂammation and neurodegeneration. Behav Pharmacol
30:642–652.

Garcia-Rill E, D’Onofrio S, Mahaffey SC, Bisagno V, and Urbano FJ (2019) Bottom-
up gamma and bipolar disorder, clinical and neuroepigenetic implications.
Bipolar Disord 21:108–116.

Garofeanu CG, Weir M, Rosas-Arellano MP, Henson G, Garg AX, and Clark WF
(2005) Causes of reversible nephrogenic diabetes insipidus: a systematic review.
Am J Kidney Dis 45:626–637.

Georgievska B, Sandin J, Doherty J, M€ortberg A, Neelissen J, Andersson A,
Gruber S, Nilsson Y, Sch€ott P, Arvidsson PI, et al. (2013) AZD1080, a novel GSK3
inhibitor, rescues synaptic plasticity deﬁcits in rodent brain and exhibits
peripheral target engagement in humans. J Neurochem 125:446–456.

Geddes JR, Goodwin GM, Rendell J, Azorin JM, Cipriani A, Ostacher MJ, Morriss R,
Alder N, and Juszczak E; BALANCE investigators and collaborators (2010) Lithium
plus valproate combination therapy versus monotherapy for relapse prevention in
bipolar I disorder (BALANCE): a randomised open-label trial. Lancet 375:385–395.
Gerhard DM, Wohleb ES, and Duman RS (2016) Emerging treatment mechanisms
for depression: focus on glutamate and synaptic plasticity. Drug Discov Today
21:454–464.

Gershon S (1970) Lithium in mania. Clin Pharmacol Ther 11:168–187.
Ghasemzadeh Z and Rezayof A (2016) Role of hippocampal and prefrontal cortical
signaling pathways in dextromethorphan effect on morphine-induced memory
impairment in rats. Neurobiol Learn Mem 128:23–32.

Gideons ES, Lin PY, Mahgoub M, Kavalali ET, and Monteggia LM (2017) Chronic
lithium treatment elicits its antimanic effects via BDNF-TrkB dependent synaptic
downscaling. eLife 6:e25480.

Ghosh S, Castillo E, Frias ES, and Swanson RA (2018) Bioenergetic regulation of

microglia. Glia 66:1200–1212.

Gim(cid:3)enez-Palomo A, Gomes-da-Costa S, Dodd S, Pachiarotti I, Verdolini N, Vieta E,
and Berk M (2022) Does metabolic syndrome or its component factors alter the course
of bipolar disorder? A systematic review. Neurosci Biobehav Rev 132:142–153.

Gitlin M (2016) Lithium side effects and toxicity: prevalence and management

strategies. Int J Bipolar disord 4:27.

Goldberg JF and Chengappa KN (2009) Identifying and treating cognitive

impairment in bipolar disorder. Bipolar Disord 11 (Suppl 2):123–137.

Gong R, Wang P, and Dworkin L (2016) What we need to know about the effect of

lithium on the kidney. Am J Physiol Renal Physiol 311:F1168–F1171.

Gonzalez-Pinto A, Mosquera F, Alonso M, L(cid:3)opez P, Ram(cid:3)ırez F, Vieta E, and
Baldessarini RJ (2006) Suicidal risk in bipolar I disorder patients and adherence
to long-term lithium treatment. Bipolar Disord 8:618–624.

Gomes-da-Costa S, Marx W, Corponi F, Anmella G, Murru A, Pons-Cabrera MT,
Gim(cid:3)enez-Palomo A, Guti(cid:3)errez-Arango F, Llach CD, Fico G, et al. (2022) Lithium
therapy and weight change in people with bipolar disorder: A systematic review
and meta-analysis. Neurosci Biobehav Rev 134:104266.

Gould TD, Chen G, and Manji HK (2004) In vivo evidence in the brain for lithium
inhibition of glycogen synthase kinase-3. Neuropsychopharmacology 29:32–38.
Grande I and Vieta E (2015) Pharmacotherapy of acute mania: monotherapy or
combination therapy with mood stabilizers and antipsychotics? CNS Drugs
29:221–227.

Grandjean EM and Aubry JM (2009) Lithium: updated human knowledge using an
evidence-based approach. Part II: Clinical pharmacology and therapeutic monitoring.
CNS Drugs 23:331–349.

Grof P, Duffy A, Cavazzoni P, Grof E, Garnham J, MacDougall M, O’Donovan C,
and Alda M (2002) Is response to prophylactic lithium a familial trait? J Clin
Psychiatry 63:942–947.

Gr€unfeld JP and Rossier BC (2009) Lithium nephrotoxicity revisited. Nat Rev

Nephrol 5:270–276.

Grunze H, Vieta E, Goodwin GM, Bowden C, Licht RW, Azorin JM, Yatham L, Mosolov
S, M€oller HJ, and Kasper S; Members of the WFSBP Task Force on Bipolar Affective
Disorders Working on this topic (2018) The World Federation of Societies of
Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar
Disorders: Acute and long-term treatment of mixed states in bipolar disorder. World
J Biol Psychiatry 19:2–58.

Guo S, Arai K, Stins MF, Chuang DM, and Lo EH (2009) Lithium upregulates
vascular endothelial growth factor in brain endothelial cells and astrocytes.
Stroke 40:652–655.

Gupta A, Schulze TG, Nagarajan V, Akula N, Corona W, Jiang XY, Hunter N,
McMahon FJ, and Detera-Wadleigh SD (2012) Interaction networks of lithium and
valproate molecular targets reveal a striking enrichment of apoptosis functional
clusters and neurotrophin signaling. Pharmacogenomics J 12:328–341.

Guttuso Jr T, Andrzejewski KL, Lichter DG, and Andersen JK (2019) Targeting
kinases in Parkinson’s disease: A mechanism shared by LRRK2, neurotrophins,
exenatide, urate, nilotinib and lithium. J Neurol Sci 402:121–130.

Haggarty SJ, Karmacharya R, and Perlis RH (2021) Advances toward precision
medicine for bipolar disorder: mechanisms & molecules. Mol Psychiatry 26:168–185.
Hajek T, Kopecek M, H€oschl C, and Alda M (2012) Smaller hippocampal volumes in
patients with bipolar disorder are masked by exposure to lithium: a meta-analysis.
J Psychiatry Neurosci 37:333–343.

Hallcher LM and Sherman WR (1980) The effects of lithium ion and other agents
on the activity of myo-inositol-1-phosphatase from bovine brain. J Biol Chem
255:10896–10901.

Hampel H, Lista S, Mango D, Nistic(cid:1)o R, Perry G, Avila J, Hernandez F, Geerts H,
and Vergallo A; Alzheimer Precision Medicine Initiative (APMI) (2019) Lithium
as a Treatment for Alzheimer’s Disease: The Systems Pharmacology Perspective.
J Alzheimers Dis 69:615–629.

Harwood AJ (2001) Regulation of GSK-3: a cellular multiprocessor. Cell 105:821–824.
Harwood AJ (2005) Lithium and bipolar mood disorder: the inositol-depletion

hypothesis revisited. Mol Psychiatry 10:117–126.

Hashimoto R, Takei N, Shimazu K, Christ L, Lu B, and Chuang DM (2002) Lithium
induces brain-derived neurotrophic factor and activates TrkB in rodent cortical
neurons: an essential step for neuroprotection against glutamate excitotoxicity.
Neuropharmacology 43:1173–1179.

Hashimoto K, Shimizu E, and Iyo M (2004) Critical role of brain-derived

neurotrophic factor in mood disorders. Brain Res Brain Res Rev 45:104–114.

Hashimoto K, Sawa A, and Iyo M (2007) Increased levels of glutamate in brains from

patients with mood disorders. Biol Psychiatry 62:1310–1316.

Haupt M, B€ahr M, and Doeppner TR (2021) Lithium beyond psychiatric indications:

the reincarnation of a new old drug. Neural Regen Res 16:2383–2387.

Haupt M, Zechmeister B, Bosche B, Lieschke S, Zheng X, Zhang L, Venkataramani V,
Jin F, Hein K, Weber MS, et al. (2020) Lithium enhances post-stroke blood-brain
barrier integrity, activates the MAPK/ERK1/2 pathway and alters immune cell
migration in mice. Neuropharmacology 181:108357.

Hayashi A, Kasahara T, Kametani M, Toyota T, Yoshikawa T, and Kato T (2009)
Aberrant endoplasmic reticulum stress response in lymphoblastoid cells from
patients with bipolar disorder. Int J Neuropsychopharmacol 12:33–43.

Hayes JF, Marston L, Walters K, Geddes JR, King M, and Osborn DP (2016)
Lithium vs. valproate vs. olanzapine vs. quetiapine as maintenance monotherapy
for bipolar disorder: a population-based UK cohort study using electronic health
records. World Psychiatry 15:53–58.

He Z, Zhou Y, Wang Q, Li J, Zheng Z, Chen J, Zhang H, Wang Z, Xu H, and Xiao J
(2017) Inhibiting endoplasmic reticulum stress by lithium chloride contributes to
the integrity of blood-spinal cord barrier and functional recovery after spinal
cord injury. Am J Transl Res 9:1012–1024.

Hetz C, Thielen P, Matus S, Nassif M, Court F, Kifﬁn R, Martinez G, Cuervo AM,
Brown RH, and Glimcher LH (2009) XBP-1 deﬁciency in the nervous system
protects against amyotrophic lateral sclerosis by increasing autophagy. Genes
Dev 23:2294–2306.

352

Bortolozzi et al.

Hibar DP, Westlye LT, van Erp TG, Rasmussen J, Leonardo CD, Faskowitz J, Haukvik
UK, Hartberg CB, Doan NT, Agartz I, et al.; Costa Rica/Colombia Consortium for
Genetic Investigation of Bipolar Endophenotypes (2016) Subcortical volumetric
abnormalities in bipolar disorder. Mol Psychiatry 21:1710–1716.

Hillmer EJ, Zhang H, Li HS, and Watowich SS (2016) STAT3 signaling in immunity.

Cytokine Growth Factor Rev 31:1–15.

Hiroi T, Wei H, Hough C, Leeds P, and Chuang DM (2005) Protracted lithium
treatment protects against the ER stress elicited by thapsigargin in rat PC12
cells: roles of intracellular calcium, GRP78 and Bcl-2. Pharmacogenomics J
5:102–111.

Hirschfeld R, Bowden CL, Gitlin MJ, Keck PE, Suppes T, Thase ME, Wagner KD,
and Perlis RH (2003) Practice guideline for the treatment of patients with
bipolar disorder (revision). Focus 1:64–110.

Homayoun H and Moghaddam B (2007) NMDA receptor hypofunction produces
opposite effects on prefrontal cortex interneurons and pyramidal neurons.
J Neurosci 27:11496–11500.

Hou L, Xiong N, Liu L, Huang J, Han C, Zhang G, Li J, Xu X, Lin Z, and Wang T
(2015) Lithium protects dopaminergic cells from rotenone toxicity via autophagy
enhancement. BMC Neurosci 16:82.

Hou L, Heilbronner U, Degenhardt F, Adli M, Akiyama K, Akula N, Ardau R, Arias
B, Backlund L, Banzato CEM, et al. (2016) Genetic variants associated with
response to lithium treatment in bipolar disorder: a genome-wide association
study. Lancet 387:1085–1093.

Hozer F, Sarrazin S, Laidi C, Favre P, Pauling M, Cannon D, McDonald C, Emsell L,
Mangin JF, Duchesnay E, et al. (2021) Lithium prevents grey matter atrophy in
patients with bipolar disorder: an international multicenter study. Psychol Med
51:1201–1210.

Hsu CW, Tsai SY, Tseng PT, Liang CS, Vieta E, Carvalho AF, Stubbs B, Kao HY, Tu
YK, and Lin PY (2022) Differences in the prophylactic effect of serum lithium
levels on depression and mania in bipolar disorder: A dose-response meta-
analysis. Eur Neuropsychopharmacol 58:20–29.

Hui TP, Kandola A, Shen L, Lewis G, Osborn DPJ, Geddes JR, and Hayes JF
(2019) A systematic review and meta-analysis of clinical predictors of lithium
response in bipolar disorder. Acta Psychiatr Scand 140:94–115.

Hunsberger JG, Chibane FL, Elkahloun AG, Henderson R, Singh R, Lawson J,
Cruceanu C, Nagarajan V, Turecki G, Squassina A, et al. (2015) Novel integrative
genomic tool for interrogating lithium response in bipolar disorder. Transl Psychiatry
5:e504.

Hunsberger JG, Fessler EB, Chibane FL, Leng Y, Maric D, Elkahloun AG, and
Chuang DM (2013) Mood stabilizer-regulated miRNAs in neuropsychiatric and
neurodegenerative diseases: identifying associations and functions. Am J Transl
Res 5:450–464.

Ilieva EV, Ayala V, Jov(cid:3)e M, Dalf(cid:3)o E, Cacabelos D, Povedano M, Bellmunt MJ,
Ferrer I, Pamplona R, and Portero-Ot(cid:3)ın M (2007) Oxidative and endoplasmic
reticulum stress interplay in sporadic amyotrophic lateral sclerosis. Brain
130:3111–3123.

Ikonomov OC and Manji HK (1999) Molecular mechanisms underlying mood
stabilization in manic-depressive illness: the phenotype challenge. Am J Psychiatry
156:1506–1514.

Ito Y, Yamada M, Tanaka H, Aida K, Tsuruma K, Shimazawa M, Hozumi I,
Inuzuka T, Takahashi H, and Hara H (2009) Involvement of CHOP, an ER-stress
apoptotic mediator, in both human sporadic ALS and ALS model mice. Neurobiol
Dis 36:470–476.

Iwahashi K, Nishizawa D, Narita S, Numajiri M, Murayama O, Yoshihara E,
Onozawa Y, Nagahori K, Fukamauchi F, Ikeda K, et al. (2014) Haplotype
analysis of GSK-3b gene polymorphisms in bipolar disorder lithium responders
and nonresponders. Clin Neuropharmacol 37:108–110.

Jacinto E, Facchinetti V, Liu D, Soto N, Wei S, Jung SY, Huang Q, Qin J, and Su B
(2006) SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt
phosphorylation and substrate speciﬁcity. Cell 127:125–137.

Jadhav S, Russo S, Cottier S, Schneiter R, Cowart A, and Greenberg ML (2016)
Valproate Induces the Unfolded Protein Response by Increasing Ceramide Levels.
J Biol Chem 291:22253–22261.

Jafferany M (2008) Lithium and skin: dermatologic manifestations of lithium

therapy. Int J Dermatol 47:1101–1111.

Jevti(cid:3)c G, Nikoli(cid:3)c T, Mir(cid:4)ci(cid:3)c A, Stojkovi(cid:3)c T, Velimirovi(cid:3)c M, Trajkovi(cid:3)c V, Markovi(cid:3)c I,
Trbovich AM, Radonji(cid:3)c NV, and Petronijevi(cid:3)c ND (2016) Mitochondrial
impairment, apoptosis and autophagy in a rat brain as immediate and long-
term effects of perinatal phencyclidine treatment - inﬂuence of restraint stress.
Prog Neuropsychopharmacol Biol Psychiatry 66:87–96.

Jim(cid:3)enez-S(cid:3)anchez L, Linge R, Campa L, Valdiz(cid:3)an EM, Pazos (cid:3)A, D(cid:3)ıaz (cid:3)A, and Adell A
(2016) Behavioral, neurochemical and molecular changes after acute deep brain
stimulation of the infralimbic prefrontal cortex. Neuropharmacology 108:91–102.
Jiang HZ, Wang SY, Yin X, Jiang HQ, Wang XD, Wang J, Wang TH, Qi Y, Yang
YQ, Wang Y, et al. (2016) Downregulation of Homer1b/c in SOD1 G93A Models of
ALS: A Novel Mechanism of Neuroprotective Effect of Lithium and Valproic Acid.
Int J Mol Sci 17:2129.

Jope RS (2011) Glycogen synthase kinase-3 in the etiology and treatment of mood

disorders. Front Mol Neurosci 4:16.

Jope RS, Cheng Y, Lowell JA, Worthen RJ, Sitbon YH, and Beurel E (2017)
Stressed and Inﬂamed, Can GSK3 Be Blamed? Trends Biochem Sci 42:180–192.
Jope RS and Johnson GV (2004) The glamour and gloom of glycogen synthase

kinase-3. Trends Biochem Sci 29:95–102.

Jope RS, Yuskaitis CJ, and Beurel E (2007) Glycogen synthase kinase-3 (GSK3):

inﬂammation, diseases, and therapeutics. Neurochem Res 32:577–595.

Jornada LK, Moretti M, Valvassori SS, Ferreira CL, Padilha PT, Arent CO, Fries GR,
Kapczinski F, and Quevedo J (2010) Effects of mood stabilizers on hippocampus and
amygdala BDNF levels in an animal model of mania induced by ouabain.
J Psychiatr Res 44:506–510.

Jun C, Choi Y, Lim SM, Bae S, Hong YS, Kim JE, and Lyoo IK (2014) Disturbance

of the glutamatergic system in mood disorders. Exp Neurobiol 23:28–35.

Jung SR, Park SY, Koh JH, and Kim JY (2021) Lithium enhances exercise-induced
glycogen breakdown and insulin-induced AKT activation to facilitate glucose
uptake in rodent skeletal muscle. Pﬂugers Arch 473:673–682.

Kaidanovich-Beilin O, Milman A, Weizman A, Pick CG, and Eldar-Finkelman H
(2004) Rapid antidepressive-like activity of speciﬁc glycogen synthase kinase-3
inhibitor and its effect on beta-catenin in mouse hippocampus. Biol Psychiatry
55:781–784.

Kakiuchi C, Ishigaki S, Oslowski CM, Fonseca SG, Kato T, and Urano F (2009)
Valproate, a mood stabilizer, induces WFS1 expression and modulates its interaction
with ER stress protein GRP94. PLoS One 4:e4134.

Kakiuchi C, Iwamoto K, Ishiwata M, Bundo M, Kasahara T, Kusumi I, Tsujita T,
Okazaki Y, Nanko S, Kunugi H, et al. (2003) Impaired feedback regulation of
XBP1 as a genetic risk factor for bipolar disorder. Nat Genet 35:171–175.

Kanazawa LK, Vecchia DD, Wendler EM, Hocayen PA, Beir~ao Jr PS, de M(cid:3)elo ML,
Dos Reis L(cid:3)ıvero FA, Corso CR, Stipp MC, Acco A, et al. (2017) Effects of acute and
chronic quercetin administration on methylphenidate-induced hyperlocomotion and
oxidative stress. Life Sci 171:1–8.

Kang HJ, Noh JS, Bae YS, and Gwag BJ (2003) Calcium-dependent prevention of
neuronal apoptosis by lithium ion: essential role of phosphoinositide 3-kinase
and phospholipase Cgamma. Mol Pharmacol 64:228–234.

Kann O, Papageorgiou IE, and Draguhn A (2014) Highly energized inhibitory
interneurons are a central element for information processing in cortical networks.
J Cereb Blood Flow Metab 34:1270–1282.

Karege F, Perroud N, Burkhardt S, Schwald M, Ballmann E, La Harpe R, and
Malafosse A (2007) Alteration in kinase activity but not in protein levels of
protein kinase B and glycogen synthase kinase-3beta in ventral prefrontal cortex
of depressed suicide victims. Biol Psychiatry 61:240–245.

Kato T (2006) The role of mitochondrial dysfunction in bipolar disorder. Drug News

Perspect 19:597–602.

Katz IR, Rogers MP, Lew R, Thwin SS, Doros G, Ahearn E, Ostacher MJ, DeLisi LE,
Smith EG, Ringer RJ, et al.; Li1 plus Investigators (2022) Lithium Treatment in
the Prevention of Repeat Suicide-Related Outcomes in Veterans With Major
Depression or Bipolar Disorder: A Randomized Clinical Trial. JAMA Psychiatry
79:24–32.

Kavalali ET and Monteggia LM (2020) Targeting Homeostatic Synaptic Plasticity

for Treatment of Mood Disorders. Neuron 106:715–726.

Kennedy SH, Lam RW, McIntyre RS, Tourjman SV, Bhat V, Blier P, Hasnain M,
Jollant F, Levitt AJ, MacQueen GM, et al.; CANMAT Depression Work Group
(2016) Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016
Clinical Guidelines for the Management of Adults with Major Depressive
Disorder: Section 3. Pharmacological Treatments. Can J Psychiatry 61:540–560.
Kerr F, Bjedov I, and Sofola-Adesakin O (2018) Molecular Mechanisms of Lithium
Action: Switching the Light on Multiple Targets for Dementia Using Animal
Models. Front Mol Neurosci 11:297.

Kerr F, Sofola-Adesakin O, Ivanov DK, Gatliff J, Gomez Perez-Nievas B, Bertrand
HC, Martinez P, Callard R, Snoeren I, Cochem(cid:3)e HM, et al. (2017) Direct Keap1-
Nrf2 disruption as a potential therapeutic target for Alzheimer’s disease. PLoS
Genet 13:e1006593.

Keshavarz M, Emamghoreishi M, Nekooeian AA, J Warsh J, and Zare HR (2013)
Increased bcl-2 protein levels in rat primary astrocyte culture following chronic
lithium treatment. Iran J Med Sci 38:255–262.

Kessing LV (2019) Lithium as the drug of choice for maintenance treatment in

bipolar disorder. Acta Psychiatr Scand 140:91–93.

Kessing LV, Forman JL, and Andersen PK (2010) Does lithium protect against

dementia? Bipolar Disord 12:87–94.

Kessing LV, Hellmund G, and Andersen PK (2011) Predictors of excellent response to
lithium: results from a nationwide register-based study. Int Clin Psychopharmacol
26:323–328.

Kessing LV, Gerds TA, Feldt-Rasmussen B, Andersen PK, and Licht RW (2015) Use
of Lithium and Anticonvulsants and the Rate of Chronic Kidney Disease: A
Nationwide Population-Based Study. JAMA Psychiatry 72:1182–1191.

Khairova R, Pawar R, Salvadore G, Juruena MF, de Sousa RT, Soeiro-de-Souza MG,
Salvador M, Zarate CA, Gattaz WF, and Machado-Vieira R (2012) Effects of lithium
on oxidative stress parameters in healthy subjects. Mol Med Rep 5:680–682.

Khan A, Jamwal S, Bijjem KR, Prakash A, and Kumar P (2015) Neuroprotective effect
of hemeoxygenase-1/glycogen synthase kinase-3b modulators in 3-nitropropionic acid-
induced neurotoxicity in rats. Neuroscience 287:66–77.

Khasraw M, Ashley D, Wheeler G, and Berk M (2012) Using lithium as a

neuroprotective agent in patients with cancer. BMC Med 10:131.

Khayachi A, Ase A, Liao C, Kamesh A, Kuhlmann N, Schorova L, Chaumette B,
Dion P, Alda M, S(cid:3)egu(cid:3)ela P, et al. (2021) Chronic lithium treatment alters the
excitatory/ inhibitory balance of synaptic networks and reduces mGluR5-PKC
signalling in mouse cortical neurons. J Psychiatry Neurosci 46:E402–E414.

Kibirige D, Luzinda K, and Ssekitoleko R (2013) Spectrum of lithium induced

thyroid abnormalities: a current perspective. Thyroid Res 6:3.

Kilic U, Caglayan AB, Beker MC, Gunal MY, Caglayan B, Yalcin E, Kelestemur T,
Gundogdu RZ, Yulug B, Yılmaz B, et al. (2017) Particular phosphorylation of
PI3K/Akt on Thr308 via PDK-1 and PTEN mediates melatonin’s neuroprotective
activity after focal cerebral ischemia in mice. Redox Biol 12:657–665.

Kim B, Kim CY, Lee MJ, and Joo YH (2009) Preliminary evidence on the
association between XBP1-116C/G polymorphism and response to prophylactic
treatment with valproate in bipolar disorders. Psychiatry Res 168:209–212.

Kim HJ and Thayer SA (2009) Lithium increases synapse formation between
hippocampal neurons by depleting phosphoinositides. Mol Pharmacol 75:1021–1030.
Kim SH, Yu HS, Park HG, Ahn YM, Kim YS, Lee YH, Ha K, and Shin SY (2013)
Egr1 regulates lithium-induced transcription of the Period 2 (PER2) gene.
Biochim Biophys Acta 1832:1969–1979.

Potential Therapeutic Effects of Lithium

353

Kim YH, Rane A, Lussier S, and Andersen JK (2011) Lithium protects against
oxidative stress-mediated cell death in a-synuclein-overexpressing in vitro and
in vivo models of Parkinson’s disease. J Neurosci Res 89:1666–1675.

King TD, Bijur GN, and Jope RS (2001) Caspase-3 activation induced by inhibition
of mitochondrial complex I is facilitated by glycogen synthase kinase-3beta and
attenuated by lithium. Brain Res 919:106–114.

Kirshenboim N, Plotkin B, Shlomo SB, Kaidanovich-Beilin O, and Eldar-Finkelman H
(2004) Lithium-mediated phosphorylation of glycogen synthase kinase-3beta involves
PI3 kinase-dependent activation of protein kinase C-alpha. J Mol Neurosci
24:237–245.

Kishi T, Ikuta T, Matsuda Y, Sakuma K, Okuya M, Mishima K, and Iwata N (2021)
Mood stabilizers and/or antipsychotics for bipolar disorder in the maintenance
phase: a systematic review and network meta-analysis of randomized controlled
trials. Mol Psychiatry 26:4146–4157.

Kishi T, Ikuta T, Matsuda Y, Sakuma K, Okuya M, Nomura I, Hatano M, and
Iwata N (2022) Pharmacological treatment for bipolar mania: a systematic
review and network meta-analysis of double-blind randomized controlled trials.
Mol Psychiatry 27:1136–1144.

Kleandrova VV and Speck-Planche A (2020) PTML Modeling for Alzheimer’s
Disease: Design and Prediction of Virtual Multi-Target Inhibitors of GSK3B,
HDAC1, and HDAC6. Curr Top Med Chem 20:1661–1676.

Klein PS and Melton DA (1996) A molecular mechanism for the effect of lithium on

development. Proc Natl Acad Sci USA 93:8455–8459.

Knable MB, Barci BM, Webster MJ, Meador-Woodruff J, and Torrey EF; Stanley
Neuropathology Consortium (2004) Molecular abnormalities of the hippocampus in
severe psychiatric illness: postmortem ﬁndings from the Stanley Neuropathology
Consortium. Mol Psychiatry 9:609–620, 544.

Koh PO, Undie AS, Kabbani N, Levenson R, Goldman-Rakic PS, and Lidow MS
(2003) Up-regulation of neuronal calcium sensor-1 (NCS-1) in the prefrontal cortex
of schizophrenic and bipolar patients. Proc Natl Acad Sci USA 100:313–317.

K€ohler-Forsberg O, Sylvia LG, Thase M, Calabrese JR, Tohen M, Bowden CL, McInnis
M, Iosifescu DV, Kocsis JH, Friedman ES, et al. (2023) Lithium plus antipsychotics or
anticonvulsants for bipolar disorder: Comparing clinical response and metabolic
changes. Aust N Z J Psychiatry 57:93–103.

Kok FK, van Leerdam SL, and de Lange ECM (2022) Potential Mechanisms
Underlying Resistance to Dementia in Non-Demented Individuals with Alzheimer’s
Disease Neuropathology. J Alzheimers Dis 87:51–81.

Kolar D, Kleteckova L, Brozka H, and Vales K (2021) Mini-review: Brain energy
metabolism and its role in animal models of depression, bipolar disorder,
schizophrenia and autism. Neurosci Lett 760:136003.

Koo JW, Chaudhury D, Han MH, and Nestler EJ (2019) Role of Mesolimbic Brain-

Derived Neurotrophic Factor in Depression. Biol Psychiatry 86:738–748.

Kosik KS (2006) The neuronal microRNA system. Nat Rev Neurosci 7:911–920.
Kreilaus F, Guerra S, Masanetz R, Menne V, Yerbury J, and Karl T (2020) Novel
behavioural characteristics of the superoxide dismutase 1 G93A (SOD1G93A)
mouse model of amyotrophic lateral sclerosis include sex-dependent phenotypes.
Genes Brain Behav 19:e12604.

Kulkarni J, Berk M, Wang W, Mu L, Scarr E, Van Rheenen TE, Worsley R, Gurvich
C, Gavrilidis E, de Castella A, et al. (2014) A four week randomised control trial
of adjunctive medroxyprogesterone and tamoxifen in women with mania.
Psychoneuroendocrinology 43:52–61.

Kupka RW, Altshuler LL, Nolen WA, Suppes T, Luckenbaugh DA, Leverich GS,
Frye MA, Keck Jr PE, McElroy SL, Grunze H, et al. (2007) Three times more
days depressed than manic or hypomanic in both bipolar I and bipolar II
disorder. Bipolar Disord 9:531–535.

Lambrichts S, Detraux J, Vansteelandt K, Nordenskj€old A, Obbels J, Schrijvers D, and
Sienaert P (2021) Does lithium prevent relapse following successful electroconvulsive
therapy for major depression? A systematic review and meta-analysis. Acta Psychiatr
Scand 143:294–306.

Lan CC, Liu CC, Lin CH, Lan TY, McInnis MG, Chan CH, and Lan TH (2015) A
reduced risk of stroke with lithium exposure in bipolar disorder: a population-
based retrospective cohort study. Bipolar Disord 17:705–714.

Lan MJ, McLoughlin GA, Grifﬁn JL, Tsang TM, Huang JT, Yuan P, Manji H,
Holmes E, and Bahn S (2009) Metabonomic analysis identiﬁes molecular changes
associated with the pathophysiology and drug treatment of bipolar disorder. Mol
Psychiatry 14:269–279.

Lau KF, Miller CC, Anderton BH, and Shaw PC (1999) Expression analysis of

glycogen synthase kinase-3 in human tissues. J Pept Res 54:85–91.

Lauterbach EC (2013) Neuroprotective effects of psychotropic drugs in Huntington’s

disease. Int J Mol Sci 14:22558–22603.

Lazarus JH (1998) The effects of lithium therapy on thyroid and thyrotropin-

releasing hormone. Thyroid 8:909–913.

Lazzara CA and Kim YH (2015) Potential application of lithium in Parkinson’s and

other neurodegenerative diseases. Front Neurosci 9:403.

Leeds PR, Yu F, Wang Z, Chiu CT, Zhang Y, Leng Y, Linares GR, and Chuang DM
(2014) A new avenue for lithium: intervention in traumatic brain injury. ACS
Chem Neurosci 5:422–433.

Levine B and Kroemer G (2008) Autophagy in the pathogenesis of disease. Cell

132:27–42.

Li N, Lee B, Liu RJ, Banasr M, Dwyer JM, Iwata M, Li XY, Aghajanian G, and
Duman RS (2010) mTOR-dependent synapse formation underlies the rapid
antidepressant effects of NMDA antagonists. Science 329:959–964.

Li XZ, Chen XP, Zhao K, Bai LM, Zhang H, and Zhou XP (2013) Therapeutic effects
of valproate combined with lithium carbonate on MPTP-induced parkinsonism in
mice: possible mediation through enhanced autophagy. Int J Neurosci 123:73–79.
Liechti FD, St€udle N, Theurillat R, Grandgirard D, Thormann W, and Leib SL
(2014) The mood-stabilizer lithium prevents hippocampal apoptosis and improves
spatial memory in experimental meningitis. PLoS One 9:e113607.

Lien E, Means TK, Heine H, Yoshimura A, Kusumoto S, Fukase K, Fenton MJ,
Oikawa M, Qureshi N, Monks B, et al. (2000) Toll-like receptor 4 imparts ligand-
speciﬁc recognition of bacterial lipopolysaccharide. J Clin Invest 105:497–504.
Lieu CA, Dewey CM, Chinta SJ, Rane A, Rajagopalan S, Batir S, Kim YH, and
Andersen JK (2014) Lithium prevents parkinsonian behavioral and striatal
phenotypes in an aged parkin mutant transgenic mouse model. Brain Res
1591:111–117.

Lim YY, Villemagne VL, Laws SM, Pietrzak RH, Snyder PJ, Ames D, Ellis KA,
Harrington K, Rembach A, Martins RN, et al.
(2015) APOE and BDNF
polymorphisms moderate amyloid b-related cognitive decline in preclinical
Alzheimer’s disease. Mol Psychiatry 20:1322–1328.

Limanaqi F, Biagioni F, Ryskalin L, Busceti CL, and Fornai F (2019) Molecular
Mechanisms Linking ALS/FTD and Psychiatric Disorders, the Potential Effects
of Lithium. Front Cell Neurosci 13:450.

Lin S and Gregory RI (2015) MicroRNA biogenesis pathways in cancer. Nat Rev

Cancer 15:321–333.

Lin Y, Maihofer AX, Stapp E, Ritchey M, Alliey-Rodriguez N, Anand A, Balaraman
Y, Berrettini WH, Bertram H, Bhattacharjee A, et al. (2021) Clinical predictors of
non-response to lithium treatment in the Pharmacogenomics of Bipolar Disorder
(PGBD) study. Bipolar Disord 23:821–831.

Lipstein N, Verhoeven-Duif NM, Michelassi FE, Calloway N, van Hasselt PM,
Pienkowska K, van Haaften G, van Haelst MM, van Empelen R, Cuppen I, et al.
(2017) Synaptic UNC13A protein variant causes increased neurotransmission
and dyskinetic movement disorder. J Clin Invest 127:1005–1018.

Liu RJ, Fuchikami M, Dwyer JM, Lepack AE, Duman RS, and Aghajanian GK (2013)
GSK-3 inhibition potentiates the synaptogenic and antidepressant-like effects of
subthreshold doses of ketamine. Neuropsychopharmacology 38:2268–2277.

Logue MW, van Rooij SJH, Dennis EL, Davis SL, Hayes JP, Stevens JS, Densmore M,
Haswell CC, Ipser J, Koch SBJ, et al. (2018) Smaller Hippocampal Volume in
Posttraumatic Stress Disorder: A Multisite ENIGMA-PGC Study: Subcortical
Volumetry Results From Posttraumatic Stress Disorder Consortia. Biol Psychiatry
83:244–253.

Lowthert L, Leffert J, Lin A, Umlauf S, Maloney K, Muralidharan A, Lorberg B,
Mane S, Zhao H, Sinha R, et al. (2012) Increased ratio of anti-apoptotic to pro-
apoptotic Bcl2 gene-family members in lithium-responders one month after
treatment initiation. Biol Mood Anxiety Disord 2:15.

Lu SM, Gui B, Dong HQ, Zhang X, Zhang SS, Hu LQ, Liu HL, Sun J, and Qian YN
(2015) Prophylactic lithium alleviates splenectomy-induced cognitive dysfunction
possibly by inhibiting hippocampal TLR4 activation in aged rats. Brain Res Bull
114:31–41.

Mably AJ and Colgin LL (2018) Gamma oscillations in cognitive disorders. Curr

Opin Neurobiol 52:182–187.

Machado-Vieira R, Manji HK, and Zarate Jr CA (2009) The role of lithium in the
treatment of bipolar disorder: convergent evidence for neurotrophic effects as a
unifying hypothesis. Bipolar Disord 11(Suppl 2)92–109.

Mafﬁoletti E, Cattaneo A, Rosso G, Maina G, Maj C, Gennarelli M, Tardito D, and
Bocchio-Chiavetto L (2016) Peripheral whole blood microRNA alterations in major
depression and bipolar disorder. J Affect Disord 200:250–258.

Makin SD, Turpin S, Dennis MS, and Wardlaw JM (2013) Cognitive impairment after
lacunar stroke: systematic review and meta-analysis of incidence, prevalence and
comparison with other stroke subtypes. J Neurol Neurosurg Psychiatry 84:893–900.
Malhi GS, Tanious M, Das P, Coulston CM, and Berk M (2013) Potential
mechanisms of action of lithium in bipolar disorder. Current understanding. CNS
Drugs 27:135–153.

Malhi GS, Bassett D, Boyce P, Bryant R, Fitzgerald PB, Fritz K, Hopwood M,
Lyndon B, Mulder R, Murray G, et al. (2015) Royal Australian and New Zealand
College of Psychiatrists clinical practice guidelines for mood disorders. Aust N Z
J Psychiatry 49:1087–1206.

Malhi GS and Outhred T (2016) Therapeutic Mechanisms of Lithium in Bipolar
Disorder: Recent Advances and Current Understanding. CNS Drugs 30:931–949.
Malhi GS, Gessler D, and Outhred T (2017) The use of lithium for the treatment of
bipolar disorder: Recommendations from clinical practice guidelines. J Affect
Disord 217:266–280.

Malhi GS, Bell E, Boyce P, Bassett D, Berk M, Bryant R, Gitlin M, Hamilton A,
Hazell P, Hopwood M, et al. (2020) The 2020 Royal Australian and New Zealand
College of psychiatrists clinical practice guidelines for mood disorders: Bipolar
disorder summary. Bipolar Disord 22:805–821.

Manchia M, Adli M, Akula N, Ardau R, Aubry J-M, Backlund L, Banzato CE,
Baune BT, Bellivier F, Bengesser S, et al. (2013) Assessment of Response to
Lithium Maintenance Treatment in Bipolar Disorder: A Consortium on Lithium
Genetics (ConLiGen) Report. PLoS One 8:e65636.

Manchia M, Rybakowski JK, Sani G, Kessing LV, Murru A, Alda M, and Tondo L

(2019) Lithium and bipolar depression. Bipolar Disord 21:458–459.

Manchia M, Sani G, and Alda M (2022) Suicide Risk and Lithium. JAMA

Psychiatry 79:513.

Manji HK and Lenox RH (2000) Signaling: cellular insights into the pathophysiology

of bipolar disorder. Biol Psychiatry 48:518–530.

Manning JS (2005) Burden of illness in bipolar depression. Prim Care Companion

J Clin Psychiatry 7:259–267.

Marangell LB, Dennehy EB, Wisniewski SR, Bauer MS, Miyahara S, Allen MH,
Martinez M, Al Jurdi RK, and Thase ME (2008) Case-control analyses of the
impact of pharmacotherapy on prospectively observed suicide attempts and
completed suicides in bipolar disorder: ﬁndings from STEP-BD. J Clin Psychiatry
69:916–922.

Marie-Claire C, Etain B, and Bellivier F (2021) Mini review: Recent advances on

epigenetic effects of lithium. Neurosci Lett 761:136116.

Martin M, Rehani K, Jope RS, and Michalek SM (2005) Toll-like receptor-mediated
cytokine production is differentially regulated by glycogen synthase kinase 3.
Nat Immunol 6:777–784.

354

Bortolozzi et al.

Martino DJ, Igoa A, Sc(cid:3)apola M, Marengo E, Samam(cid:3)e C, and Strejilevich SA (2017)
Functional Outcome in the Middle Course of Bipolar Disorder: A Longitudinal
Study. J Nerv Ment Dis 205:203–206.

Matsunaga S, Kishi T, Annas P, Basun H, Hampel H, and Iwata N (2015) Lithium as
a Treatment for Alzheimer’s Disease: A Systematic Review and Meta-Analysis.
J Alzheimers Dis 48:403–410.

McCarthy MJ, Leckband SG, and Kelsoe JR (2010) Pharmacogenetics of lithium

response in bipolar disorder. Pharmacogenomics 11:1439–1465.

McCarthy MJ, Wei H, Landgraf D, Le Roux MJ, and Welsh DK (2016) Disinhibition of
the extracellular-signal-regulated kinase restores the ampliﬁcation of circadian
rhythms by lithium in cells from bipolar disorder patients. Eur Neuropsychopharmacol
26:1310–1319.

McCarthy MJ, Wei H, Marnoy Z, Darvish RM, McPhie DL, Cohen BM, and Welsh
DK (2013) Genetic and clinical factors predict lithium’s effects on PER2 gene
expression rhythms in cells from bipolar disorder patients. Transl Psychiatry
3:e318.

McFarthing K, Rafaloff G, Baptista M, Mursaleen L, Fuest R, Wyse RK, and Stott
SRW (2022) Parkinson’s Disease Drug Therapies in the Clinical Trial Pipeline:
2022 Update. J Parkinsons Dis 12:1073–1082.

McGrath JJ and Berk M (2017) Could Lithium in Drinking Water Reduce the

Incidence of Dementia? JAMA Psychiatry 74:983–984.

McIntyre RS, McElroy SL, Eudicone JM, Forbes RA, Carlson BX, and Baker RA (2011)
A 52-week, double-blind evaluation of the metabolic effects of aripiprazole and lithium
in bipolar I disorder. Prim Care Companion CNS Disord 13:PCC.11m01182.

McKnight RF, Adida M, Budge K, Stockton S, Goodwin GM, and Geddes JR (2012)
Lithium toxicity proﬁle: a systematic review and meta-analysis. Lancet 379:721–728.
McKnight RF, de La Motte de Bro€ons de Vauvert SJGN, Chesney E, Amit BH,
Geddes J, and Cipriani A (2019) Lithium for acute mania. Cochrane Database
Syst Rev 6:CD004048.

Meehan AD, Udumyan R, Kardell M, Land(cid:3)en M, J€arhult J, and Wallin G (2018)
Lithium-Associated Hypercalcemia: Pathophysiology, Prevalence, Management.
World J Surg 42:415–424.

Mertens J, Wang QW, Kim Y, Yu DX, Pham S, Yang B, Zheng Y, Diffenderfer KE,
Zhang J, Soltani S, et al.; Pharmacogenomics of Bipolar Disorder Study (2015)
Differential responses to lithium in hyperexcitable neurons from patients with
bipolar disorder [published correction appears in Nature (2016) 530:242]. Nature
527:95–99.

Mishra HK, Ying NM, Luis A, Wei H, Nguyen M, Nakhla T, Vandenburgh S, Alda
M, Berrettini WH, Brennand KJ, et al.; Pharmacogenomics of Bipolar Disorder
Study (2021) Circadian rhythms in bipolar disorder patient-derived neurons
predict lithium response: preliminary studies. Mol Psychiatry 26:3383–3394.

Mohammadianinejad SE, Majdinasab N, Sajedi SA, Abdollahi F, Moqaddam MM, and
Sadr F (2014) The effect of lithium in post-stroke motor recovery: a double-blind,
placebo-controlled, randomized clinical trial. Clin Neuropharmacol 37:73–78.

Molendijk ML, Spinhoven P, Polak M, Bus BA, Penninx BW, and Elzinga BM (2014)
Serum BDNF concentrations as peripheral manifestations of depression: evidence
from a systematic review and meta-analyses on 179 associations (N59484). Mol
Psychiatry 19:791–800.

Montibeller L and de Belleroche J (2018) Amyotrophic lateral sclerosis (ALS) and
Alzheimer’s disease (AD) are characterised by differential activation of ER stress
pathways: focus on UPR target genes. Cell Stress Chaperones 23:897–912.

Moore GJ, Bebchuk JM, Wilds IB, Chen G, and Manji HK (2000) Lithium-induced
increase in human brain grey matter [published correction appears in Lancet
(2000) 356:2104]. Lancet 356:1241–1242.

Morris G and Berk M (2016) The Putative Use of Lithium in Alzheimer’s Disease.

Curr Alzheimer Res 13:853–861.

Morris G, Walder K, McGee SL, Dean OM, Tye SJ, Maes M, and Berk M (2017) A
model of the mitochondrial basis of bipolar disorder. Neurosci Biobehav Rev 74
(Pt A):1–20.

Motoi Y, Shimada K, Ishiguro K, and Hattori N (2014) Lithium and autophagy.

ACS Chem Neurosci 5:434–442.

M€uller-Oerlinghausen B and Lewitzka U (2010) Lithium reduces pathological

aggression and suicidality: a mini-review. Neuropsychobiology 62:43–49.

Nabi Z, Stansfeld J, Pl€oderl M, Wood L, and Moncrieff J (2022) Effects of lithium on
suicide and suicidal behaviour: a systematic review and meta-analysis of randomised
trials. Epidemiol Psychiatr Sci 31:e65.

Naik MU, Benedikz E, Hernandez I, Libien J, Hrabe J, Valsamis M, Dow-Edwards D,
Osman M, and Sacktor TC (2000) Distribution of protein kinase Mzeta and the
complete protein kinase C isoform family in rat brain. J Comp Neurol 426:243–258.
Nakamura T, Jimbo K, Nakajima K, Tsuboi T, and Kato T (2018) De novo UNC13B
mutation identiﬁed in a bipolar disorder patient increases a rare exon-skipping
variant. Neuropsychopharmacol Rep 38:210–213.

Nakashima H, Ishihara T, Suguimoto P, Yokota O, Oshima E, Kugo A, Terada S,
Hamamura T, Trojanowski JQ, Lee VM, et al. (2005) Chronic lithium treatment
decreases tau lesions by promoting ubiquitination in a mouse model of tauopathies.
Acta Neuropathol 110:547–556.

Nam Y, Wie MB, Shin EJ, Nguyen TT, Nah SY, Ko SK, Jeong JH, Jang CG, and Kim
HC (2015) Ginsenoside Re protects methamphetamine-induced mitochondrial
burdens and proapoptosis via genetic inhibition of protein kinase C d in human
neuroblastoma dopaminergic SH-SY5Y cell lines. J Appl Toxicol 35:927–944.

Nelson JC, Baumann P, Delucchi K, Joffe R, and Katona C (2014) A systematic
lithium augmentation of tricyclic and second

review and meta-analysis of
generation antidepressants in major depression. J Affect Disord 168:269–275.
Nestsiarovich A, Gaudiot CES, Baldessarini RJ, Vieta E, Zhu Y, and Tohen M
(2022) Preventing new episodes of bipolar disorder in adults: Systematic review
and meta-analysis of randomized controlled trials. Eur Neuropsychopharmacol
54:75–89.

National Collaborating Centre for Mental Health (UK) (2014) Bipolar Disorder:
The NICE Guideline on the Assessment and Management of Bipolar Disorder in

Adults, Children and Young People in Primary and Secondary Care, The British
Psychological Society and The Royal College of Psychiatrists, London, England.
Niemsiri V, Rosenthal SB, Nievergelt CM, Maihofer AX, Marchetto MC, Santos R,
Shekhtman T, Alliey-Rodriguez N, Anand A, Balaraman Y, et al. (2023) Focal
adhesion is associated with lithium response in bipolar disorder: evidence from a
network-based multi-omics analysis. Mol Psychiatry DOI: 10.1038/s41380-022-01909-9
[published ahead of print].

Nigam SM, Xu S, Kritikou JS, Marosi K, Brodin L, and Mattson MP (2017)
Exercise and BDNF reduce Ab production by enhancing a-secretase processing of
APP. J Neurochem 142:286–296.

Nivoli AM, Colom F, Murru A, Pacchiarotti I, Castro-Loli P, Gonz(cid:3)alez-Pinto A,
Fountoulakis KN, and Vieta E (2011) New treatment guidelines for acute bipolar
depression: a systematic review. J Affect Disord 129:14–26.

Novick AM, Scott AT, Neill Epperson C, and Schneck CD (2020) Neuropsychiatric
effects of tamoxifen: Challenges and opportunities. Front Neuroendocrinol 59:100869.
Nowicki MO, Dmitrieva N, Stein AM, Cutter JL, Godlewski J, Saeki Y, Nita M,
Berens ME, Sander LM, Newton HB, et al. (2008) Lithium inhibits invasion of
glioma cells; possible involvement of glycogen synthase kinase-3. Neuro-oncol
10:690–699.

O’Brien WT, Harper AD, Jov(cid:3)e F, Woodgett JR, Maretto S, Piccolo S, and Klein PS
(2004) Glycogen synthase kinase-3beta haploinsufﬁciency mimics the behavioral
and molecular effects of lithium. J Neurosci 24:6791–6798.

O’Brien WT, Huang J, Buccafusca R, Garskof J, Valvezan AJ, Berry GT, and Klein
for b-arrestin-2 complex

PS (2011) Glycogen synthase kinase-3 is essential
formation and lithium-sensitive behaviors in mice. J Clin Invest 121:3756–3762.
Ochoa ELM (2022) Lithium as a Neuroprotective Agent for Bipolar Disorder: An

Overview. Cell Mol Neurobiol 42:85–97.

O’Donnell BF, Hetrick WP, Vohs JL, Krishnan GP, Carroll CA, and Shekhar A
(2004) Neural synchronization deﬁcits to auditory stimulation in bipolar disorder.
Neuroreport 15:1369–1372.

€Ong€ur D, Jensen JE, Prescot AP, Stork C, Lundy M, Cohen BM, and Renshaw PF
(2008) Abnormal glutamatergic neurotransmission and neuronal-glial interactions
in acute mania. Biol Psychiatry 64:718–726.

Osete JR, Akkouh IA, de Assis DR, Szabo A, Frei E, Hughes T, Smeland OB, Steen
NE, Andreassen OA, and Djurovic S (2021) Lithium increases mitochondrial
respiration in iPSC-derived neural precursor cells from lithium responders. Mol
Psychiatry 26:6789–6805.

Osete JR, Akkouh IA, Ievglevskyi O, Vandenberghe M, de Assis DR, Ueland T,
Kondratskaya E, Holen B, Szabo A, Hughes T, et al. (2023) Transcriptional and
functional effects of lithium in bipolar disorder iPSC-derived cortical spheroids.
Mol Psychiatry 28:3033–3043.

Oruch R, Elderbi MA, Khattab HA, Pryme IF, and Lund A (2014) Lithium: a review of

pharmacology, clinical uses, and toxicity. Eur J Pharmacol 740:464–473.

Pahl S, Tapken D, Haering SC, and Hollmann M (2014) Trafﬁcking of kainate

receptors. Membranes (Basel) 4:565–595.

Palacios J, Yildiz A, Young AH, and Taylor MJ (2019) Tamoxifen for bipolar
disorder: Systematic review and meta-analysis. J Psychopharmacol 33:177–184.
Palmos AB, Duarte RRR, Smeeth DM, Hedges EC, Nixon DF, Thuret S, and Powell
TR (2021) Lithium treatment and human hippocampal neurogenesis. Transl
Psychiatry 11:555.

Palomino A, Gonz(cid:3)alez-Pinto A, Martinez-Cengotitabengoa M, Ruiz de Azua S,
Alberich S, Mosquera F, and Matute C (2013) Relationship between negative
symptoms and plasma levels of insulin-like growth factor 1 in ﬁrst-episode
schizophrenia and bipolar disorder patients. Prog Neuropsychopharmacol Biol
Psychiatry 44:29–33.

Pasquali L, Busceti CL, Fulceri F, Paparelli A, and Fornai F (2010) Intracellular

pathways underlying the effects of lithium. Behav Pharmacol 21:473–492.

Pei L and Wallace DC (2018) Mitochondrial Etiology of Neuropsychiatric Disorders.

Biol Psychiatry 83:722–730.

Pendlebury ST and Rothwell PM (2009) Prevalence, incidence, and factors associated
with pre-stroke and post-stroke dementia: a systematic review and meta-analysis.
Lancet Neurol 8:1006–1018.

Pereira AC, McQuillin A, Puri V, Anjorin A, Bass N, Kandaswamy R, Lawrence J,
Curtis D, Sklar P, Purcell SM, et al. (2011) Genetic association and sequencing of
the insulin-like growth factor 1 gene in bipolar affective disorder. Am J Med
Genet B Neuropsychiatr Genet 156:177–187.
P(cid:3)erez-Castro P, Al Shaban Rodriguez OWMA, and

(cid:3)
Alvarez-Castro P (2021) Thyroid
alterations in bipolar patients on treatment with lithium. Alteraciones tiroideas en
pacientes bipolares a tratamiento con litio. Rev Psiquiatr Salud Ment 14:73–74.

Perlis RH, Ostacher MJ, Patel JK, Marangell LB, Zhang H, Wisniewski SR, Ketter TA,
Miklowitz DJ, Otto MW, Gyulai L, et al. (2006) Predictors of recurrence in bipolar
disorder: primary outcomes from the Systematic Treatment Enhancement Program
for Bipolar Disorder (STEP-BD). Am J Psychiatry 163:217–224.

Perlis RH, Smoller JW, Ferreira MA, McQuillin A, Bass N, Lawrence J, Sachs GS,
Nimgaonkar V, Scolnick EM, Gurling H, et al. (2009) A genomewide association
study of response to lithium for prevention of recurrence in bipolar disorder. Am
J Psychiatry 166:718–725.

Pfaffenseller B, Wollenhaupt-Aguiar B, Fries GR, Colpo GD, Burque RK, Bristot G,
Ferrari P, Ceres(cid:3)er KM, Rosa AR, Klamt F, et al. (2014) Impaired endoplasmic
reticulum stress response in bipolar disorder: cellular evidence of illness progression.
Int J Neuropsychopharmacol 17:1453–1463.

Phiel CJ and Klein PS (2001) Molecular targets of lithium action. Annu Rev

Pharmacol Toxicol 41:789–813.

Phiel CJ, Wilson CA, Lee VM, and Klein PS (2003) GSK-3alpha regulates

production of Alzheimer’s disease amyloid-b peptides. Nature 423:435–439.

Pillinger T, McCutcheon RA, Vano L, Mizuno Y, Arumuham A, Hindley G, Beck
K, Natesan S, Efthimiou O, Cipriani A, et al. (2020) Comparative effects of 18
antipsychotics on metabolic function in patients with schizophrenia, predictors
of metabolic dysregulation, and association with psychopathology: a systematic
review and network meta-analysis. Lancet Psychiatry 7:64–77.

Potential Therapeutic Effects of Lithium

355

Pinna M, Manchia M, Puddu S, Minnai G, Tondo L, and Salis P (2017) Cutaneous
adverse reaction during lithium treatment: a case report and updated systematic
review with meta-analysis. Int J Bipolar Disord 5:20.

Piovesan D, Proﬁti G, Martelli PL, and Casadio R (2012) The human “magnesome”:
detecting magnesium binding sites on human proteins. BMC Bioinformatics
13(Suppl 14)S10.

Pisanu C, Melis C, and Squassina A (2016) Lithium Pharmacogenetics: Where Do

We Stand? Drug Dev Res 77:368–373.

Pisanu C, Heilbronner U, and Squassina A (2018) The Role of Pharmacogenomics in
Bipolar Disorder: Moving Towards Precision Medicine. Mol Diagn Ther 22:409–420.
Pisanu C, Merkouri Papadima E, Melis C, Congiu D, Loizedda A, Orr(cid:1)u N, Calza S,
Orr(cid:1)u S, Carcassi C, Severino G, et al. (2019) Whole Genome Expression Analyses
of miRNAs and mRNAs Suggest the Involvement of miR-320a and miR-155-3p
and their Targeted Genes in Lithium Response in Bipolar Disorder. Int J Mol Sci
20:6040.

Pouladi MA, Brillaud E, Xie Y, Conforti P, Graham RK, Ehrnhoefer DE, Franciosi
S, Zhang W, Poucheret P, Compte E, et al. (2012) NP03, a novel low-dose lithium
formulation,
is neuroprotective in the YAC128 mouse model of Huntington
disease. Neurobiol Dis 48:282–289.

Popovic D, Reinares M, Goikolea JM, Bonnin CM, Gonzalez-Pinto A, and Vieta E
(2012) Polarity index of pharmacological agents used for maintenance treatment
of bipolar disorder. Eur Neuropsychopharmacol 22:339–346.

Preston G, Kirdar F, and Kozicz T (2018) The role of suboptimal mitochondrial
function in vulnerability to post-traumatic stress disorder. J Inherit Metab Dis
41:585–596.

Price JB, Yates CG, Morath BA, Van De Wakker SK, Yates NJ, Butters K, Frye
MA, McGee SL, and Tye SJ (2021) Lithium augmentation of ketamine increases
insulin signaling and antidepressant-like active stress coping in a rodent model
of treatment-resistant depression. Transl Psychiatry 11:598.

Price RB, Nock MK, Charney DS, and Mathew SJ (2009) Effects of intravenous
ketamine on explicit and implicit measures of suicidality in treatment-resistant
depression. Biol Psychiatry 66:522–526.

Prillo J, Soh JF, Park H, Beaulieu S, Linnaranta O, and Rej S (2021) Obesity and
metabolic comorbidity in bipolar disorder: do patients on lithium comprise a
subgroup? A naturalistic study. BMC Psychiatry 21:558.

Puglisi-Allegra S, Ruggieri S, and Fornai F (2021) Translational evidence for lithium-
induced brain plasticity and neuroprotection in the treatment of neuropsychiatric
disorders. Transl Psychiatry 11:366.

Qi L, Tang Y, He W, Pan H, Jiang W, Wang L, and Deng W (2017) Lithium chloride
promotes neuronal differentiation of rat neural stem cells and enhances neural
regeneration in Parkinson’s disease model. Cytotechnology 69:277–287.

Quirk MC, Sosulski DL, Feierstein CE, Uchida N, and Mainen ZF (2009) A deﬁned
network of fast-spiking interneurons in orbitofrontal cortex: responses to behavioral
contingencies and ketamine administration. Front Syst Neurosci 3:13.

Quiroz JA, Gould TD, and Manji HK (2004) Molecular effects of lithium. Mol Interv

4:259–272.

Quiroz JA, Machado-Vieira R, Zarate Jr CA, and Manji HK (2010) Novel insights
into lithium’s mechanism of action: neurotrophic and neuroprotective effects.
Neuropsychobiology 62:50–60.

Rao JS and Rapoport SI (2009) Mood-stabilizers target the brain arachidonic acid

cascade. Curr Mol Pharmacol 2:207–214.

Rakofsky JJ, Lucido MJ, and Dunlop BW (2022) Lithium in the treatment of acute
bipolar depression: A systematic review and meta-analysis. J Affect Disord
308:268–280.

Reilley DJ, Arraf Z, and Alexandrova AN (2021) Contrasting Effects of Inhibitors
Li1 and Be21 on Catalytic Cycle of Glycogen Synthase Kinase-3b. J Phys Chem
B 125:9480–9489.

Reinbold CS, Forstner AJ, Hecker J, Fullerton JM, Hoffmann P, Hou L, Heilbronner
U, Degenhardt F, Adli M, Akiyama K, et al. (2018) Analysis of the Inﬂuence of
microRNAs in Lithium Response in Bipolar Disorder. Front Psychiatry 9:207.

Reis C, Wang Y, Akyol O, Ho WM, Ii RA, Stier G, Martin R, and Zhang JH (2015)
What’s New in Traumatic Brain Injury: Update on Tracking, Monitoring and
Treatment. Int J Mol Sci 16:11903–11965.

Ren M, Senatorov VV, Chen RW, and Chuang DM (2003) Postinsult treatment with
lithium reduces brain damage and facilitates neurological recovery in a rat
ischemia/reperfusion model. Proc Natl Acad Sci USA 100:6210–6215.

R(cid:3)eus GZ, Abaleira HM, Titus SE, Arent CO, Michels M, da Luz JR, dos Santos MA,
Carlessi AS, Matias BI, Bruchchen L, et al. (2016) Effects of ketamine administration
on the phosphorylation levels of CREB and TrKB and on oxidative damage after
infusion of MEK inhibitor. Pharmacol Rep 68:177–184.

Rhee TG, Olfson M, Nierenberg AA, and Wilkinson ST (2020) 20-Year Trends in
the Pharmacologic Treatment of Bipolar Disorder by Psychiatrists in Outpatient
Care Settings. Am J Psychiatry 177:706–715.

Rojo AI, Rada P, Egea J, Rosa AO, L(cid:3)opez MG, and Cuadrado A (2008) Functional
interference between glycogen synthase kinase-3 beta and the transcription
factor Nrf2 in protection against kainate-induced hippocampal cell death. Mol
Cell Neurosci 39:125–132.

Rong H, Liu TB, Yang KJ, Yang HC, Wu DH, Liao CP, Hong F, Yang HZ, Wan F, Ye XY,
et al. (2011) MicroRNA-134 plasma levels before and after treatment for bipolar
mania. J Psychiatr Res 45:92–95.

Rowland LM, Bustillo JR, Mullins PG, Jung RE, Lenroot R, Landgraf E, Barrow R,
Yeo R, Lauriello J, and Brooks WM (2005) Effects of ketamine on anterior
cingulate glutamate metabolism in healthy humans: a 4-T proton MRS study.
Am J Psychiatry 162:394–396.

Rowland T, Perry BI, Upthegrove R, Barnes N, Chatterjee J, Gallacher D, and
Marwaha S (2018) Neurotrophins, cytokines, oxidative stress mediators and mood
state in bipolar disorder: systematic review and meta-analyses. Br J Psychiatry
213:514–525.

Rowse AL, Naves R, Cashman KS, McGuire DJ, Mbana T, Raman C, and De Sarno P
(2012) Lithium controls central nervous system autoimmunity through modulation
of IFN-c signaling. PLoS One 7:e52658.

Rubinsztein DC, Codogno P, and Levine B (2012) Autophagy modulation as a potential

therapeutic target for diverse diseases. Nat Rev Drug Discov 11:709–730.

Rybakowski JK, Permoda-Osip A, and Borkowska A (2009) Response to prophylactic
lithium in bipolar disorder may be associated with a preservation of executive
cognitive functions. Eur Neuropsychopharmacol 19:791–795.

Rybakowski JK and Suwalska A (2010) Excellent lithium responders have normal
cognitive functions and plasma BDNF levels. Int J Neuropsychopharmacol
13:617–622.

Rybakowski JK, Suwalska A, and Hajek T (2018) Clinical Perspectives of Lithium’s

Neuroprotective Effect. Pharmacopsychiatry 51:194–199.

Rybakowski JK (2022) Lithium. Eur Neuropsychopharmacol 57:86–87.
Salagre E and Vieta E (2021) Precision psychiatry: Complex problems require

complex solutions. European Neuropsychopharmacol 52:94–95.

Sagu(cid:3)e-Vilavella M, Sol(cid:3)e E, Pinz(cid:3)on-Espinosa J, Sandra-Hern(cid:3)andez A, Roda E, Vieta E,
and Roca A (2022) Obstetric outcomes regarding the use of lithium in pregnant
women with bipolar disorders: a prospective cohort study. Arch Women Ment Health
25:729–737.

Sakrajda K and Szczepankiewicz A (2021) Inﬂammation-Related Changes in Mood
Disorders and the Immunomodulatory Role of Lithium. Int J Mol Sci 22:1532.
Sarkar S, Krishna G, Imarisio S, Saiki S, O’Kane CJ, and Rubinsztein DC (2008) A
rational mechanism for combination treatment of Huntington’s disease using lithium
and rapamycin. Hum Mol Genet 17:170–178.

Sarkar S and Rubinsztein DC (2006) Inositol and IP3 levels regulate autophagy:

biology and therapeutic speculations. Autophagy 2:132–134.

Sasaki T, Han F, Shioda N, Moriguchi S, Kasahara J, Ishiguro K, and Fukunaga K
(2006) Lithium-induced activation of Akt and CaM kinase II contributes to its
neuroprotective action in a rat microsphere embolism model. Brain Res 1108:98–106.
Sawe N, Steinberg G, and Zhao H (2008) Dual roles of the MAPK/ERK1/2 cell

signaling pathway after stroke. J Neurosci Res 86:1659–1669.

Saxena A, Scaini G, Bavaresco DV, Leite C, Valvassori SS, Carvalho AF, and Quevedo
J (2017) Role of Protein Kinase C in Bipolar Disorder: A Review of the Current
Literature [published correction appears in Mol Neuropsychiatry (2018) 3:180]. Mol
Neuropsychiatry 3:108–124.

Scaini G, Rezin GT, Carvalho AF, Streck EL, Berk M, and Quevedo J (2016)
Mitochondrial dysfunction in bipolar disorder: Evidence, pathophysiology and
translational implications. Neurosci Biobehav Rev 68:694–713.

Schlecker C, Boehmerle W, Jeromin A, DeGray B, Varshney A, Sharma Y, Szigeti-Buck
K, and Ehrlich BE (2006) Neuronal calcium sensor-1 enhancement of InsP3 receptor
activity is inhibited by therapeutic levels of lithium. J Clin Invest 116:1668–1674.

Schloesser RJ, Huang J, Klein PS, and Manji HK (2008) Cellular plasticity cascades
in the pathophysiology and treatment of bipolar disorder. Neuropsychopharmacology
33:110–133.

Schubert KO, Thalamuthu A, Amare AT, Frank J, Streit F, Adl M, Akula N,
Akiyama K, Ardau R, Arias B, et al.; Major Depressive Disorder Working Group
of the Psychiatric Genomics Consortium (2021) Combining schizophrenia and
depression polygenic risk scores improves the genetic prediction of lithium
response in bipolar disorder patients [published correction appears in Transl
Psychiatry (2022) 12:278]. Transl Psychiatry 11:606.

Schulze TG, Alda M, Adli M, Akula N, Ardau R, Bui ET, Chillotti C, Cichon S,
Czerski P, Del Zompo M, et al. (2010) The International Consortium on Lithium
Genetics (ConLiGen): an initiative by the NIMH and IGSLI to study the genetic
basis of response to lithium treatment. Neuropsychobiology 62:72–78.

Shopsin B, Shenkman L, Blum M, and Hollander CS (1973) Iodine and lithium-
induced hypothyroidism. Documentation of synergism. Am J Med 55:695–699.
Scola G and Andreazza AC (2015) The role of neurotrophins in bipolar disorder.

Prog Neuropsychopharmacol Biol Psychiatry 56:122–128.

Seelan RS, Khalyfa A, Lakshmanan J, Casanova MF, and Parthasarathy RN (2008)
Deciphering the lithium transcriptome: microarray proﬁling of lithium-modulated
gene expression in human neuronal cells. Neuroscience 151:1184–1197.

Segal J, Berk M, and Brook S (1998) Risperidone compared with both lithium and
haloperidol in mania: a double-blind randomized controlled trial. Clin Neuropharmacol
21:176–180.

Senatorov VV, Ren M, Kanai H, Wei H, and Chuang DM (2004) Short-term lithium
treatment promotes neuronal survival and proliferation in rat striatum infused
with quinolinic acid, an excitotoxic model of Huntington’s disease. Mol Psychiatry
9:371–385.

Shao L, Sun X, Xu L, Young LT, and Wang JF (2006) Mood stabilizing drug lithium
increases expression of endoplasmic reticulum stress proteins in primary
cultured rat cerebral cortical cells. Life Sci 78:1317–1323.

Shao L, Young LT, and Wang JF (2005) Chronic treatment with mood stabilizers
lithium and valproate prevents excitotoxicity by inhibiting oxidative stress in rat
cerebral cortical cells. Biol Psychiatry 58:879–884.

Shi Y, Gerritsma D, Bowes AJ, Capretta A, and Werstuck GH (2007) Induction of
GRP78 by valproic acid is dependent upon histone deacetylase inhibition. Bioorg
Med Chem Lett 17:4491–4494.

Shim SS and Stutzmann GE (2016) Inhibition of Glycogen Synthase Kinase-3: An
Emerging Target in the Treatment of Traumatic Brain Injury. J Neurotrauma
33:2065–2076.

Shirayama Y, Chen AC, Nakagawa S, Russell DS, and Duman RS (2002) Brain-
derived neurotrophic factor produces antidepressant effects in behavioral models
of depression. J Neurosci 22:3251–3261.

Shah JH, DeLeon-Jones FA, Schickler R, Nasr S, Mayer M, and Hurks C (1986)
Symptomatic reactive hypoglycemia during glucose tolerance test in lithium-treated
patients. Metabolism 35:634–639.

Shorter E (2009) The history of lithium therapy. Bipolar Disord 11(Suppl 2, Suppl 2)4–9.
Sinha D, Wang Z, Ruchalski KL, Levine JS, Krishnan S, Lieberthal W, Schwartz JH,
and Borkan SC (2005) Lithium activates the Wnt and phosphatidylinositol 3-kinase

356

Bortolozzi et al.

Akt signaling pathways to promote cell survival in the absence of soluble survival
factors. Am J Physiol Renal Physiol 288:F703–F713.

Snitow ME, Bhansali RS, and Klein PS (2021) Lithium and Therapeutic Targeting

of GSK-3. Cells 10:255.

Soares JC, Chen G, Dippold CS, Wells KF, Frank E, Kupfer DJ, Manji HK, and
Mallinger AG (2000) Concurrent measures of protein kinase C and phosphoinositides
in lithium-treated bipolar patients and healthy individuals: a preliminary study.
Psychiatry Res 95:109–118.

Song L, De Sarno P, and Jope RS (2002) Central role of glycogen synthase kinase-
3beta in endoplasmic reticulum stress-induced caspase-3 activation. J Biol Chem
277:44701–44708.

Sportiche S, Geoffroy PA, Brichant-Petitjean C, Gard S, Khan JP, Azorin JM,
Henry C, Leboyer M, Etain B, Scott J, et al. (2017) Clinical factors associated
with lithium response in bipolar disorders. Aust N Z J Psychiatry 51:524–530.
Squassina A, Costa M, Congiu D, Manchia M, Angius A, Deiana V, Ardau R,
Chillotti C, Severino G, Calza S, et al. (2013) Insulin-like growth factor 1 (IGF-1)
expression is up-regulated in lymphoblastoid cell lines of lithium responsive
bipolar disorder patients. Pharmacol Res 73:1–7.

Squassina A, Manchia M, Borg J, Congiu D, Costa M, Georgitsi M, Chillotti C,
Ardau R, Mitropoulos K, Severino G, et al. (2011) Evidence for association of an
ACCN1 gene variant with response to lithium treatment in Sardinian patients
with bipolar disorder. Pharmacogenomics 12:1559–1569.

Squassina A, Niola P, Lopez JP, Cruceanu C, Pisanu C, Congiu D, Severino G, Ardau
R, Chillotti C, Alda M, et al. (2020) MicroRNA expression proﬁling of lymphoblasts
from bipolar disorder patients who died by suicide, pathway analysis and
integration with postmortem brain ﬁndings. Eur Neuropsychopharmacol 34:39–49.
Squassina A, Pisanu C, Corbett N, and Alda M (2017) Telomere length in bipolar

disorder and lithium response. Eur Neuropsychopharmacol 27:560–567.

Steelman LS, Pohnert SC, Shelton JG, Franklin RA, Bertrand FE, and McCubrey JA
(2004) JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression
and leukemogenesis. Leukemia 18:189–218.

Stone W, Nunes A, Akiyama K, Akula N, Ardau R, Aubry JM, Backlund L, Bauer
M, Bellivier F, Cervantes P, et al. (2021) Prediction of lithium response using
genomic data. Sci Rep 11:1155.

Stout J, Hozer F, Coste A, Mauconduit F, Djebrani-Oussedik N, Sarrazin S, Poupon
J, Meyrel M, Romanzetti S, Etain B, et al. (2020) Accumulation of Lithium in the
Hippocampus of Patients With Bipolar Disorder: A Lithium-7 Magnetic Resonance
Imaging Study at 7 Tesla. Biol Psychiatry 88:426–433.

Sudduth TL, Wilson JG, Everhart A, Colton CA, and Wilcock DM (2012) Lithium
treatment of APPSwDI/NOS2-/- mice leads to reduced hyperphosphorylated tau,
increased amyloid deposition and altered inﬂammatory phenotype. PLoS One
7:e31993.

Suliman M, Schmidtke MW, and Greenberg ML (2021) The Role of the UPR
Pathway in the Pathophysiology and Treatment of Bipolar Disorder. Frontiers in
cellular neuroscience 15:735622.

Swann AC, Bowden CL, Morris D, Calabrese JR, Petty F, Small J, Dilsaver SC,
and Davis JM (1997) Depression during mania. Treatment response to lithium or
divalproex. Arch Gen Psychiatry 54:37–42.

Szalat A, Mazeh H, and Freund HR (2009) Lithium-associated hyperparathyroidism:

report of four cases and review of the literature. Eur J Endocrinol 160:317–323.

Takadera T, Fujibayashi M, Kaniyu H, Sakota N, and Ohyashiki T (2007) Caspase-
dependent apoptosis induced by thapsigargin was prevented by glycogen
synthase kinase-3 inhibitors in cultured rat cortical neurons. Neurochem Res
32:1336–1342.

Talaei A, Pourgholami M, Khatibi-Moghadam H, Faridhosseini F, Farhoudi F, Askari-
Noghani A, and Sadeghi R (2016) Tamoxifen: A Protein Kinase C Inhibitor to Treat
Mania: A Systematic Review and Meta-Analysis of Randomized, Placebo-Controlled
Trials. J Clin Psychopharmacol 36:272–275.

Tam V, Patel N, Turcotte M, Boss(cid:3)e Y, Par(cid:3)e G, and Meyre D (2019) Beneﬁts and

limitations of genome-wide association studies. Nat Rev Genet 20:467–484.

Tang M, Liu T, Jiang P, and Dang R (2021) The interaction between autophagy and
neuroinﬂammation in major depressive disorder: From pathophysiology to
therapeutic implications. Pharmacol Res 168:105586.

Tian N, Kanno T, Jin Y, and Nishizaki T (2014) Lithium potentiates GSK-3b
activity by inhibiting phosphoinositide 3-kinase-mediated Akt phosphorylation.
Biochem Biophys Res Commun 450:746–749.

Toker L and Agam G (2015) Mitochondrial dysfunction in psychiatric morbidity:
current evidence and therapeutic prospects. Neuropsychiatr Dis Treat 11:2441–2447.
Tong M, He Z, Lin X, Zhou Y, Wang Q, Zheng Z, Chen J, Xu H, and Tian N (2018)
Lithium chloride contributes to blood-spinal cord barrier integrity and functional
recovery from spinal cord injury by stimulating autophagic ﬂux. Biochem
Biophys Res Commun 495:2525–2531.

Tramontina JF, Andreazza AC, Kauer-Sant’anna M, Stertz L, Goi J, Chiarani F,
and Kapczinski F (2009) Brain-derived neurotrophic factor serum levels before
and after treatment for acute mania. Neurosci Lett 452:111–113.

Tramutola A, Triplett JC, Di Domenico F, Niedowicz DM, Murphy MP, Coccia R,
Perluigi M, and Butterﬁeld DA (2015) Alteration of mTOR signaling occurs early
in the progression of Alzheimer disease (AD): analysis of brain from subjects
with pre-clinical AD, amnestic mild cognitive impairment and late-stage AD.
J Neurochem 133:739–749.

Tsaltas E, Kontis D, Boulougouris V, and Papadimitriou GN (2009) Lithium and
cognitive enhancement: leave it or take it? Psychopharmacology (Berl) 202:457–476.
Tsankova NM, Berton O, Renthal W, Kumar A, Neve RL, and Nestler EJ (2006)
Sustained hippocampal chromatin regulation in a mouse model of depression and
antidepressant action. Nat Neurosci 9:519–525.

Tunca Z, Ozerdem A, Ceylan D, Yalc¸ın Y, Can G, Resmi H, Akan P, Erg€or G,
Aydemir O, Cengisiz C, et al.
(2014) Alterations in BDNF (brain derived
neurotrophic factor) and GDNF (glial cell line-derived neurotrophic factor) serum
levels in bipolar disorder: The role of lithium. J Affect Disord 166:193–200.

Turecki G, Grof P, Grof E, D’Souza V, Lebuis L, Marineau C, Cavazzoni P, Duffy A,
B(cid:3)etard C, Zvolsk(cid:3)y P, et al. (2001) Mapping susceptibility genes for bipolar disorder:
a pharmacogenetic approach based on excellent response to lithium. Mol Psychiatry
6:570–578.

Undurraga J, Sim K, Tondo L, Gorodischer A, Azua E, Tay KH, Tan D, and
Baldessarini RJ (2019) Lithium treatment for unipolar major depressive disorder:
Systematic review. J Psychopharmacol 33:167–176.

Undurraga J, Baldessarini RJ, Valent(cid:3)ı M, Pacchiarotti I, Tondo L, V(cid:3)azquez G, and
Vieta E (2012) Bipolar depression: clinical correlates of receiving antidepressants.
J Affect Disord 139:89–93.

Vall(cid:3)ee A, Vall(cid:3)ee JN, and Lecarpentier Y (2021) Parkinson’s Disease: Potential
Actions of Lithium by Targeting the WNT/b-Catenin Pathway, Oxidative Stress,
Inﬂammation and Glutamatergic Pathway. Cells 10:230.

Valvezan AJ and Klein PS (2012) GSK-3 and Wnt Signaling in Neurogenesis and

Bipolar Disorder. Front Mol Neurosci 5:1.

Vancampfort D, Correll CU, Galling B, Probst M, De Hert M, Ward PB, Rosenbaum
S, Gaughran F, Lally J, and Stubbs B (2016) Diabetes mellitus in people with
schizophrenia, bipolar disorder and major depressive disorder: a systematic
review and large scale meta-analysis. World Psychiatry 15:166–174.

van Eijk RPA, Jones AR, Sproviero W, Shatunov A, Shaw PJ, Leigh PN, Young CA,
Shaw CE, Mora G, Mandrioli J, et al.; For UKMND-LiCALS and LITALS Study
Group (2017) Meta-analysis of pharmacogenetic interactions in amyotrophic
lateral sclerosis clinical trials. Neurology 89:1915–1922.

van Erp TG, Hibar DP, Rasmussen JM, Glahn DC, Pearlson GD, Andreassen OA,
Agartz I, Westlye LT, Haukvik UK, Dale AM, et al. (2016) Subcortical brain
volume abnormalities in 2028 individuals with schizophrenia and 2540 healthy
controls via the ENIGMA consortium. Mol Psychiatry 21:585.

van Rensburg DJ, Lindeque Z, Harvey BH, and Steyn SF (2022) Reviewing the
mitochondrial dysfunction paradigm in rodent models as platforms for neuropsychiatric
disease research. Mitochondrion 64:82–102.

Vats A, Gourie-Devi M, Ahuja K, Sharma A, Wajid S, Ganguly NK, and Taneja V
(2018) Expression analysis of protein homeostasis pathways in the peripheral blood
mononuclear cells of sporadic amyotrophic lateral sclerosis patients. J Neurol Sci
387:85–91.

V(cid:3)azquez GH, Holtzman JN, Lolich M, Ketter TA, and Baldessarini RJ (2015)
Recurrence rates in bipolar disorder: Systematic comparison of long-term prospective,
naturalistic studies versus randomized controlled trials. Eur Neuropsychopharmacol
25:1501–1512.

V(cid:3)azquez GH, Bahji A, Undurraga J, Tondo L, and Baldessarini RJ (2021) Efﬁcacy and
Tolerability of Combination Treatments for Major Depression: Antidepressants plus
Second-Generation Antipsychotics vs. Esketamine vs. Lithium. J Psychopharmacol
35:890–900.

Vecchio D, Piras F, Piras F, Banaj N, Janiri D, Simonetti A, Sani G, and Spalletta G
(2020) Lithium treatment impacts nucleus accumbens shape in bipolar disorder.
Neuroimage Clin 25:102167.

Velosa J, Delgado A, Finger E, Berk M, Kapczinski F, and de Azevedo Cardoso T
(2020) Risk of dementia in bipolar disorder and the interplay of lithium: a
systematic review and meta-analyses. Acta Psychiatr Scand 141:510–521.

Verdolini N, Hidalgo-Mazzei D, Del Matto L, Muscas M, Pacchiarotti I, Murru A,
Samalin L, Aedo A, Tohen M, Grunze H, et al. (2021) Long-term treatment of
bipolar disorder type I: A systematic and critical review of clinical guidelines
with derived practice algorithms. Bipolar Disord 23:324–340.

Vieta E and Valent(cid:3)ı M (2013) Pharmacological management of bipolar depression:

acute treatment, maintenance, and prophylaxis. CNS Drugs 27:515–529.

Vieta E, Berk M, Schulze TG, Carvalho AF, Suppes T, Calabrese JR, Gao K, Miskowiak

KW, and Grande I (2018) Bipolar disorders. Nat Rev Dis Primers 4:18008.

Vignaux PA, Minerali E, Foil DH, Puhl AC, and Ekins S (2020) Machine Learning

for Discovery of GSK3b Inhibitors. ACS Omega 5:26551–26561.

Walker AJ, Price JB, Borreggine K, Sutor SL, Gogos A, McGillivray JA, Frye MA,
and Tye SJ (2019) Insulin-stimulated mTOR activation in peripheral blood
mononuclear cells associated with early treatment response to lithium
augmentation in rodent model of antidepressant-resistance. Transl Psychiatry
9:113.

Wang HY and Friedman E (1996) Enhanced protein kinase C activity and
translocation in bipolar affective disorder brains. Biol Psychiatry 40:568–575.
Wang HY, Markowitz P, Levinson D, Undie AS, and Friedman E (1999) Increased
membrane-associated protein kinase C activity and translocation in blood
platelets from bipolar affective disorder patients. J Psychiatr Res 33:171–179.
Wang SY, Ren M, Jiang HZ, Wang J, Jiang HQ, Yin X, Qi Y, Wang XD, Dong GT,
Wang TH, et al. (2015) Notch pathway is activated in cell culture and mouse
models of mutant SOD1-related familial amyotrophic lateral sclerosis, with
suppression of its activation as an additional mechanism of neuroprotection for
lithium and valproate. Neuroscience 301:276–288.

Weiner ID, Leader JP, Bedford JJ, Verlander JW, Ellis G, Kalita P, Vos F, de Jong
S, and Walker RJ (2014) Effects of chronic lithium administration on renal acid
excretion in humans and rats. Physiol Rep 2:e12242.

Welling LC, Welling MS, and Figueiredo EG (2017) Traumatic Brain Injury and
Mood Stabilizers: Recent Cumulative Evidence. World Neurosurg 105:983–984.
Wilkowska A, Szałach Ł, and Cubała WJ (2020) Ketamine in Bipolar Disorder: A

Review. Neuropsychiatr Dis Treat 16:2707–2717.

Williams NR, Heifets BD, Blasey C, Sudheimer K, Pannu J, Pankow H, Hawkins J,
Birnbaum J, Lyons DM, Rodriguez CI, et al. (2018) Attenuation of antidepressant
effects of ketamine by opioid receptor antagonism. Am J Psychiatry 175:1205–1215.
Wilson EN, Do Carmo S, Welikovitch LA, Hall H, Aguilar LF, Foret MK, Iulita MF, Jia
DT, Marks AR, Allard S, et al. (2020) NP03, a Microdose Lithium Formulation,
Blunts Early Amyloid Post-Plaque Neuropathology in McGill-R-Thy1-APP Alzheimer-
Like Transgenic Rats. J Alzheimers Dis 73:723–739.

Wingo AP, Wingo TS, Harvey PD, and Baldessarini RJ (2009) Effects of lithium on

cognitive performance: a meta-analysis. J Clin Psychiatry 70:1588–1597.

Potential Therapeutic Effects of Lithium

357

Won E and Kim YK (2017) An Oldie but Goodie: Lithium in the Treatment of
Bipolar Disorder through Neuroprotective and Neurotrophic Mechanisms. Int
J Mol Sci 18:2679.

Wurzelmann M, Romeika J, and Sun D (2017) Therapeutic potential of brain-
derived neurotrophic factor (BDNF) and a small molecular mimics of BDNF for
traumatic brain injury. Neural Regen Res 12:7–12.

Xing G, Russell S, Hough C, O’Grady J, Zhang L, Yang S, Zhang LX, and Post R
(2002) Decreased prefrontal CaMKII a mRNA in bipolar illness. Neuroreport
13:501–505.

Xiong N, Jia M, Chen C, Xiong J, Zhang Z, Huang J, Hou L, Yang H, Cao X, Liang
(2011) Potential autophagy enhancers attenuate rotenone-induced

Z, et al.
toxicity in SH-SY5Y. Neuroscience 199:292–302.

Xu J, Culman J, Blume A, Brecht S, and Gohlke P (2003) Chronic treatment with a
low dose of lithium protects the brain against ischemic injury by reducing
apoptotic death. Stroke 34:1287–1292.

Xu P, Rosen KM, Hedstrom K, Rey O, Guha S, Hart C, and Corfas G (2013) Nerve
injury induces glial cell line-derived neurotrophic factor (GDNF) expression in
Schwann cells through purinergic signaling and the PKC-PKD pathway. Glia
61:1029–1040.

Xu AJ, Niciu MJ, Lundin NB, Luckenbaugh DA, Ionescu DF, Richards EM, Vande
Voort JL, Ballard ED, Brutsche NE, Machado-Vieira R, et al. (2015a) Lithium
and Valproate Levels Do Not Correlate with Ketamine’s Antidepressant Efﬁcacy
in Treatment-Resistant Bipolar Depression. Neural Plast 2015:858251.

Xu H, Czerwinski P, Xia N, F€orstermann U, and Li H (2015b) Downregulation of BDNF
Expression by PKC and by TNF-a in Human Endothelial Cells. Pharmacology
96:1–10.

Yan XB, Hou HL, Wu LM, Liu J, and Zhou JN (2007a) Lithium regulates hippocampal
learning and
ischemia. Neuropharmacology

neurogenesis by ERK pathway and facilitates recovery of spatial
memory in rats after transient global cerebral
53:487–495.

Yan XB, Wang SS, Hou HL, Ji R, and Zhou JN (2007b) Lithium improves the
behavioral disorder in rats subjected to transient global cerebral ischemia. Behav
Brain Res 177:282–289.

Yang ML, Li JJ, So KF, Chen JY, Cheng WS, Wu J, Wang ZM, Gao F, and Young W
(2012) Efﬁcacy and safety of lithium carbonate treatment of chronic spinal cord
injuries: a double-blind, randomized, placebo-controlled clinical trial. Spinal
Cord 50:141–146.

Yao HB, Shaw PC, Wong CC, and Wan DC (2002) Expression of glycogen synthase
kinase-3 isoforms in mouse tissues and their transcription in the brain. J Chem
Neuroanat 23:291–297.

Yasuda S, Liang MH, Marinova Z, Yahyavi A, and Chuang DM (2009) The mood
stabilizers lithium and valproate selectively activate the promoter IV of brain-
derived neurotrophic factor in neurons. Mol Psychiatry 14:51–59.

Yatham LN (2005) Atypical antipsychotics for bipolar disorder. Psychiatr Clin

North Am 28:325–347.

Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Bond DJ, Frey BN, Sharma V,
Goldstein BI, Rej S, Beaulieu S, et al. (2018) Canadian Network for Mood and
Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders
(ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Bipolar Disord 20:97–170.

Yildiz A, Guleryuz S, Ankerst DP, Ong€ur D, and Renshaw PF (2008) Protein kinase
C inhibition in the treatment of mania: a double-blind, placebo-controlled trial of
tamoxifen. Arch Gen Psychiatry 65:255–263.

Yildiz A, Aydin B, G€okmen N, Yurt A, Cohen B, Keskinoglu P,

€
Ong€ur D, and Renshaw
P (2016) Antimanic Treatment With Tamoxifen Affects Brain Chemistry: A Double-
Blind, Placebo-Controlled Proton Magnetic Resonance Spectroscopy Study. Biol
Psychiatry Cogn Neurosci Neuroimaging 1:125–131.

York JD, Guo S, Odom AR, Spiegelberg BD, and Stolz LE (2001) An expanded view

of inositol signaling. Adv Enzyme Regul 41:57–71.

York JD, Ponder JW, and Majerus PW (1995) Deﬁnition of a metal-dependent/
Li(1)-inhibited phosphomonoesterase protein family based upon a conserved
three-dimensional core structure. Proc Natl Acad Sci USA 92:5149–5153.

Yu F, Wang Z, Tanaka M, Chiu CT, Leeds P, Zhang Y, and Chuang DM (2013)
Posttrauma cotreatment with lithium and valproate: reduction of lesion volume,

attenuation of blood-brain barrier disruption, and improvement in motor coordination
in mice with traumatic brain injury. J Neurosurg 119:766–773.

Yu W and Greenberg ML (2016) Inositol depletion, GSK3 inhibition and bipolar

disorder. Future Neurol 11:135–148.

Yuan P, Zhou R, Wang Y, Li X, Li J, Chen G, Guitart X, and Manji HK (2010)
Altered levels of extracellular signal-regulated kinase signaling proteins in
postmortem frontal cortex of individuals with mood disorders and schizophrenia.
J Affect Disord 124:164–169.

Yuan Y, Wang H, Wei Z, and Li W (2015) Impaired autophagy in hilar mossy cells of
the dentate gyrus and its implication in schizophrenia. J Genet Genomics 42:1–8.
Zang X, Chen S, Zhu J, Ma J, and Zhai Y (2022) The Emerging Role of Central and
Peripheral Immune Systems in Neurodegenerative Diseases. Front Aging Neurosci
14:872134.

Zanni G, Michno W, Di Martino E, Tj€arnlund-Wolf A, Pettersson J, Mason CE,
Hellspong G, Blomgren K, and Hanrieder J (2017) Lithium Accumulates in
Neurogenic Brain Regions as Revealed by High Resolution Ion Imaging. Sci Rep
7:40726.

Zanos P, Moaddel R, Morris PJ, Georgiou P, Fischell J, Elmer GI, Alkondon M,
Yuan P, Pribut HJ, Singh NS, et al. (2016) NMDAR inhibition-independent
antidepressant actions of ketamine metabolites. Nature 533:481–486.

Zarate Jr CA, Du J, Quiroz J, Gray NA, Denicoff KD, Singh J, Charney DS, and
Manji HK (2003) Regulation of cellular plasticity cascades in the pathophysiology
and treatment of mood disorders: role of the glutamatergic system. Ann N Y Acad
Sci 1003:273–291.

Zarate Jr CA, Singh J, and Manji HK (2006a) Cellular plasticity cascades: targets
for the development of novel therapeutics for bipolar disorder. Biol Psychiatry
59:1006–1020.

Zarate Jr CA and Machado-Vieira R (2016) GSK-3: A key regulatory target for
ketamine’s rapid antidepressant effects mediated by enhanced AMPA to
NMDA throughput. Bipolar Disord 18:702–705.

Zarate CA and Manji HK (2009) Protein kinase C inhibitors: rationale for use and

potential in the treatment of bipolar disorder. CNS Drugs 23:569–582.

Zarate Jr CA, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney
DS, and Manji HK (2006b) A randomized trial of an N-methyl-D-aspartate antagonist
in treatment-resistant major depression. Arch Gen Psychiatry 63:856–864.

Zhang F, Phiel CJ, Spece L, Gurvich N, and Klein PS (2003) Inhibitory
phosphorylation of glycogen synthase kinase-3 (GSK-3) in response to lithium.
Evidence for autoregulation of GSK-3. J Biol Chem 278:33067–33077.

Zhao Q, Liu H, Cheng J, Zhu Y, Xiao Q, Bai Y, and Tao J (2019) Neuroprotective
effects of lithium on a chronic MPTP mouse model of Parkinson’s disease via
regulation of a-synuclein methylation. Mol Med Rep 19:4989–4997.

Zheng F, Zhou X, Luo Y, Xiao H, Wayman G, and Wang H (2011) Regulation of brain-
derived neurotrophic factor exon IV transcription through calcium responsive
elements in cortical neurons. PLoS One 6:e28441.

Zhou R, Gray NA, Yuan P, Li X, Chen J, Chen G, Damschroder-Williams P, Du J,
Zhang L, and Manji HK (2005) The anti-apoptotic, glucocorticoid receptor
cochaperone protein BAG-1 is a long-term target for the actions of mood stabilizers.
J Neurosci 25:4493–4502.

Zhou R, Yuan P, Wang Y, Hunsberger JG, Elkahloun A, Wei Y, Damschroder-Williams
P, Du J, Chen G, and Manji HK (2009) Evidence for selective microRNAs and their
effectors as common long-term targets for the actions of mood stabilizers.
Neuropsychopharmacology 34:1395–1405.

Zhu J, Wu Y, Wang M, Li K, Xu L, Chen Y, Cai Y, and Jin J (2020) Integrating
Machine Learning-Based Virtual Screening With Multiple Protein Structures and
Bio-Assay Evaluation for Discovery of Novel GSK3b Inhibitors. Front Pharmacol
11:566058.

Zhu Z, Kremer P, Tadmori I, Ren Y, Sun D, He X, and Young W (2011) Lithium
suppresses astrogliogenesis by neural stem and progenitor cells by inhibiting
STAT3 pathway independently of glycogen synthase kinase 3 beta. PLoS One
6:e23341.

Zhu ZF, Wang QG, Han BJ, and William CP (2010) Neuroprotective effect and
cognitive outcome of chronic lithium on traumatic brain injury in mice. Brain
Res Bull 83:272–277.

_Zurawek D and Turecki G (2021) The miRNome of Depression. Int J Mol Sci

22:11312.
